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Abstract	  
Explosion is responsible for almost 80% of Coalition injuries in today’s conflicts. 
Haemorrhage is the leading cause of death and blast lung injury is evident in 11% of 
Coalition casualties surviving to reach the (UK) Field Hospital. Military prehospital 
evacuation times can be prolonged and the combined insults of haemorrhage and 
blast injury present a ‘double hit’ to oxygen delivery.  Resuscitation strategies must 
be capable of preserving life from such trauma for several hours.  Alongside fluid 
therapy, adjuncts to resuscitation might improve battlefield survival. 
 
This randomized controlled animal trial assessed two adjuncts: supplemental 
inspired oxygen and recombinant activated Factor VII (rFVIIa).  Neither adjunct is 
currently available in the far-forward military echelon, but with modern technology, 
both are potentially deployable. 
 
18 terminally anaesthetized swine were exposed to blast, controlled haemorrhage 
and grade IV liver laceration (uncontrolled haemorrhage).  Animals were allocated 
randomly into three treatment groups.  All animals were resuscitated with normal 
saline to a hypotensive systolic target (80mmHg), which continued until the 8hr end 
point.  Thirty minutes after the onset of resuscitation each group received one of the 
following: single (180mcg/kg) dose of rFVIIa; supplemental oxygen (min FiO2 0.3 to 
maintain SaO2>95%) or the control group (breathed air throughout and received 
saline placebo 0.18ml/kg).  
 
5/6 control animals died within 4 hours. Supplemental oxygen improved survival (4/6 
survival to 8h endpoint, P=0.014).  Single dose rFVIIa did not prolong survival 
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compared to control (2/6 survived, p=0.65).   Oxygen arrested physiological decline 
while control and rFVIIa animals continued to decline until death.  
 
Supplemental oxygen is a useful adjunct to fluid resuscitation in the context of 
haemorrhage and blast injury.  Delivery of oxygen support capability to forward 
echelon units is recommended.  By contrast, a single intravenous (pre-hospital) dose 
of rFVIIa was not an effective treatment for blast lung based on our model of 
complex battlefield injury. 
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1 Introduction 
Trauma accounts for 10% of all deaths worldwide (1;2).  In western countries, it is 
the leading killer before 40 years of age (NCEPOD Report 2009) and the cost of 
trauma to the United Kingdom lies at well over £1.2 billion per annum (Department of 
Health 1998).   
 
Military operations in the Middle East have increased awareness of military trauma.  
In Afghanistan (OP HERRICK) since 2001, over 360 UK Military or MOD civilians 
have died as a result of hostile action.  Since 2006, 1871 UK military or MOD civilian 
personnel have been wounded in action.  Of these, 267 have been listed as ‘Very 
Seriously Ill’ and a further 275, ‘Seriously Ill’(4). 
 
Trauma represents a significant burden on both humanitarian and financial levels.  
Measures that ameliorate the consequences will lessen the impact of this disease. 
1.1 Classification by mechanism 
Trauma is typically classified into either blunt or penetrating mechanisms.  Blunt 
mechanisms cause the majority of trauma injuries in the developed urban 
environment (5), although modern US data shows an increasing burden from 
penetrating injury (6).  Protagonists of conflict deliberately employ ballistic weapons 
and high explosive fragmenting munitions to incapacitate their enemies, so military 
trauma is predominantly penetrating.   
 
In addition to the typical division of traumatic injury into blunt and penetrating 
mechanisms, blast injury represents a third injury mechanism of particular relevance 
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to the military.  Exploding munitions and improvised explosive devices (IED) are 
increasingly responsible for both military and civilian trauma casualties. 
1.2 Civilian and Military Trauma  
Urban trauma has demonstrated a tri-modal distribution of deaths (7) . Approximately 
half die within minutes from catastrophic wounding (Immediate deaths): there is little 
one can do for these victims; instead the priority lies in injury prevention.  A second 
peak is seen over the ensuing few hours. This peak is termed ‘early deaths’ and is 
the area most relevant to military trauma care and to this thesis.  The third peak, ‘late 
deaths’, occurs days to weeks after injury, usually as a result of sepsis or multiple 
organ failure.  As trauma systems mature, this third cohort represents a declining 
proportion, now accounting for only 7% of all deaths (6).   
 
Military data has not reproduced Trunkey’s tri-modal distribution.  Instead a large 
proportion of fatalities die instantly (6).  Most subsequent deaths occur in the ‘early’ 
phase and late deaths are uncommon.  The greatest potential for improvement 
remains in preventing the ‘early deaths’. 
 
It is understood that evacuation to surgical facilities must be achieved swiftly to 
maximise survivability after major trauma.  National and regional frameworks are 
capable of covering the population in a timely manner (8).  95% of all ‘Category A’ 
calls should be reached by a fully equipped ambulance within 19 minutes.  
Ambulances are manned by highly trained paramedics. Patients normally reach 
hospital within 1 hour of wounding.  Time delay to surgery following penetrating 
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trauma at The Royal London Hospital has a mean time of 86 min and all were in 
surgery within two hours from wounding (9). 
 
On military operations, logistic constraints and the tactical situation potentially 
impede evacuation.  The UK Armed Forces deploy medical assets in a manner 
which enables rapid recognition, assessment and management of high priority 
casualties, swift evacuation to a surgical facility and, thereafter, onwards repatriation 
to the UK.  Individual soldiers and embedded medics instigate medical aid in the 
immediate post-injury period.  If there is considerable distance between the ‘front 
line’ and the surgical facility, the Regimental Aid Post (RAP) provides an interim 
echelon in the evacuation chain.  High priority casualties should reach here within 
the hour. The RAP is manned by at least one doctor.  At this point casualties receive 
the battlefield-modified version of advanced trauma life support (10).  A recent paper 
by Tai and military surgical colleagues, recommends that all battlefield casualties 
should reach a surgical facility within two hours from wounding (11). This facility may 
be designed to perform only damage control procedures, but in current conflicts is 
usually a dedicated Field Hospital.   
 
Despite good planning, delayed evacuation on military operations is sometimes 
unavoidable.  US data from Operation Iraqi Freedom demonstrated evacuation times 
of up to 20 hours (12).  Data from the US mission in Afghanistan specifically 
mentioned delay to initial surgical care (5 hours) as a contributing factor for casualty 
mortality (13).  Short evacuation times, although achievable for the majority of 
casualties, can neither be guaranteed in the military context; nor after a major civilian 
incident. 
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1.3 The Problem of Haemorrhage 
Haemorrhage is the principal cause of battlefield death; responsible for 44% of pre-
hospital fatalities after wounding (14).  In urban trauma, haemorrhage is the second 
commonest cause of pre-hospital death, but remains the leading cause of early 
hospital deaths (15). Addressing haemorrhage effectively will improve survival. 
 
The body mounts a physiological response to haemorrhage in an effort to maintain 
perfusion of vital organs and minimise bleeding.  If despite this compensation, organ 
perfusion begins to suffer, the casualty enters ‘haemorrhagic shock’.  This 
progressive phenomenon is the result of increasingly compromised oxygen delivery 
to the tissues: the level of ‘shock’ depends on the rate and duration of haemorrhage, 
and the time delay before restoration of normal perfusion.  Metabolic acidosis 
develops as a result of insufficient oxygen delivery and can be considered a marker 
of oxygen debt.  Coagulopathy, common after traumatic haemorrhage, is an 
independent predictor of poor outcome (16).  It develops as a result of several 
contributing events after injury, and recent work suggests that, in the early phase 
after injury, hypoperfusion plays a key role in coagulopathy, irrespective of acidosis 
or dilution (17).  Coagulopathy and acidosis reduce survival from trauma (18;19), but 
also increase morbidity in surviving patients (20;21).  With hypoperfusion driving 
acidosis and coagulopathy, the degree and duration of the haemorrhagic shock state 
is critical to overall outcome. 
 
The most obvious intervention is to stop the bleeding.  Extremity haemorrhage 
should be controllable with simple first aid interventions, but Bellamy’s data from the 
Vietnam war showed that a third of battlefield exsanguinations occurred from 
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extremity injury (22).  Troops carry a range of products to help control extremity 
haemorrhage.  Novel haemostatic dressings may gain temporary control in some 
cases of junctional injury (23;24), but incompressible haemorrhage requires surgical 
control.   
 
It is clear that haemorrhage must be stopped as quickly as possible and that this 
normally requires surgical intervention in severely wounded casualties.  In the pre-
surgical interval, prompt restoration of tissue oxygen delivery, without precipitating 
rebleeding, should reduce mortality and morbidity. 
1.4 The Problem of Blast 
‘Blast injuries’ describe the sequellae of exposure to an explosive detonation.  They 
represent an increasing problem in both military and civilian environments (25). US 
data from Iraq and Afghanistan indicated that blast injuries are present in between 
31% and 55% of combat casualties (26-29).  Another US paper illustrated that 78% 
of wounds are sustained as a result of exploding munitions (29). 
 
There is a growing threat posed by enhanced blast weapons (EBW) (30).  EBW 
specifically exploit the capabilities of a blast wave to incapacitate or kill enemy over a 
larger target area than conventional weapons.  The blast wave can penetrate 
traditional defences and the prolonged over-pressure can destroy buildings (30).   
Thermobaric weapons incorporate both enhanced blast and thermal output and they 
have been used in conflicts before (30).   If EBW are deployed, we should expect 
large numbers of casualties with primary blast, burns, translational and crush injuries 
(31).     
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As protagonists of terror deploy increasingly lethal explosive devices our perceived 
vulnerability to terror attacks increases (25).  Terrorist attacks have produced several 
civilian casualties with primary blast injury, particularly where explosions have 
occurred in confined spaces, such as buildings and vehicles (32).   
 
Exposure to high explosive can injure through several means.  The wave might 
cause few external signs of injury, yet may still be fatal.  It particularly affects the 
lungs causing profound hypoxia (33).  Exposure to the blast wave has been shown 
to modify the response to haemorrhage (35).  Other features of explosive munition 
detonation make it likely that, aside from sustaining lung injury, a blast victim will also 
sustain both penetrating and blunt trauma (34).  These injuries will result in severe 
haemorrhage.    
 
We know that injury and blood loss produce significant physiological sequellae; and 
that the principal cause of deterioration after haemorrhage is inadequate delivery of 
oxygen to the tissues.  If thoracic exposure to a blast wave is added, oxygenation of 
what blood remains is reduced.  The blast-injured bleeding casualty therefore 
sustains a ‘double hit’ to his capacity to deliver oxygen to tissues and will deteriorate 
more swiftly. 
1.5 Current and Potential Pre-hospital Interventions 
We cannot rely on prompt access to surgery, so we must develop pre-hospital 
strategies to maintain life and delay physiological demise after trauma. 
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The physiological goal of pre-hospital resuscitation is to maximise tissue oxygen 
delivery.  By augmenting the depleted intravascular volume, fluid therapy bolsters 
cardiac output and maintains tissue oxygenation.  The type of fluid and what targets 
should guide therapy remain subjects of debate, with Bickell’s study even 
questioning whether fluid should be given at all in the first hour or so after injury (36).  
Work previously undertaken at Dstl Porton Down has illustrated the survival and 
physiological penalties of prolonged hypotensive resuscitation after blast and 
haemorrhage (37;38).  The problem with the hypotensive concept is its inability to 
support perfusion enough to prevent physiological decay.  A subsequent study 
assessed a ‘novel hybrid’ fluid resuscitation protocol (39): this addressed the 
concerns of inadequate tissue perfusion, while also avoiding rebleeding from sites of 
injury; a potential risk of more aggressive fluid administration (40).   
 
Fluid therapy aside, it would be advantageous to improve oxygen delivery to the 
tissues after trauma, without increasing the hydrostatic pressure exerted on a blood 
clot.  Two such adjuncts have been identified: supplemental oxygen and 
recombinant activated Factor VII.  
 
Although pre-hospital supplemental oxygen is standard in civilian emergency 
medicine, it is not a part of far forward UK military medical doctrine.  The principal 
limitation is logistic: regular resupply is difficult to achieve and forward medical 
assets must remain ‘light’ to respond to the battle picture.  However, modern 
technologies increase the feasibility of deploying remote oxygen support. 
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Supplemental oxygen should increase the oxygen content of arterial blood (CaO2) 
and improve tissue oxygen delivery, independent of fluid resuscitation.  This should 
be particularly effective in hypoxic blast-injured casualties.  
 
Recombinant Activated Factor VII (rFVIIa) is a haemostatic agent.  It has been 
shown to increase the blood pressure at which re-bleeding occurs after swine 
aortotomy (41).  Rebleeding is a concern during fluid resuscitation.  In blast lung, by 
enabling strong clots at sites of haemorrhage, rFVIIa may reduce the volume of intra-
alveolar haemorrhage and so preserve blood oxygenation.  rFVIIa has been shown 
to reduce the incidence of Adult Respiratory Distress Syndrome (ARDS) and Multiple 
Organ Failure (MOF) in severely injured trauma patients (42).  ARDS and MOF are 
significant contributors to ‘late deaths’ from trauma, so any ‘anti-inflammatory’ effect 
could improve outcomes.  rFVIIa has demonstrated Level IV efficacy in diffuse 
alveolar haemorrhage, a pathology similar to blast lung (see section3.3.6).  An Israeli 
clinician, with experience in managing blast-injured casualties, has reported 
anecdotally that rFVIIa might reduce lung injury after blast (43).  A heat stable 
preparation of the drug is now available and FDA approved; improving its potential 
for use as a pre-hospital drug in austere environments (44).   
 
Both haemorrhage and blast injury produce significant clinical problems.  There is a 
requirement to develop effective strategies to manage casualties injured by these 
means.  This thesis will explore current understanding of the problems of 
haemorrhage and blast injury, both as discrete and combined insults, and assess 
two potential interventions that might attenuate the sequellae of these events. 
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2 Basic Science of Haemorrhage and Blast Injury 
After traumatic injury, casualties are subject to a range of stimuli capable of 
producing physiological responses. The term, ‘Shock’, describes inadequate oxygen 
delivery to the tissues: it is common after trauma.  Oxygen delivery (DO2) is the total 
amount of oxygen delivered to tissues per unit of time.  It is a product of blood flow 
through the circulation in a minute (cardiac output) and the amount of oxygen within 
that blood (oxygen content) (Equation 1).  The degree and duration of the oxygen 
delivery shortfall will correlate with survival and morbidity.  The goal of trauma 
resuscitation is to restore normal oxygen delivery as soon as possible.  During this 
Basic Sciences Chapter, the physiological effects of haemorrhage and blast injury, 
their interactions, and the potential benefits of therapy, will be related to their impact 
on this oxygen delivery equation.  
 (DO2) (ml/min) = cardiac output (CO) x arterial oxygen content (CaO2) 
Equation 1 - Oxygen delivery equation 
CO = Stroke Volume (SV) (ml) x Heart Rate (HR) (bpm) 
CaO2 = [Haemoglobin (Hb)] (g/dl) x Oxygen Saturation (SaO2) (%) x 1.34* x 10 / 1001 
* Hüffner Constant – Oxygen carrying capacity 100% saturated Haemoglobin (ml O2/g Hb) 
 
Example: 
CO = [75 (SV) x 70 (HR)] = 5.25 l/min  
CaO2 = [14 [Hb] x 98 (SaO2) x 1.34 10/100] = 183.85 
DO2 = 5.25 x 183.85 = 965 ml/min 
                                            
1 The amount of unbound O2 dissolved in plasma at 1 atmosphere is clinically negligible and not 
therefore included in this representation of the DO2 equation    
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2.1 Haemorrhage 
The primary purpose of the circulatory system is to distribute oxygen and nutrients to 
the organs and tissues.  Under normal circumstances (patient with normal levels of 
haemoglobin breathing air at atmospheric pressures) most of the oxygen 
(approximately 99%) is carried in blood bound to haemoglobin, which is found inside 
erythrocytes.  The remainder of the oxygen is simply dissolved in plasma (3.2.1).  
One of the functions of the circulatory system is to transport the erythrocytes to the 
tissues via the vasculature, driven by pumping of the heart.  Damage to the 
vasculature or the pump can rapidly impair the transfer of oxygenated blood.  Loss of 
blood from injured vessels is termed haemorrhage.   
 
Significant blood loss produces shock, with reduced circulating volume and 
haemoglobin levels leading to impaired oxygen delivery – a critical factor of trauma 
outcome.  
2.1.1 Shock 
The term ‘Shock’ is defined as pathologically inadequate tissue oxygen delivery 
(relative to the tissue’s needs).  Tissue oxygen delivery is dependent upon both the 
oxygen content of arterial blood and the flow of blood into tissues (Equation 1).  
Therefore one impairment that can lead to shock is poor tissue perfusion.  This can 
be the result of several processes including: haemorrhage; myocardial failure and 
spinal cord injury.  Haemorrhage is the leading cause of death on the battlefield and 
the most common cause of shock in trauma (45).  
 
The sequellae of shock occur in a dose-dependent fashion: the longer and more 
severe the shock state, so the more severe the physiological penalties and the 
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higher the mortality.  An understanding of key features of the response to 
haemorrhage and the pathophysiology of shock allows one to identify potential 
targets for therapy. 
2.1.2 Biphasic response to simple haemorrhage 
In controlled laboratory environments, where isolated haemorrhage can be imposed 
upon test subjects, there is a predictable sequence of physiological responses to 
ongoing haemorrhage.  Of course, in the world of trauma medicine, isolated 
haemorrhage is uncommon.  Factors such as tissue injury, pain and blast injury all 
have significant effects on the response to ‘simple’ haemorrhage and will therefore 
be discussed after the basic response to blood loss.  
 
Phase one is characterized by maintenance of arterial blood pressure, tachycardia 
and increased vascular resistance. Phase Two occurs when blood pressure, heart 
rate and vascular resistance fall. 
2.1.2.1 Phase One Events 
Phase one occurs because the baroreceptor reflex attempts to maintain the arterial 
blood pressure despite a haemorrhage-induced fall in cardiac output.  To describe 
the events chronologically, this phase is initiated by reduced venous return to the 
heart following blood loss from the circulation.  Reduced venous return results in 
decreased filling of the heart during diastole.  Starling’s law of the heart (46) dictates 
that decreased end diastolic volume will result in a reduced cardiac stroke volume.  
Reduced stroke volume in turn reduces cardiac output: 
(Cardiac Output (CO) = Stroke Volume (SV) x Heart Rate (HR)) 
Equation 2 - Cardiac Output Equation 
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Reduced CO could result in a fall in blood pressure, as blood pressure is determined 
by the product of cardiac output and systemic vascular resistance. 
Mean Arterial Blood Pressure = Systemic Vascular Resistance (SVR) x CO 
Equation 3 - Mean Arterial Pressure 
 
However, the baroreceptor reflex is able to maintain blood pressure despite a fall in 
CO.  This is achieved because baroreceptors are responsive to the rate of change of 
blood pressure as well as mean pressure (at normal or sub-normal pressures) (47) 
Reduced SV results in a reduced arterial pulse pressure, which in turn leads to 
unloading of baroreceptor afferent discharge (through detection of rate of change of 
pressure mentioned above).   The baroreceptor response to this unloading involves 
initial withdrawal of Vagal tone which results in initiation of tachycardia (48). Very 
soon thereafter (a few seconds later), there is an increase in sympathetic efferent 
activity to both the heart and vasculature (49). 
 
In contrast to the effects of vagal stimulation of the heart, which are only 
chronotropic, the sympathetic efferents innervate both the pacemaker cells to 
influence heart rate and the ventricular myocardium to increase the force of 
contraction (50).  
 
As a consequence of this sympatho-activation there is an increased tachycardia and 
a positive inotropic effect which, in part, offsets the fall in SV which has resulted from 
the Starling mechanism described earlier.  
 
35 
 
The end result of these mechanisms on the heart is that the fall in CO (initiated by 
haemorrhage) has now been limited (but not reversed).  The final part of the 
baroreceptor reflex to maintain blood pressure relies on effects of sympatho-
activation on the vasculature.  Sympathetic-driven vasoconstriction increases 
vascular resistance and therefore helps maintain blood pressure (Equation 3 - Mean 
Arterial Pressure).  The effects of this sympathetically-mediated vasoconstriction on 
different vascular beds is not however uniform.  Some beds experience intense 
vasoconstriction, while others undergo little or no contraction.  Blood flow to critical 
organs, such as the brain, is therefore maintained at the expense of reduced flow 
into other organs, such as the gut; kidneys and skeletal muscle, which are more 
tolerant of transient ischaemia (51;52).  
 
This compensatory baroreceptor-mediated response to haemorrhage cannot 
however maintain blood pressure indefinitely.  Despite the aforementioned 
mechanisms, loss of approximately 30% of blood volume will result in a cardiac 
output of about 50-60% of baseline (53).  At this stage a second phase, ‘Phase Two’ 
takes over (54). 
2.1.2.2 Phase Two Events 
With ongoing haemorrhage, a reversible depressor phase occurs; characterised by a 
profound bradycardia and a significant drop in systemic vascular resistance, which in 
turn results in a profound drop in blood pressure (54;55) .  This drop is so severe that 
most patients will faint at this stage (48).   
 
At the end of Phase one, the heart is beating very forcefully around very under-filled 
chambers and there is marked deformation of the myocardial wall.  This deformation 
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is thought to activate a group of mechanoreceptors in the ventricular wall, which 
relay in unmyelinated Vagal C-fibres (53).  Stimulation of these receptors is known to 
produce a bradycardia (due to increased vagal efferent activity) and a decreased 
vascular resistance (due to sympatho-inhibition) (56;57). 
 
While counter-intuitive for survival advantage at first glance, this bradycardia has two 
potentially beneficial effects. First, the bradycardia increases diastolic filling time, 
which results in a small increase in stroke volume.  Second, the same increase in 
diastolic time allows better perfusion of the heart musculature and may therefore be 
cardio-protective.  Indeed, attempts to block the bradycardia of Phase Two with 
atropine have lead to increased mortality in a clinical study (58).  Furthermore, the 
reduction in systemic vascular resistance that occurs due to the sympatho-inhibition 
described above, reduces afterload on the heart and therefore reduces cardiac work 
at a time when coronary perfusion is in danger of being impaired. This reflex was 
actually described by Hunter in 1794 as an increase in skeletal muscle perfusion 
noted in individuals as they approached the point of fainting during venesection (59). 
 
This concept of a ventricular cardiac inhibitory reflex being the sole cause of the 
Phase Two response to haemorrhage is not uniformly accepted however, since 
Scherrer and colleagues demonstrated the depressor effect in a cardiac transplant 
subject with presumably no ventricular cardiac innervation (60). 
2.1.3 Auto-resuscitation during Haemorrhage 
Haemorrhage results in loss of whole blood. Therefore, immediately after 
haemorrhage, the haematocrit (HCT) and haemoglobin (Hb) concentration remain 
unchanged.  A little later however, fluid shifts expand and dilute the intravascular 
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compartment and reduce both HCT and Hb.  As we have seen in the previous 
paragraphs, the Phase One response to haemorrhage involves significant 
vasoconstriction.  Most of this constriction occurs in arterioles which precede 
capillary beds.  The constriction upstream reduces capillary pressure within these 
vascular beds.  Filtration and fluid shifts in capillary beds are governed by Starling’s 
Forces (61).  Decreased capillary pressure (Pc) results in reduced filtration (↓Jv) of 
blood and an increase in intravascular fluid volume as blood exits the capillary bed.  
This process increases blood volume and dilutes the blood.  Experimental plasma 
volume measurements in sheep resulted in 57% restoration of lost volume at 3 hours 
following 15% controlled haemorrhage and 42% restoration following 45% controlled 
haemorrhage (62).  𝐽𝑣 = 𝐾𝑓 𝑃𝑐 − 𝑃𝑖 − 𝜎 𝜋! − 𝜋!   
Jv = Net fluid movement across (capillary) membrane 
Kf = Filtration coefficient (water permeability of capillary) 
Pc= Capillary hydrostatic pressure 
Pi = Interstitial hydrostatic pressure 
σ  = Reflection coefficient (1= zero permeability to water) 
πc = Capillary oncotic pressure 
πi = Interstitial oncotic pressure 
Equation 4 - Starling's Forces 
 
Of course, a mainstay of medical treatment following haemorrhage is intravascular 
fluid resuscitation, which will rapidly both expand and dilute the blood. 
2.1.4 Coagulopathy and Haemorrhage 
With ongoing haemorrhage driving shock it is vital to arrest bleeding as swiftly as 
possible.  While extremity haemorrhage can usually be controlled by direct means, 
incompressible haemorrhage is often impossible to stop in the pre-hospital 
environment.  Cessation of bleeding relies on surgical control and a functioning 
coagulation system.  However, surgery may not be available for many hours 
following injury and trauma is frequently associated with deranged coagulation. 
38 
 
 
Coagulopathy requiring transfusion after injury has been defined as an increase in 
Prothrombin (PT) and Activated partial Thromboplastin times (APTT) to greater than 
1.5 times normal(63).  Coagulopathy has been demonstrated in 24% of 1088 
severely injured urban trauma patients (Injury Severity Score > 15) at a median time 
of 73 minutes following injury.  75% of these patients had suffered blunt trauma (16).  
Presence of coagulopathy at this early stage increased mortality 4-fold and was 
present only in those with increased base deficit, but independent of the amount or 
type of pre-hospital fluid therapy.  Another survey of the German Trauma Registry 
(64) demonstrated similar findings from a population of 8724 severely injured (96% 
blunt trauma) patients. 34% demonstrated coagulopathy on admission to hospital.  A 
third retrospective survey of civilian trauma data found an incidence on admission of 
28% for abnormal PT and 8% for abnormal APTT in a cohort of 7,638 trauma 
patients with median ISS 9 (19).  All of these studies underline the early generation 
of coagulopathy after injury.  Its importance is clear as mortality and morbidity are 
both increased in the presence of early coagulopathy (16;19;65) 
2.1.4.1 Proposed Mechanisms of Coagulopathy Following Trauma 
Coagulopathy in trauma is multifactorial.  Researchers and clinicians have attempted 
both to address its consequences and establish the mechanisms involved in its 
development following injury.  The problem has been approached from several 
angles, focussing on: dilution; consumption of clotting factors; changes in clotting 
factors’ environment and more complex mechanisms, which people now believe are 
highly relevant in the acute phase following injury.  These include anticoagulation 
and fibrinolysis due to tissue hypoperfusion.   Cosgriff and his colleagues reviewed a 
series of 58 massive transfusion patients with a mean ISS of 30.6 (66).  47% of 58 
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patients developed life-threatening coagulopathy.  They identified four risk factors for 
coagulopathy development: pH<7.1; Temp<34°C; ISS>25 and SBP<70mmHg.  
Absence of any of these risk factors yielded a 1% chance of life-threatening 
coagulopathy development.  1 of 4 led to a 10-40% incidence of coagulopathy 
development and 4 of 4 risk factors produced a 98% incidence of coagulopathy.  
Coagulopathy is not however confined only to these variables. Some important 
aspects of coagulopathy are discussed below. 
Dilutional Coagulopathy 
Haemorrhage results in loss of whole blood.  As mentioned previously (2.1), 
intravascular fluid becomes diluted following major haemorrhage as fluid from the 
interstitium shifts to the blood.  The auto-resuscitated fluid now in the vessels has 
low protein and cellular content and therefore dilutes the blood.   
 
The problem of dilution is exacerbated by large-volume fluid therapy, which is given 
to support flow of blood to the tissues in shock. Most resuscitation fluids (Crystalloids 
and colloid plasma substitutes), contain few or no clotting elements and packed red 
blood cells also contain little plasma.  Aside from oxygen transport capacity, the 
haematocrit is important for haemostasis.  Turitto demonstrated a five-fold increase 
in platelet adhesion as haematocrit rose from 10% to 40% (67).  This effect of 
haematocrit is thought to be due to its influence on the transport of platelets to site of 
endothelial damage for adhesion. 
 
Hiippala assessed clotting factor levels in patients undergoing major surgery, whose 
haemorrhage volume was replaced with packed red cells and colloid (68).  
Replacement of 1.4 times blood volume caused fibrinogen levels to fall below critical 
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values for haemostasis (1g/L).  Replacement of 2-2.3 times’ blood volume caused 
platelet count to fall below 50x103/mm3 and the activity of Prothrombin, factor V and 
factor VII to fall below their critical levels for haemostasis.  During haemodilution, 
fibrinogen levels fall sooner than other coagulation factors.  Large animal models of 
injury and blood loss have been used to assess the efficacy of fibrinogen therapy in 
reversing dilutional coagulopathy.  Fries demonstrated that a single dose (250 
mg.kg-1) of fibrinogen could normalise clot propagation following 65% haemodilution 
with a colloid fluid, used to replace haemorrhage volume caused by a Grade III liver 
laceration (69). In a subsequent study (70) he administered fibrinogen in combination 
with a prothrombin complex concentrate (Beriplex) in a placebo controlled trial.  
Animals again underwent 65% replacement haemodilution with hydroxyethyl starch 
and then suffered the liver injury.  Combination therapy significantly improved 
survival (100% vs. 20% survival) and blood loss (240ml vs.1800ml).  TEG and PT 
both improved significantly in the treatment arm. Histology and autopsy found no 
sign of thromboembolic complications of this combined therapy.   
 
Another approach has been to administer antifibrinolytic agents to reduce blood loss 
and compensate for dilutional compromise in fibrinogen action. The CRASH 2 
randomised controlled trial (71) recently reported efficacy of Tranexamic Acid (TXA) 
in acute traumatic injury.  20,211 trauma patients with, or at risk of severe bleeding, 
were entered within 8hr from injury.  Patients were enrolled in 274 hospitals and 40 
countries. 10,096 patients received 1g TXA over 10 minutes followed by an infusion 
of another 1g over 8hr.  All cause mortality within 4 weeks was significantly reduced 
in the TXA group vs. placebo (14.5% vs. 16%, RR 0.91(0.85-0.97)).  Death from 
haemorrhage was also reduced (4.9% vs. 5.7%, RR 0.85 (0.76-0.96).  TXA therapy 
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has recently been recommended for bleeding trauma patients in a Cochrane review 
(72). 
 
Modern massive transfusion strategies, including those now employed by the UK 
and US militaries; recognise the importance of early factor replacement.  Aggressive 
protocols recommend plasma administration at ratios of 1:1 with packed red cells. A 
retrospective study of 246 combat casualty patients, (median ISS=18), who 
underwent massive transfusion was performed, based on Joint Theatre Trauma 
Registry data (73).  It remarkably improved mortality rates with high FFP:PRBC 
ratios (65% with 1:8 ratio vs. 19% with 1:1.14 ratio (p<0.001).  Despite some 
difficulties with the equivalence of groups in terms of injury severity, the mortality 
rates remained significantly different as ratios increased from 1:8 (FFP:PRBC) to 
1:1.14; even when thoracic and neuro-trauma patients had been excluded from the 
cohorts. While retrospective, this data nevertheless supports expert consensus that 
high ratio FFP and factor replacement protocols should be used in the management 
of haemorrhaging trauma patients. The UK military massive transfusion protocol is 
illustrated below (Figure 1).  
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Figure 1 UK Military Massive Transfusion Protocol. Taken from Joint Doctrine Publication: Clinical Guidelines 
for Operations: management of massive haemorrhage on operations. Section 8, Policy 2, 2009:21-3 (JDP 4-
03.1). 
Consumption of Clotting Factors 
Explosive injury can generate enormous tissue damage (74).  Tissue injury initiates 
coagulation as endothelial damage exposes sub-endothelial collagen and tissue 
factor (TF).  These bind Von Willebrand factor, platelets and activated FVII (75).  The 
FVIIa/TF complex activates factors X (and co-factor V) to initiate the process of 
thrombin generation.  TF also activates factor IX which then mediates the 
propagation phase of coagulation on the surface of activated platelets (76). 
Widespread activation of coagulation, at numerous sites of endothelial damage, 
results in consumption of circulating coagulation factors and platelets (77).   
 
As well as inducing thrombin generation, tissue injury and ischaemia promotes 
fibrinolysis as endothelial damage releases tissue plasminogen activator (tPA) (78).  
The presence of thrombin can also act as an anticoagulant.  Thrombomodulin binds 
thrombin both to impair its capacity for fibrinogen cleavage and to facilitate binding 
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with Protein C (79).  Activated Protein C inactivates cofactors Va and VIIIa therefore 
limiting the progression of clotting (80).  As widespread activation is controlled by this 
mechanism, inactivated cofactors build up in the local environment. Clearance of 
these inactivated factors is impaired and these then interfere with active factor 
complex assembly (81).  In a situation of limited tissue injury, a balance is achieved 
between controlling bleeding at the site of injury and limiting widespread 
inappropriate activation of the coagulation system.  With extensive tissue insult, 
however, this localisation may be lost (82), so developing a state of both excessive 
clot formation and hyperfibrinolysis.  The net result is consumption of available 
coagulation factors. Despite initiating both coagulation and fibrinolysis, tissue injury 
alone may not be enough to generate clinical coagulopathy (83).  More likely, it 
contributes to the problems generated by acidosis, hypothermia, dilution and the 
acute coagulopathy of trauma shock.  
Clotting Factor Environment 
Trauma and hypovolaemic shock effect major changes on the intravascular and 
interstitial environment.  Among these changes, acidosis and hypothermia have 
particular relevance to coagulopathy.  Cosgriff  highlighted the contribution of 
acidosis and hypothermia to development of life-threatening coagulopathy (66).  Of 
the four risk factors for identified in the study, acidosis was the most important and 
hypothermia the second most influential.  
 
Laboratory studies by Meng et al have illustrated dynamic changes in activities of 
factor VIIa and the VIIa/TF complex as acidosis develops (84). At a pH of 7, activity 
of FVIIa falls by 90% and the activity of the VIIa/TF complex by 60%.   
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Martini and colleagues induced acidosis in anaesthetized swine via hydrochloric acid 
infusion (85).  Animals were then subjected to a standardized liver laceration.  
Acidosis increased splenic bleeding time by 47% compared to controls.  Fibrinogen 
concentration fell by 18%.  Thrombin generation in acidotic animals was over 50% 
reduced compared to controls. 
 
It is thought that excess hydrogen ion concentrations interfere with interactions 
between coagulation proteins and complexes and the negatively charged 
phospholipid activated platelet surface (86). 
  
Hypothermia has been reported on admission to hospital in two thirds of seriously 
injured patients (87).  Severe hypothermia in the operating theatre in patients 
undergoing trauma laparotomy (temp 33.8 +/- 0.5°C) resulted in a 2.4 fold increase 
in blood loss, compared with an injury severity-matched group, whose temperature 
was 36.1 +/- 0.7°C (88). 
 
Laboratory studies have assessed the effects of hypothermia on coagulation factor, 
platelet and TF/VIIa complex activity (84;89).  Watts studied 112 adult trauma 
patients with ISS>9 fewer than 2 hours post-injury (89).  64% were hypothermic and 
6% were severely hypothermic with temperatures below 34°C.  34°C was found on 
multivariate analysis of TEG, PT and APTT to be the critical point, below which there 
was significant decrease in enzyme activity and platelet function.  Fibrinolysis was 
not however affected.   
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Cosgriff’s study, mentioned earlier in this section, demonstrated that core 
temperature below 34ºC increased the odds of developing life-threatening 
coagulopathy by nearly nine-fold (66). 
 
In response to current understanding of the dangers of hypothermia, modern trauma 
systems seek to prevent hypothermia at all stages of evacuation and resuscitation 
and it is now a rare occurrence for a military trauma patient to experience severe 
hypothermia (90). 
Acute Coagulopathy of Trauma Shock and Protein C Pathway 
Shock has recently been described as the prime driver of coagulopathy early after 
injury, with severity and duration of hypoperfusion influencing the impact (91).  A 
base-deficit >6mM suggests significant hypoperfusion and was associated with 
coagulopathy in 25% of admitted patients at The Royal London Trauma Centre (16).  
Mortality was increased 4-fold in those patients with coagulopathy on arrival.  
Coagulopathy in the acute stage (approximately 30 minutes post injury) was 
independent of injury severity score, and only occurred with hypoperfusion.  There 
were also no changes in fibrinogen levels in any patients.  This suggests that 
hypoperfusion is a key driver of early coagulopathy and that dilution and factor 
consumption are not responsible at this stage (91).  The mechanisms of this early 
(arrival at trauma centre) coagulopathy have been attributed to activation of 
Thrombomodulin-Protein C pathway and fibrinolysis.  Hypoperfusion after injury 
increases Thrombomodulin, which impairs thrombin’s ability to generate fibrin and 
instead prompts activation of protein C.   Activation of Protein C results in 
prolongation of PTT and PT clotting times and increased fibrinolysis with raised tPA 
levels (91).  Increased thrombomodulin levels and reduced (un-activated) Protein C 
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levels were associated with increased mortality, blood transfusion requirements and 
organ injury rates (91). Later on in a patient’s progress from time of injury, the effect 
of widespread activation of Protein C might be consumption of (unactivated) stores.  
This could lead to a depletion of Protein C pathway activity and the relative 
hypercoagulability that is seen hours or days after injury (91). 
Blast Induced Hypercoagulability 
Previous experimental work at DSTL has demonstrated a hypercoagulative state that 
begins ‘ultra early’ after primary blast wave exposure in anaesthetized swine, and 
which is visible on Thromboelastography (TEG) analysis (93). The first samples to 
demonstrate the hypercoagulability were drawn almost immediately following blast 
wave exposure.  The hypercoagulability persisted over the next hour, during which 
the animals sustained 30% haemorrhage and received hypotensive normal saline 
resuscitation.   The animals later became hypocoagulable.  Brohi’s paper, which 
demonstrated ‘early’ hypocoagulability, looked at early clotting dynamics in seriously 
injured civilian trauma patients, 75% of whom had suffered blunt injury and none of 
whom had sustained primary blast injury (16).  The DSTL work looks at ’ultra early’ 
(minutes from blast until 1 hour post injury) effects of trauma on clotting and 
demonstrates hypercoagulability after blast injury. The mechanism of this ultra-early 
hypercoagulability is unclear, but it is possible that blast injury exposes enormous 
quantities of tissue factor to circulating blood, causing un-localised activation of the 
coagulation process.  
Inflammation and coagulopathy 
It is increasingly clear that coagulation and inflammatory pathways overlap (92).  
Coagulation factors induce inflammation via protease receptors and complement 
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activation.  Also, monocytes can express TF and adhere to activated platelets to 
promote coagulation.    
 
Initially, haemorrhaging trauma patients tend to be hypocoagulable (16), but later, 
through inflammatory pathways and perhaps depletion of anticoagulant stores (91), 
they become hypercoagulable with increased risk of thrombotic events.  A detailed 
examination of inflammation following haemorrhage and coagulopathy is beyond the 
scope of this thesis.  However, some important markers of inflammation are 
discussed later (2.1.5) in order to provide context for results of inflammatory markers 
used in this study. 
 
The diagram below (Figure 2) integrates the concepts discussed in this section and 
affords a modern perspective on trauma coagulopathy. 
 
Figure 2 Hess JR et al.  Mechanisms of Coagulopathy following Trauma.  Reproduced from  (94) 
2.1.5 Markers of Inflammation following haemorrhage 
The majority of deaths from trauma occur either at the scene, or within the first 24hrs 
of injury, but a later phase of deaths (>48hr to weeks after injury) also occurs in 
those who have survived the first two days following trauma (7).  Systemic 
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inflammation is considered a key driver of conditions such as ARDS, sepsis and 
Multi Organ Failure (MOF): common causes of these late trauma deaths (5).  The 
inflammatory response to injury tends to peak around days 3 to 5 and begins to 
subside by days 7-10 (95). An individual’s progress towards either recovery or 
demise is influenced by: injury severity; duration of hypoperfusion; pre-injury 
physiological reserve; delay until adequate treatment and the presence of 
subsequent insults (95). Figure 3 illustrates the concept of initial shock followed by 
hyper-inflammation and the possibility of further organ failure over the ensuing days 
to weeks. What causes some patients to recover without complications, while others 
(similarly injured) succumb to later complications is not yet clear. 
 
  
Figure 3 Patterns of Inflammatory Response following initial survival from injury.  Modified from (95) 
 
Recent work has questioned the established notion that anti-inflammatory processes 
sequentially follow initial hyper-inflammation predisposing to second hits and that 
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these hits induce further gene expression changes.  Xiao and colleagues measured 
genome-wide expression in collected leukocytes within 12hr out to 28 days in 167 
severe blunt trauma patients (mean ISS 31) who were shocked or acidotic and 
required blood product transfusion (96).  Gene expression was compared with 37 
healthy controls and analysed within the trauma group based on complicated or 
uncomplicated recovery.  Their data illustrated rapid alteration of over 80% of the 
genome’s expression, which was maintained up to 28 days: the authors refer to the 
term, ‘genomic storm’. Rather than a discreet inflammatory phase, followed by anti-
inflammatory expression, there was simultaneous expression of pro and anti-
inflammatory genes.  Further, there was no evidence of a second hit in terms of gene 
expression profiles.  Complicated recovery resulted in longer alteration of gene 
expression, but neither new gene recruitment, nor dropout compared to those with 
uncomplicated recoveries.   Strategies that manipulate the balance between 
inflammatory and anti-inflammatory pathways have the potential to reduce 
complication rates after injury.  
 
While it is important to understand the importance of inflammation after haemorrhage 
and trauma, a complete review of inflammation is beyond the scope of this thesis.  
However, certain molecules, from among the whole range of mediators involved in 
inflammation, have been used as markers of inflammation in both experimental and 
clinical practice; some have been shown to correlate with organ failure and death.  
The inflammatory markers used in our study merit discussion in this section.   
2.1.5.1 Inflammatory Cytokines 
Cytokines are small protein molecules, released by many types of cell, that influence 
interactions with and behaviour of other cells. During inflammation, both pro- and 
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anti-inflammatory cytokines are produced.  Tumour Necrosis Factor, Interleukin-1 
and Interleukin-6 have been implicated in sepsis pathways and the inflammatory 
response (97).   
 
Interleukins are a family of cytokines and many have been described.   
Interleukin-1 
IL-1 cytokines has several effects in inflammation.  IL-1 receptors exist in both 
membrane bound and soluble forms.  IL-1 is present in the epidermis of normal 
human skin and is vital for the maintenance of effective skin barrier against 
microorganisms (98).  Many other immune cells can also be stimulated to produce 
IL-1 including: macrophages; mast cells; fibroblasts and endothelial cells. 
 
IL-1 induces the release of other factors, including Prostaglandin E2, collagenase 
and nitric oxide and increases expression of adhesion molecules on endothelial 
cells; a function it shares with TNF (TNF can also increase neutrophil adhesion 
molecule expression).   Alongside TNF, it has been implicated in the development of 
septic shock (99). TNF and IL-1 both rise following ischaemia/reperfusion injury in rat 
models (100).  The same experiments demonstrated that a rise in these cytokines 
was associated with Interstitial oedema formation (101). 
Interleukin-6 
IL-6 functions as both a pro-inflammatory and anti-inflammatory cytokine. It is 
principally secreted by T-cells and macrophages, but can also be produced by 
exercising muscle, osteoblasts (102) and vessel wall muscle cells.  It is one of the 
most important acute phase mediators.  It can cross the blood-brain-barrier (BBB) 
and acts on the hypothalamus to alter the baseline temperature threshold (103).  
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This produces pyrexia.  It also stimulates catabolism of protein and mobilisation of 
lipid reserves, both of which processes generate heat.  As such, IL-6 is a strong 
driver of fever.  
 
IL-6 levels are raised within minutes after trauma and their levels correlate with injury 
severity and mortality as early as six hours after injury (104).  As such, IL-6 can be 
used as both a marker of injury extent and a prognostic tool (105).   
Tumour Necrosis Factor (TNF) 
Although TNFα is an important mediator of inflammation in sepsis, and can be 
elevated in some species after trauma, it does not appear to play a major role in 
porcine models of trauma (106), and for the sake of brevity will not be considered 
further in this thesis. 
2.1.5.2 Adhesion molecules 
As endothelial cells line blood vessels, effects of their damage correlate closely with 
organ dysfunction (107). In normal conditions the endothelium displays anticoagulant 
and anti-platelet surface properties.  Following injury, the endothelium plays an 
important role in the orchestration of the inflammatory response.  Activated 
neutrophils in the tissues are critical protagonists of the tissue damage and organ 
dysfunction (108;109).  In order for neutrophils to migrate from the intravascular 
compartment to the tissues, they must interact with, and then cross, the endothelium.  
Cell adhesion molecules facilitate this process and they are derived from three 
families:  the Immunoglobulin super-family; the Integrins  and the Selectins 
(110;111).  Three steps, adhesion (rolling), tethering and diapedesis have been 
characterised in this process of migration of neutrophils from the blood to the tissues.   
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Haemorrhagic shock and subsequent resuscitation represents a ‘whole body’ 
ischaemia-reperfusion injury (112).  Prolonged cellular hypoxia and subsequent 
reperfusion produces endothelial cell swelling, loss of cytoskeletal organisation and 
altered membrane dynamics (113).  This occurs particularly in the post-capillary 
venules.  This damage results in: leukocyte adhesion; trans-endothelial migration; 
platelet and leukocyte aggregation and oxidative molecule formation.  If localised this 
contributes to the classic features on inflammation (pain, swelling, heat, redness and 
loss of function).  Widespread endothelial damage can lead to multiple organ 
dysfunction syndromes and death. Adhesion of neutrophils is a key step in the 
inflammatory response following ischaemia-reperfusion injury (108). Markers of 
activation in this pathway to inflammation after injury are relevant to studies 
investigating different resuscitation strategies for haemorrhage and blast injury.   
Selectins 
Three Selectins have been described: L-Selectin; E-Selectin and P-Selectin.  All 3 
are lectin-domain glycoproteins (111). Selectins are responsible for the first step in 
the process of neutrophil migration: ‘rolling’.  Rolling slows neutrophil transport along 
the endothelium and allows firm attachment, which is required before transmigration 
can occur (114).  Leukocytes begin to roll along venule walls within minutes after 
tissue reperfusion (115) and Selectin levels remain high for at least 2 hours (116).  
Both in vitro and in vivo studies have examined the contributions of Selectins to 
leukocyte accumulation and migration (117) and they are implicated in remote tissue 
injury following ischaemia-reperfusion (114). 
 
L-Selectin is expressed on the surface of most circulating neutrophils, eosinophils 
and monocytes (118) and shed from their surface following activation by cytokines 
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(119). L-Selectin mediates rolling attachment of neutrophils to cytokine-stimulated 
endothelium, even in the absence of neutrophil activation (111;120).  Vedder 
demonstrated improved survival following haemorrhagic shock by treating rabbits 
with anti-L-Selectin antibodies (108). Schlag and colleagues employed anti-L-
Selectin antibodies in primates following haemorrhagic shock and found improved 
mortality, haemodynamics, organ damage and reduced fluid requirements in the L-
Selectin-blocked group (121). 
 
P-Selectin is stored in basal conditions within Weibel-Palade bodies of the 
endothelial cytoplasm and within α granules of platelets (109;122).  Within 5 minutes 
it is  exported to the cell surface, following activation by Thrombin; Histamine and 
cytokines (109;111;122)  It is therefore the first adhesion molecule to be expressed 
on the endothelial cell after trauma (109).  After 3-4hr its expression can also be 
induced by TNF and lipopolysaccharide (122).  P-Selectin mediates rolling of 
neutrophils, as well as facilitating platelet adhesion to activated neutrophils and 
monocytes (111). The importance of P-Selectin in leukocyte-endothelial adherence 
following haemorrhage and reperfusion has been demonstrated in several 
experimental studies.  Scalia employed a mouse model of ischaemia-reperfusion, 
where P-Selectin deficient mice and those given monoclonal antibodies to P-
Selectin, were compared to wild type controls (115).  MAP was significantly higher 
following 45min ischaemia in P-Selectin-blocked subjects.  Leukocyte rolling 
increased threefold from baseline very soon (few minutes) after reperfusion in 
subjects with intact P-Selectin, but remained at baseline levels in those groups with 
P-Selectin deficiency or monoclonal antibody.  The same study also demonstrated 
significant reductions in neutrophils within liver, lung and intestinal tissues following 
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reperfusion in P-Selectin deficient subjects (115).  Another small animal model 
demonstrated survival increase following severe haemorrhage and resuscitation, 
from 30% to 70% at 3 days in the P-Selectin-blocked group (109).  Liver injury 
parameters were also decreased in the P-Selectin –blocked group.  A clinical study 
has demonstrated the prognostic significance of raised soluble P-Selectin levels in 
acute lung injury (123).  
 
E-Selectin requires synthesis within endothelial cells and therefore takes 
approximately 4 hours to peak following cytokine activation of endothelium (124).  
Like the other Selectins, E-Selectin’s function is to facilitate neutrophil rolling (111). 
 
Ramos-Kelly and colleagues used a Sialyl Lewis antagonist molecule, known to 
block L-Selectin, P- and E-Selectin, in an uncontrolled haemorrhagic shock model in 
rats (125). Treatment resulted in survival advantage at 3 days of 80% compared to 
20% in untreated controls.   There was also a significant reduction in liver enzymes, 
myeloperoxidase and histological evidence of hepatic parenchymal destruction. 
Cellular Adhesion Molecules (ICAM, VCAM and PECAM) 
Once the (Selectin-mediated) process of rolling along the endothelial wall has 
occurred, the next phase in the interactions between leukocytes and the endothelium 
involves firm adherence of leukocytes to the endothelium.   
 
Leukocytes express ‘binding proteins’ on their surface, which enable them to adhere 
to activated endothelium.  Neutrophils express two surface monomers: CD11 and 
CD18.  The pair forms a complex, CD11/CD18. This complex is the ligand for ICAM-
1.  Both are required for leukocyte adherence to endothelial cells and subsequent 
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migration into tissues, so the CD11/CD18 – ICAM-1 interaction is pivotal in 
neutrophil mediated inflammation within tissues (108;126).  
ICAM-1 
ICAM-1 is a cell-surface molecule.  It can be expressed on several cell surfaces, 
including damaged or activated endothelial cells and alveolar pneumocytes (127).  
ICAM-1 expression is potentiated by the pro-inflammatory cytokines(128), Tumour 
Necrosis Factor (TNF)-α and Interleukin (IL)-1(129) and by activated platelets (130).   
In addition to facilitating binding of leukocytes via the CD11/CD18 ligand, ICAM-1 
expression reduces the barrier function of the endothelium and thus further enables 
leukocyte migration into the tissues (131).  Soluble ICAM-1 can be detected in blood 
using PCA techniques and can therefore be used as a marker of systemic 
inflammation and endothelial damage.  Circulating levels of ICAM-1 increase within 4 
hours of haemorrhagic shock and remain raised at 24hr (132). Following 
haemorrhagic shock in rats, ICAM-1 was expressed in gastrointestinal smooth 
muscle and associated with neutrophil invasion and muscle dysfunction. Sun et al 
demonstrated almost immediate up-regulation of both ICAM and vascular cell 
adhesion molecule (VCAM) in a rat model of haemorrhage and fluid resuscitation 
(133).  Both ICAM-1 and VCAM were elevated in the lung and spleen and associated 
with tissue injury. In the lung, ICAM-1 can be expressed on type-1 pneumocytes and 
capillary endothelium.  Expression is rapidly up-regulated in Goodpasture’s 
syndrome, a pathology which results in diffuse alveolar haemorrhage (134).  ICAM-1 
expression was associated with early influx of activated neutrophils (1.5hr) and later 
accumulation of macrophages (6hr). 
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ICAM-1 expression has been examined in clinical studies of trauma patients and in 
sepsis.  A correlation exists both between the degree of trauma and ICAM-1 
expression, and between initial levels of ICAM-1 and subsequent development of 
MOF(135).  ICAM-1 levels increase following haemorrhagic shock and predict 
mortality at day 0 in sepsis (136). 
 
 
VCAM-1 
A second member of the Immunoglobulin family is VCAM-1, which is also expressed 
on activated endothelium.  Like ICAM-1, VCAM-1 mediates the adhesion of 
leukocytes through interaction with Very Late Antigen-4 (an Integrin expressed on 
activated leukocyte surface) (111). Up-regulation of VCAM-1 is stimulated by 
cytokines such as TNF and IL-1.  Sun’s rat model of haemorrhage and resuscitation, 
demonstrated an almost immediate up-regulation of VCAM in spleen and lung tissue 
(133).  As for ICAM, raised VCAM levels were associated with tissue injury. Another 
clinical study assessed admission adhesion molecule levels after both trauma and 
sepsis (137). While sepsis produced higher levels of adhesion molecules than did 
trauma, for both pathologies, mortality was associated with raised VCAM-1 levels. 
Platelet Endothelial Cell Adhesion Molecule (PECAM-1) 
PECAM-1 is the third member of the Immunoglobulin super-family involved in 
leukocyte-endothelial interactions.  In vessels, it is highly concentrated around the 
junctions between endothelial cells and is a key player in the final step in leukocyte 
migration into the tissues (138).  It is also expressed on the surface of platelets and 
leukocytes. After Selectins, Integrins, and their ligands, have achieved ‘rolling’ and 
‘adhesion’, leukocytes need to cross into the tissues.  PECAM-1 blockade with 
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monoclonal antibody reduces trans-endothelial migration by 70 to 90% (138). 
Blockade of PECAM-1 also reduces neutrophil accumulation and suggests therefore 
a role also in neutrophil recruitment (139). Animal studies of ischaemia-reperfusion in 
the myocardium have demonstrated reduced infarct size in PECAM-1-blocked 
subjects (139).  
2.1.5.3 Summary of Inflammatory Markers 
We focussed on two Integrins in our study, ICAM and VCAM.  These have been 
shown to rise rapidly in injured ling tissue before being shed into the circulation for 
systemic analysis using PCR techniques.   Their expression correlates with mortality 
in a clinical trauma study.  Analysis will highlight any significant differences between 
groups and should therefore reflect the impact of the different adjuncts to 
resuscitation on post-injury inflammation. 
2.2 Blast Injury 
As mentioned previously (1.4), blast injuries represent an increasing threat to civilian 
and military populations. 
2.2.1 Physics of Blast 
Explosives can generate an explosion from within their own substance.  They may 
be termed ‘high’ or ‘low’ explosives:  low explosives (black gunpowder) burn, rather 
than detonate.  High explosives, such as Tri-Nitro-Toluene (TNT), detonate very 
rapidly with blast wave velocities reaching 7000m/s in air.  Their ability to release 
enormous amounts of energy over a very short time is integral to explosives’ 
enormous power as weapons. 
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On detonation, chemical bonds begin to decay in an exothermic chain, and 
temperature rises exponentially.  While contained within the charge, this hugely 
increases pressure, forming a supersonic detonation wave which propagates 
through the explosive.  A detonation wave describes a shock, supported by a trailing 
exothermic reaction.  This wave travels through the highly combustible medium (e.g. 
high explosive) and is driven by the chemical energy released from the trailing 
exothermic process.  As the detonation wave reaches the limits of the explosive it 
generates a ‘shock wave’ in the surrounding medium (normally air), by compressing 
a rim of air around the sphere of explosive products. The pressure rise from the 
resultant shock wave lasts only a matter of milliseconds, too short a time for 
significant translational effects to be exerted on victims, but nevertheless capable of 
causing significant injury.  In enclosed environments (buildings or vehicles), 
reflection of the shock wave results in amplification of overpressure and formation of 
complex blast waves, increasing the chance and severity of shock wave injuries 
(32;140). 
 
The heated cloud of gaseous explosive products initially expands supersonically and 
remains attached to the shock wave rim of compressed air. However, as gases 
expand, they cool and slow down, so the sphere’s velocity falls to subsonic speeds. 
At this point the shock wave detaches to continue its journey through the 
atmosphere (Figure 4). Therefore, close to the explosion, the blast wave comprises a 
high pressure shock wave and adjoined heated gas products.  Further away, 
gaseous products are absent. 
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Figure 4 Separation of Shock Wave (black arrows) and Expanding Gaseous Sphere 
 
The Friedlander waveform (Figure 5) offers a clear illustration of pressure changes 
after detonation of an explosive in a free field environment.  Pressure changes are 
recorded at a given point over time. There is a virtually instantaneous rise in 
pressure; the maximum amplitude is termed ‘peak overpressure’.  As the wave 
passes the given point, pressure rapidly decreases, falling beyond atmospheric 
pressure because of initial overexpansion, before recovering to baseline.   
 
Figure 5 Friedlander's 'Ideal Blast Wave' 
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The peak overpressure of a shock wave declines rapidly as it propagates through 
the atmosphere in an inverse cube relation (distance x 2 → amplitude / 8) (Figure 6).   
 
Figure 6 Attenuation of Peak Overpressure with Distance 
As well as increasing air pressure, expanding gases accelerate the surrounding 
medium (air or water).  This mass movement of air is called ‘the dynamic 
overpressure’ or ‘blast wind’. This dynamic overpressure, a separate entity from 
the cloud of gaseous products, lasts long enough to produce significant translation of 
objects in its path.   
 
Together, the shock wave and the dynamic overpressure are termed, ‘blast wave’.  
Aside from these elements, one must remember that the casings of explosive 
munitions, (often preformed metallic fragments), become energised by the explosion.  
If these collide with people, penetrating injury will result.  Furthermore, exposure to 
the heated gases of an explosion can wound through burning and inhalational injury. 
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2.2.2 Classification of Blast Injuries 
Zuckerman classified blast injuries into four groups (Table 1) (34).  A fifth group, 
recently proposed by Kluger, involves a hyper-inflammatory response to blast, seen 
in victims of a high explosive Penta-Erythrittol -TNT suicide bombing in Israel (141).  
Type of Blast Injury Mechanism of injury 
Primary Interaction of shock wave with body 
Ear, lung, abdominal hollow viscera, (brain) 
Secondary Energised bomb fragments and debris, or environmental 
debris accelerated by blast wind 
Penetrating trauma 
Tertiary Translational Effects - body thrown by blast wind 
Blunt trauma from impact, or crush from building collapse 
Quaternary Other miscellaneous effects  
Psychological; burn; radiation and inhalational injury 
(Quintinary) Hyper-inflammatory response to PE-TNT explosion 
Table 1 Zuckerman Classification of Blast Injuries (34) 
 
Primary blast injuries occur when a shock wave interacts with the body.  As the 
shock wave encounters materials of differing densities it is coupled into the body.  
Once within the body, as the wave encounters materials of differing acoustic 
impedance, energy is deposited.  This causes injury predominantly at gas-tissue 
interfaces such as the lung and bowel.  The brain too is increasingly believed to be 
affected by primary blast injury; although the mechanism is likely to be different here 
as there is no gas-tissue interface in the brain (142;143).  Solid organs are relatively 
protected from blast (Mayo and Kluger 2006) and the skin is also resistant; indeed 
casualties with serious blast injuries may exhibit few or no visible external signs of 
injury (144;145).   
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Secondary blast injury results from fragments and other missiles, energised by the 
explosion, colliding with the body.  Explosive munitions may have metallic casings, 
or house pre-formed fragments in order to maximise the fragment burden. These 
fragments and missiles will cause predominantly penetrating injury and, following 
conventional munition detonation in open areas, will be responsible for the majority 
of injuries from blast (30). 
 
Tertiary blast injury occurs when the body is accelerated by the dynamic 
overpressure of the blast wave.  Victims can be thrown against objects and limbs 
can be amputated or stripped by the force.  In the case of lower limb amputation 
from blast, it is believed that the shock wave fractures the tibia and the blast wind 
then strips the soft tissues to complete the amputation (146).  
 
Quaternary injuries include a miscellaneous group of mechanisms, such as burns; 
inhalational injury; crush and asphyxiation. 
 
The overall trauma burden from each type of blast injury depends on the quantity 
and nature of the explosive; the design of the explosive device; the standoff of 
casualties from the blast and the environment in which detonation occurs.  It is 
therefore difficult to predict.   Table 2 gives some idea of the scale of gross damage 
and injury one might expect with various overpressures, assuming a 4 millisecond 
duration (147).   
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Overpressure (KPa) Probable effect 
7 Damage to standard buildings and windows break 
14 Slight risk of perforation of tympanic membrane  
100 50% chance of tympanic membrane rupture 
275 Reinforced structures suffer significant damage 
480 50% chance of marked pulmonary damage 
900 50% mortality risk 
Table 2 Likely effects given 4ms exposure to blast overpressure - adapted from (147) 
 
In 1968, Bowen produced curves to estimate threshold for lung injury and lethality 
based on amplitude and duration of overpressure and position of a 70kg man with 
respect to free field blast wave propagation (148). Later, Cooper and colleagues at 
Dstl produced injury modelling in 16-60Kg swine with 2ms overpressure (149) and 
Yang and colleagues exposed sheep (15-42Kg) to blast overpressures of up to 5ms 
duration (150).  The lethality and lung injury thresholds for these experiments are 
presented together in Courtney’s recent article relating to traumatic brain injury 
(151). 
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Figure 7 Lethality and Lung damage thresholds from experimental data. Bowen curves, Coopers’s 2ms swine 
overpressure data to produce respiratory tract injury (A) and Yang’s lung injury threshold (B1) and overpressure 
required to produce severe lung injury (B2) given 5ms overpressure in sheep.  (Reprinted from (151) with 
permission) 
 
There is clearly significant variation in observed lung injury threshold, even in 
laboratory conditions.  Furthermore, other authors in small animal models have 
demonstrated antioxidant depletion in the lungs after single low overpressure blast 
(62KPa).  This depletion occurs in the absence of macroscopic lung tissue damage 
and is accompanied by inflammation that progresses beyond 24h (152).  It is 
therefore probable that we underestimate the true incidence of microscopic blast 
lung and potential vulnerability of lung tissue to secondary damage.  
 
As mentioned previously, fragments (secondary blast injury), cause the most injuries 
in an open environment.  The amplitude of the shock wave declines very sharply with 
increasing stand off from the explosion.  For an unprotected individual in an open 
environment, secondary blast injuries are therefore likely to be more common in 
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survivors than primary blast injuries.    Taking the example of a commonly used 
indirect fire munition, the 81mm mortar, these rules can be related to a clinically 
relevant prediction of damage.  The 81 mm mortar typically contains about 1Kg of 
TNT.  If set to ground detonation, an overpressure peak of 1300KPa will occur at a 
stand off of one metre.  By two metres, however, this peak pressure has declined to 
280KPa.  The overpressure would last for 2ms.  At 2 metres, the pressure and 
duration are below the threshold for lung damage (149).  It is therefore unlikely that 
an 81mm mortar round will result in primary blast injury; instead it will injure through 
penetrating injury (secondary blast effects) from energised metallic casing 
fragments.    
 
The likely burden of blast injury may, however, change.  Improvements in combat 
body armour will increase survivability for a given fragment burden, potentially 
affording survival within the zone of danger for primary blast injury. Also, the 
deployment of enhanced blast weapons (153) is likely to increase.  These carry little 
fragment burden, but possess the capability to produce prolonged blast 
overpressures over a wide radius.  Civilian terrorist attacks have already exploited 
the influence of creating explosions in confined spaces, where reflection 
amplification of the shock wave increases the chance and severity of primary blast 
injury (140;154;155). 
2.2.3 Primary Blast Injury 
Blast lung injury is the most important factor with regards mortality after exposure to 
a blast wave (149).  The term blast lung describes direct damage to the organ 
produced by the shock wave of an explosion: hypoxia can result from pulmonary 
contusions, pneumothoraces; haemothoraces; air emboli and oedema, but contusion 
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and pulmonary oedema are most common (34;156).  Blood enters the alveoli, 
reducing their capacity to exchange gas.  The degree of injury can range from 
occasional petechiae to widespread and contiguous haemorrhage of the entire lung.  
The amplitude and duration of the blast overpressure correlate with the extent of 
lung injury (157).  
 
Figure 8 Pulmonary Contusion in Porcine right lung 
 
Table 3 summarises the progress of blast lung over time.  While contusions can 
affect both lungs, they are often confined to the lung nearer the explosion.  A 
physiological redirection of blood to better ventilated (uninjured) regions occurs.  
Lung oedema follows alveolar haemorrhage and an acute inflammatory response 
occurs. Interstitial oedema reduces the compliance of a contused lung, increasing 
the work of breathing and leading to hypoxia (158).  In more severe cases this can 
later develop into the Acute Respiratory Distress Syndrome (ARDS).  Although the 
extent of the lung injury can propagate up to days after exposure (159), the worst of 
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the respiratory compromise will normally occur within the first 72 hours (158).  This is 
a condition which can, at first, appear relatively benign, but later develop into 
profound respiratory failure.  This not only presents a triage challenge to clinicians, 
but also directs research into the pathophysiology and early treatment of blast lung.   
 
Time  Event Clinical Features CXR 
0 (h) 
Shock Wave Hypoxia 
Tachypnoea 
Haemoptysis/Cough 
Pneumothorax 
Haemothorax 
Retinal air emboli 
Contusion 
Pneumothorax 
Haemothorax 
Emphysema 
Rib Fracture 
Alveolar capillary rupture 
Interstitial and alveolar haemorrhage 
Redirection of blood flow 
Reduced Lung Compliance 
3 
Free Hb & blood 
Hypoxic resp. failure 
High airway pressures 
Contusion 
Oedema 
Free radical reactions / Oxidative Stress 
Pro Inflammatory Response / Chemotaxis 
Increasing Oedema 
12-72 
Leukocyte Accumulation 
Disrupted tissue architecture ARDS 
SIRS 
MOF 
Diffuse 
pulmonary 
infiltrates 
Increased oxidative stress 
Increased Inflammation 
Increasing Oedema 
5 -10 
days 
Resolution 
Improved gas exchange 
Improved compliance 
Resolution of 
lung contusions 
Table 3 Natural History of Blast Lung 
2.2.4 Pathology of Blast Lung 
Irwin outlines three mechanisms of lung damage that have been described due to 
the blast wave of an explosion: ‘spalling’; ‘implosion’ and ‘inertial damage’ (160). 
 
Spalling occurs at tissue/air interfaces.  Cavitation and turbulence ‘throws’ the 
denser media (lung tissue) into the less dense media (air).   
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Implosion occurs as the shock wave passes through gas containing organs.  There 
is a rapid compression and decompression of the gas; instantaneous expansion of 
this gas causes small ‘secondary explosions’. 
 
Inertial damage describes shearing forces that occur because the pressure wave 
accelerates tissues with differing densities. 
 
These effects can produce: alveolar capillary rupture; extravasation of blood and 
fluid into the alveoli and interstitium; pneumothorax; air embolism and even massive 
pulmonary haemorrhage. 
 
Electron microscopy of blast wave-exposed rat lungs demonstrated capillary rupture; 
intra-alveolar haemorrhage; tearing of the inter-alveolar septa; changes to the 
epithelium and type II pneumocytes (156).  In lung less exposed (on the far side from 
the focus of the blast) there were oedematous changes within the interstitium and 
alveoli, capillary endothelial swelling and alveolar rupture.  
 
Aside from impairing diffusion directly, the resultant free haemoglobin within alveoli 
following blast wave exposure has been shown to augment the inflammatory 
response to blast lung through increased oxidative stress.  This occurs rapidly (within 
a few hours) and can progress for 24h or more.  The evidence for this process is 
discussed later (3.2.6).   
2.2.5 Cardio-Respiratory Physiological Consequences of Blast 
In addition to the direct effects on lung tissue, significant physiological responses 
occur.  Hooker described a ‘condition of shock which was unrelated to obvious 
69 
 
trauma since no external wounds were visible’  in soldiers exposed to the 
‘concussion of large shells’ during the First World War (144).  As for the biphasic 
response to simple haemorrhage, the cardio-respiratory response is largely 
mediated by the autonomic nervous system, but other mediators such as Nitric 
Oxide (NO) contribute.  
 
During the Second World War, Barrow described bradycardia and hypotension in 
200 soldiers after air blast exposure (161).  More recently, Irwin noted hypotension in 
survivors of the Oklahoma bombing in 1995, despite apparent absence of external 
injury (160).   
 
Most work on the physiology of primary blast injury employs animal experiments.  
Hooker pioneered this work in the 1920s, when he studied muzzle blasts in dogs and  
noted changes to the pattern of respiration and blood pressure (144).  
 
While blast lung is the most life-threatening problem after exposure to a blast wave, 
a rapid-onset triad of cardio-respiratory reflexes also occurs; characterised by 
apnoea (162-164), bradycardia (160;161;164;165) and hypotension 
(161;162;165).  These reflexes may be immediately fatal (asystole), or contribute to 
the mortality from accompanying injuries victims of an explosion are likely to have 
suffered.   
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Figure 9 Blast pad traces of ECG and respiratory pattern from a typical animal.  Green dotted line represents 
moment of blast exposure.  Respiratory pattern detected via thermocouple device attached to endotracheal tube.  
Increased temperature of exhaled breath produces upwards deflection in trace pattern. 10s scale line drawn to 
illustrate duration of apnoea and bradycardia. 
 
Vagal afferent and efferent activity has been implicated in these reflexes (160;162).  
Ohnishi exposed rats to primary thoracic blast, or sham blast and recorded 
breathing, heart rate and blood pressure immediately after exposure (166).  Animals 
exposed to blast demonstrated almost immediate apnoea, bradycardia and 
hypotension.  If animals received pre-blast vagotomy, the apnoea and bradycardia 
were removed, but hypotension only partially ameliorated.  Atropine pre-treatment 
attenuated the bradycardia response, but had no effect on the apnoea or 
hypotension.  These results suggest the Vagus nerve is responsible for the 
bradycardia and apnoea; and for part of the hypotensive response.  The authors 
note that this reflex triad is similar to that produced by stimulation of pulmonary 
afferent C-fibres (J receptors) which travel within the Vagus nerve (167;168).  
Ohnishi explains the partial response of the hypotension to vagotomy by postulating 
an impairment of the baroreceptor reflex by blast; which would normally produce a 
sympathetically-mediated increase in vascular tone and a tachycardia (166).  
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2.2.6 Interactions between Injury Mechanisms 
2.2.6.1 Blast and Haemorrhage 
Sawdon linked knowledge of haemorrhage physiology to the reflex responses 
associated with a primary blast injury in a study employing anaesthetized rats.  
Groups received a blast, or sham blast thoracic insult.  They were then subjected to 
haemorrhage (169).    Blast exposure reduced the compensatory tachycardic 
response to haemorrhage and enhanced the bradycardic hypotensive phase. 
 
The implications of this effect can be related to oxygen delivery.  The PaO2 of blast-
exposed subjects is reduced for a prolonged period, despite swift return to normal 
respiratory patterns within 5 min (166).  Hypoxia persists, with or without 
hypercarbia, because gas transport across the alveolar tissue-blood barrier is 
impaired in blast lung.  At the same time, the haemorrhagic sequellae of blast injury 
(secondary and tertiary blast injury) reduce cardiac output and so compromise the 
flow component of the oxygen delivery equation.  
 
In the clinical setting this means that casualties exposed to the combined insults of 
blast wave exposure and major haemorrhage, have sustained a ‘double hit’ to their 
capacity to deliver oxygen to their tissues. 
2.2.6.2 Tissue Injury and Haemorrhage 
Simple haemorrhage, uncomplicated by pain or tissue damage, is uncommon in 
trauma.  Certainly, trauma victims suffer a degree of tissue damage and the effect of 
an afferent nociceptive storm could also influence the response patterns to 
haemorrhage. 
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Pain and tissue injury can produce a variety of stimuli that alter one’s response to 
haemorrhage.  Little and colleagues showed that musculoskeletal injury produces a 
reflex tachycardia and hypertension (170) and his rat model of haemorrhage and 
tissue injury (54), showed that hind limb ischaemia reduced the depressor response 
to haemorrhage, delaying hypotension and limiting the bradycardia. Opioid receptors 
have also been examined for their impact on response to haemorrhage.  Ohnishi’s 
rat haemorrhage model compared groups pre-treated with morphine (into a cerebral 
ventricle) against controls and those given Naloxone (an opioid receptor antagonist).  
Rats treated with morphine demonstrated a delayed onset of hypotension and no 
bradycardic response.  Those animals given Naloxone responded in the same 
fashion as the control groups (171). A subsequent study by the same group 
employed intravenous morphine with similar findings.  They also administered 
morphine at a late stage in the haemorrhage, by which time bradycardia and 
hypotension had become established.  Again, morphine removed the bradycardia 
and limited the hypotension (172).   
 
While it may be thought that this would improve tissue perfusion and reduce the 
degree of ‘shock’ suffered by the trauma victim, this reflex has been shown by 
Overman and colleagues to decrease survival in dogs after haemorrhage (173).  
Perhaps the bradycardic response is protective?  With low venous return and a very 
high heart rate, stroke volume will be very small and myocardial perfusion poor.  If 
the heart rate were to reduce, this would allow more time for ventricular filling and 
myocardial perfusion.   
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2.2.6.3 Haemorrhage, Blast and Musculoskeletal Injury  
Military trauma has the potential to inflict all three types of insult simultaneously.  All 
three insults can modify the potential requirements for resuscitation and the 
response to therapy.  The net result of these responses is not known. By 
incorporating all three insults, this study will produce a relevant model of severe, but 
not immediately overwhelming, military wounding, against which background 
adjuncts to fluid resuscitation can be assessed. 
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3 Current and Potential Interventions 
3.1 Intravascular Fluid Therapy 
The study employs only a simple, widely available crystalloid (0.9% Saline) for 
resuscitation. A detailed discussion surrounding fluid therapy is not therefore 
relevant.  However, a brief summary will add context to the problem we are trying to 
address. 
 
In 1977 Baker performed an epidemiological autopsy study into trauma deaths in 
San Francisco (5).  This highlighted both the significant burden of trauma and the 
need for improved trauma care.  In reviewing Baker’s data, Trunkey described a tri-
modal distribution of death after trauma: ‘immediate deaths’ - within 2hrs of injury 
(≈45% of deaths); ‘early hospital deaths’ - within 4hrs of injury (≈ 34%) and ‘late’ - 
days to weeks after injury (≈20%) (7).  This produced ‘windows of opportunity’ for 
clinicians to prevent trauma deaths after injury and, from this, the concept of ‘The 
Golden Hour’ arose. Since the early 1980s, a systems approach for delivering 
trauma care has been implemented in several States within the US and they have 
been shown to improve outcome after trauma (174-177).  While modern data has 
questioned whether this pattern is still relevant, the concept is still widely taught in 
ATLS courses worldwide (6;178).  A mainstay of the prehospital intervention has 
been fluid resuscitation.  This aims to augment the intravascular volume which has 
become depleted as a result of traumatic haemorrhage, thus preserving preload and 
maintaining cardiac output.  Of course, the oxygen content of the blood will reduce 
as haemoglobin-rich blood is replaced with fluid, but the net effect is still to increase 
DO2 to tissues. 
 
75 
 
Fluid therapy strategies have changed over time as our understanding of 
resuscitation and trauma physiology improves and as we see the potential side 
effects of accepted doctrine (179). To this day clinicians, both civilian and military, 
debate the ideal fluid type and administration regimes for post-trauma resuscitation.  
While most accept that whole blood is an ideal resuscitation fluid, practically this is 
not available to most pre-hospital casualties.   
3.1.1 Blood Pressure Resuscitation Target 
As with the type of fluid used, there is ongoing debate regarding the ideal blood 
pressure target that should be employed, to guide the rate and volume of fluid to be 
given.  There are two well established concepts for prehospital fluid resuscitation: the 
Advanced Trauma Life Support system (178), which advocates a normotensive 
resuscitation target and the permissive hypotensive target, preferred by the National 
Institute for Health and Clinical Excellence (NICE). Each has advantages and 
potential limitations.  
3.1.1.1 Normotensive Resuscitation 
The normotensive target dictates that baseline blood pressure, or Mean Arterial 
Pressure (MAP) be restored as swiftly as possible.  It is an aggressive concept and 
includes an initial one-to-two litre bolus of fluid for the clinically shocked adult trauma 
patient.  Advanced Trauma Life Support (ATLS) is a course designed to provide a 
safe and logical framework for doctors to employ when managing casualties. It has 
now been taught to over 1 million doctors worldwide and is a compulsory 
qualification for completion of surgical training in the UK. Brief note only is made of 
the concept of delaying aggressive fluid resuscitation until surgical haemorrhage 
control has been achieved (178).   By rapidly restoring the intravascular volume, the 
preload will increase and this will increase cardiac output.  The remaining 
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haemoglobin (and its bound oxygen) will therefore be delivered more rapidly to the 
tissues.  There are concerns, though, that this rapid volume expansion will place a 
large hydrostatic pressure on any clots that have formed at sites of vessel damage; 
the risk is bursting of the clot and rebleeding.   In the prehospital environment and in 
the presence of incompressible haemorrhage, rebleeding could precipitate 
exsanguination. 
3.1.1.2 Hypotensive Resuscitation 
The permissive hypotensive approach accepts temporary hypoperfusion in order to 
allow a strong clot to form at sites of vessel injury.  The aim is to support perfusion of 
critical organs just enough to allow temporary survival, while not disrupting any clots 
that have managed to form.  Landmark evidence supporting this concept is Bickell’s 
prospective clinical trial in an urban major trauma centre of immediate versus 
delayed fluid resuscitation for shocked (SBP<90mmHg) penetrating adult (>16yrs) 
torso trauma (36).  Patients were randomised to receive either no fluid therapy from 
point of wounding until they entered the operating room, or they received standard 
prehospital fluid therapy. Randomisation was based on even vs. odd days of the 
month.  Fluid therapy comprised continuous high flow infusion of Ringer’s Lactate 
with transfusion of red cells as indicated. Other than fluid therapy, treatment pre-
surgery was identical.   
 
The study enrolled 598 adult trauma patients. 309 received prehospital fluid therapy, 
289 received no pre-surgical fluid therapy.  Demographics were similar between 
groups, except the interval to surgery was marginally longer in the delayed group 
(134±101 vs. 114±105 min).  Overall survival was improved in the delayed fluid 
therapy group: 70% vs. 62%.  There was a trend towards greater surgical 
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haemorrhage in the immediate treatment group. Immediate treatment resulted in 
longer hospital stay.  There was a trend towards more complications in the 
immediate fluid therapy group.   
 
This study shaped modern prehospital trauma doctrine and it’s findings were 
influential when NICE developed their prehospital guidelines (180).  Hypotensive-
target fluid therapy was also, until recently, recommended by the Battlefield 
Advanced Trauma Life Support (BATLS) doctrine (10).  
 
There are important differences between those patients enrolled in Bickell’s study 
and the modern combat trauma patient.  First, the delay to first treatment of any kind 
is extremely short (8±6min) with interval to arrival in the trauma centre averaging 44 
and 52 min.  Surgery interval was around the two-hour mark.  While in mature 
theatres of operation, evacuation times to surgical care might match this; military 
evacuation is unpredictable and, as mentioned before, can be very prolonged.  If we 
are to maintain a casualty in a pre-surgical environment for several hours, will this 
hypoperfusion cause irreversible metabolic dysfunction?  Furthermore, no casualty in 
Bickell’s series had been exposed to a primary blast injury (although Bickell 
describes a ‘shotgun-blast’ mechanism in 3 and 6%, this does not equate to the 
shock wave of an explosion interacting with the body.  Add the problem of blast 
injury, with its impaired oxygenation and myocardial depression, to prolonged 
reduction in oxygen delivery from delayed fluid therapy or hypotensive strategies and 
there will be potentially severe consequences.  Third, despite a mean ISS of 26±14, 
admission arterial gases demonstrated mean pH 7.29.  While this is clearly acidotic, 
the degree of acidosis is not reflective of the seriously injured casualties arriving in 
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military surgical facilities after injury from explosive munitions.  Perhaps the 
casualties in Bickell’s study are less severely injured and therefore more tolerant of a 
delay in restoring oxygen delivery? 
 
Balancing the risk of ‘blowing off nascent clots’ against the penalties of prolonged 
hypotension forms a fulcrum for the debate regarding fluid therapy strategies in 
trauma.  From the military perspective, we must be prepared to maintain casualties 
for prolonged periods without surgical haemorrhage control and cannot ignore the 
problem of blast injury that is present in a significant number of our injured.  
 
3.1.1.3 Work at the Defence Science and Technology Laboratories Porton Down 
The Defence Science and Technology Laboratories (DSTL) at Porton Down have 
been investigating the implications of these strategies in the context of prolonged 
resuscitation after blast injury and haemorrhage. 
3.1.1.4 Blast and Haemorrhage Programme 
Previous work at DSTL has examined the efficacy of prolonged permissive 
hypotensive resuscitation (37;181) to address two areas of concern for military 
casualties, namely extended evacuation timelines and concomitant blast injury.  
Terminally anaesthetized swine were subjected to blast loading and 30% controlled 
haemorrhage.  These animals were compared to a similar group who received sham 
(no) blast, but the same haemorrhagic insult.  Fluid therapy (normal saline) was 
targeted to either the hypotensive systolic target of 80mmHg (control group) or to a 
normotensive target (systolic arterial pressure of 110 mmHg, the original ATLS 
strategy). The purpose of this study was to compare the physiological problems 
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associated with prolonged hypotensive resuscitation with those associated with the 
aggressive fluid administration necessary to attain a normotensive target.   
 
In the presence of a combined blast and haemorrhage insult, prolonged hypotensive 
resuscitation was not compatible with life (Figure 10).  Survival was initially good 
over the first hour of resuscitation, but thereafter fell sharply resulting in 
approximately 50% mortality after two hours of resuscitation and 100% mortality after 
4 hours of resuscitation.   
 
Figure 10 Kaplan Meier survival plot for four groups of animals.  Two groups received blast exposure; sham 
animals received no blast.  Two groups were resuscitated (normal saline for all groups) to a normotensive target 
of 110mmHg; the other two were resuscitated to a hypotensive target of 80mmHg. 
 
Although survival was good with hypotensive resuscitation after haemorrhage in the 
absence of blast, significant physiological penalties were seen.   
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Figure 11 Actual Base Excess plots for four groups of animals.  See legend to Figure 10 for explanation of 
groups. 
 
The underlying problem with prolonged hypotensive resuscitation was found to be 
inadequate tissue oxygen delivery, due to the low blood flow state during 
hypotension.  Tissue oxygen delivery became grossly inadequate when there was 
concomitant blast injury, which reduced arterial oxygen content and therefore 
compounded the problem of low tissue blood flow (37;181).  
 
The study did not however allow for the potential re-bleeding that is a feared 
consequence of normotensive resuscitation. It was therefore necessary to develop 
strategies that could improve the delivery of oxygen to tissues, without increasing the 
risk of rebleeding.  Implicit in this objective was the need to alter the animal model to 
allow for rebleeding. 
3.1.1.5 Novel Hybrid Programme 
The next project involved development of a capacity for rebleeding while continuing 
the theme of blast/sham blast exposure and controlled haemorrhage.   
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A liver snare was developed that could be implanted at time of preparatory surgery 
and later deployed to produce a Grade IV liver injury (39) (Figure 22).  This is both 
an arterial and venous injury with the capacity to re-bleed at any stage after initial 
clot formation. 
   
A novel fluid resuscitation strategy was designed (Novel hybrid – NH), which 
assimilated the best of both the hypotensive and normotensive resuscitation 
philosophies.  For the first hour of fluid therapy, the resuscitation target was the 
hypotensive 80mmHg.  Thereafter, however, the target increased to the 
normotensive 110mmHg.  Normal Saline was used throughout.  The first hour’s low 
pressure target allowed nascent clot formation without exerting undue hydrostatic 
pressure across sites of vessel injury.  By one hour, clot integrity has reached 80% 
of maximum (182) and it was felt that improving flow (and hence oxygen delivery) 
was now more important than protecting the clot. 
 
Figure 12 Novel Hybrid study survival plot for four groups of animals. Blast groups received primary blast 
injury, the ‘sham’ group received blast wave exposure.  All animals received total 35% blood volume controlled 
haemorrhage and grade IV liver injury. NH animals received hypotensive fluid therapy for the first hour and 
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then normotensive fluid resuscitation (SBP 110mmHg) for the remainder of the experiment.  Hypotensive 
animals received fluid therapy to the hypotensive (SBP 80mmHg) target throughout. 
 
The novel hybrid strategy proved effective and safe (Figure 12).  Animals survived to 
the end of the experiments and demonstrated physiological recovery – evidence that 
oxygen delivery had been restored enough to repay an acquired oxygen debt (Figure 
13).  Importantly there was no evidence of increased rebleeding compared to 
hypotensive controls (39).   
Figure 13 Base Deficit and Oxygen extraction ratio plots for the same four groups of animals.  First dotted line 
represent onset of fluid resuscitation.  Second dotted line represents T60, when NH animals began to receive 
normotensive fluid therapy. 
 
While NH proved effective and no increase in rebleeding was identified in the study, 
there are other approaches to augmentation of oxygen delivery, which exert no 
increased pressure across blood clots: two such adjuncts were selected for this 
study. 
3.2 Supplemental Inspired Oxygen 
Fluid resuscitation attempts to address the impaired flow component (cardiac output) 
of the oxygen delivery equation after haemorrhage (Equation 1)   
 
As mentioned before, the NH strategy is effective in the prolonged prehospital setting 
after haemorrhage, and in the presence of primary blast injury, where lung injury 
produces hypoxia (39). It is recommended as the default prehospital fluid 
resuscitation strategy for UK military casualties (10).  Although NH did not cause 
increased bleeding in the animal model, there may be clinical situations where the 
nature of the injuries suggests an unacceptably high risk of re-bleeding were arterial 
pressure to be elevated to normal levels.  A potential alternative strategy in this 
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circumstance would be to increase arterial oxygen content.  The simplest means of 
achieving this would be to increase inspired oxygen, although this would only have a 
large effect on oxygen content if pre-treatment arterial oxygen saturation was 
significantly depressed while breathing air.     
 
In the civilian prehospital arena, oxygen therapy is ubiquitous.  However, oxygen 
support capability is not routinely available in the far-forward military environment.   
 
How does military trauma differ from civilian trauma and where is the role for 
supplemental oxygen?  A recent epidemiological study has supported the widely 
held consensus that civilian trauma is predominantly blunt in nature (183).  A recent 
prospective study into blunt thoracic injury reported a 6.3% incidence of significant 
chest injury in 2 urban trauma centres (184).  31 of 492 consecutive patients had 
significant thoracic injury (including any one or more of: aortic injury, two or more rib 
fractures; sternal fracture; pulmonary contusion; haemothorax or pneumothorax).  
Chest pain and hypoxia on admission to the Emergency Department were the two 
best diagnostic indicators.  
 
In contrast to the predominance of blunt injury in civilian trauma, Schreiber’s study 
confirmed that military trauma is predominantly penetrating, with 80% of combat-
injured casualties suffering penetrating injury (183).   In addition to penetrating 
(missile or fragment) injury, the effects of primary blast must also be considered.  
While it is difficult to estimate the true incidence of blast lung, we know that 78% of 
combat casualties between 2005 and 2006 in Afghanistan and Iraq have been 
injured in an explosive event (185).  A recent UK paper has demonstrated an 11% 
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incidence of blast lung in casualties surviving to reach the field hospital in 
Afghanistan (186).  However, another case series from Iraq, reported a lower 
incidence of primary blast injury (3.7%) in UK casualties (187).  The Joint Theater 
Trauma Registry (JTTR) – the database of the US Department of Defence – has 
yielded a 4.6% incidence of blast lung in soldiers wounded between 2005 and 2006 
(188).  So how worried should we be about primary blast?  It is important to note 
that, for both Ramasamay’s series and the US JTTR report, Iraqi insurgents were 
deploying a very specific form of IED, the explosively formed projectile (EFP).   EFPs 
contain a relatively small, shaped explosive charge and function by creating a 
supersonic molten slug of copper which is designed to defeat vehicle armour.  The 
blast overpressure transmitted into the vehicle is much smaller than the 
overpressure adjacent to the vehicle.  Champion’s paper cites test data addressing 
this concept (188).  A bare 17Kg C-4 explosive charge was detonated 3m from a 
vehicle.  Pressure readings were gathered both within and outside the vehicle.  The 
peak overpressure within the vehicle was 28 times lower than the peak pressure 
adjacent (outside) to the vehicle.  Inside the vehicle, a peak pressure recorded of 
approximately 6PSI would be expected to produce tympanic membrane rupture, but 
lies well below the threshold for blast lung injury.   Those outside the vehicle would in 
contrast suffer significant or fatal blast exposure.  Injury patterns from EFPs followed 
a bimodal distribution: those hit by the main slug sustained catastrophic, normally 
unsurvivable, injuries; while those adjacent to the slug’s path sustained minor 
fragmentation injuries from spalling within the vehicle (personal experience from Op 
TELIC 10).  
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We know that, following open-air blast, blast overpressure declines by the inverse 
cube law with distance from the explosion (e.g. a doubling of the distance reduces 
peak overpressure to one eighth) (2.2.1).  In previous conflicts, those close enough 
to a blast epicentre to suffer primary blast injury have normally succumbed to the 
devastating fragment load at that range (189).   A recent review of over 1000 large 
animal (<30ms) blast injury experiments supports this concept (190).   The authors 
concluded that blast lung would not occur in an open-air environment when the 
subject was over 20m from the epicentre of a 100Kg TNT explosion.  20m however, 
would lie within the lethal fragment zone of a real-world explosive device detonation.  
The lethal fragment zone of a 155mm (100Kg) shell is 24m and significant injury 
from fragments remains a risk out to well beyond 100m (188). Another laboratory 
study demonstrated that 17-24 PSI overpressures would be required to produce 
blast lung. Again this would equate to a distance from the explosion of 10-20m (191).   
 
In Afghanistan, the current operation in which UK forces are deployed in large 
numbers, several conventional high explosive munitions are being piled together to 
form IEDs with a huge total quantity of explosive charge.  The geography and 
military taskings within the country mandates a high proportion of dismounted 
operations; rendering troops more vulnerable to primary blast effects.  Recent UK 
data confirms that casualties with significant primary blast lung are reaching the Field 
Hospital (186).   
 
It seems therefore that the Ramasamay and Champion’s figures may not represent 
the true risk in the current Afghanistan conflict.  EFPs do not feature as the IED 
design of choice; the quantities of explosive charge used by insurgents in 
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Afghanistan are larger and dismounted operations are more common in Afghanistan 
than Iraq; removing the protective effect of the vehicle hull in reducing the 
overpressure of blast.  Other potential reasons for the increased incidence of primary 
blast injury being reported from Helmand Province are the improvements in issued 
body armour; prehospital haemorrhage control and resuscitation and shortened 
evacuation times to hospital.  All these potentially increase the survivability of 
exposure to significant fragment burden and potentially enable survival from 
fragmentation within the zone of primary blast effect of an explosive detonation. 
 
If a potential benefit from supplying oxygen to far forward, highly mobile military 
medical assets is acknowledged, then the delivery of such a capability would incur a 
logistic expense.  Many severely wounded military casualties will not derive 
significant benefit from an increase in inspired oxygen concentration: without thoracic 
trauma, their arterial oxygen saturation (SaO2) will be over 95%.  The potential 
increase in DO2 from supplementing oxygen is therefore very limited and one must 
not ignore the issue that high concentrations of oxygen might produce unwanted 
sequellae (3.2.6.1). 
 
A complete military prehospital resuscitation strategy must look ahead to future 
threats.  Enhanced blast weapons have been discussed previously (1.4), as have the 
effects of closed-space explosions on blast wave amplitude and duration.  These 
weapons could significantly increase the incidence of severe primary blast injury in 
otherwise survivable casualties.  Hypoxia must not therefore be ignored. 
87 
 
3.2.1 Oxygen Transport 
The lungs comprise conducting airways and a respiratory zone.  The conducting 
airways do not play a part in gas exchange.  The respiratory zone contains alveoli, 
the functional units of gas exchange. Each alveolus has a diameter of approximately 
200 micrometers (µm) and the total gas exchange surface area is approximately 
70m2. The interface layer between the alveolus and capillary is, in normal 
circumstances, extremely thin, optimizing diffusion.  The internal surface of the 
alveolus is thinly coated with surfactant, which reduces surface tension and the 
tendency towards atelectasis.   
3.2.2 Gas Exchange in the Lung 
Diffusion of gases is governed by Fick’s law (Equation 5), which states that the 
diffusion rate of a gas through a tissue is proportional to tissue area and the 
difference in partial pressure of gas on either side of the tissue, and inversely 
proportional to the thickness of the tissue through which diffusion must occur. 
𝑉𝑔𝑎𝑠   ∝ 𝐴𝑇   ×𝐷  × 𝑃1− 𝑃2  
Equation 5 Fick’s Law of Diffusion. Vgas = Volume of gas per unit time which diffuses across a membrane.  A 
= Surface Area for Diffusion. D = Diffusion Constant or permeability coefficient of the gas: D α  
Solubility/√Molecular Weight. P1-P2 = Difference in partial pressure of gas on either side of tissue. T = Thickness of 
tissue sheet across which diffusion must occur. 
 
 
The healthy lung, with huge surface area and extremely thin diffusion distance, is 
optimised to allow efficient transfer of gases: in normal conditions, a single 
erythrocyte will complete its journey through the gas exchange zone of a lung 
capillary in approximately 0.75s, but PO2 in blood will equilibrate with alveolar partial 
pressure by 1/3 of its journey through the capillary (Figure 14). There is a large 
functional reserve for diffusion.  The amount of oxygen taken up by the blood 
therefore depends on the flow and exchange is described as ‘perfusion limited’. 
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Figure 14 Oxygen diffusion in capillary 
 
During exertion, flow increases and an erythrocyte may spend less time in the 
capillary, but there is normally still sufficient time for equilibration to occur.  However, 
any pathology that increases the thickness of this barrier will slow diffusion.  If a 
difference between alveolar PO2 and end-capillary PO2 exists, oxygen exchange will 
have become ‘diffusion limited’.  Blast lung is characterized by interstitial 
haemorrhage and oedema, both of which significantly increase the diffusion 
distance.  At the same time, haemorrhage and hypotensive resuscitation reduce the 
flow.  Given the common finding of hypoxia, it is likely that diffusion limitation exists 
in the context of blast lung.  
3.2.3 Haemoglobin and Gas Transport 
Oxygen can be carried in the blood either dissolved in solution, or bound to 
haemoglobin.  The amount of dissolved oxygen is proportional to the tension of 
oxygen in the plasma, which is in turn influenced by the alveolar oxygen tension.  For 
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every mmHg O2 (0.13KPa) in alveolar gas, the blood will contain 0.003ml O2/100ml 
blood.  At sea level, the alveolar gas oxygen tension (PAO2) is 13.3KPa. This 
equates to a dissolved content of 3ml O2/L of blood: assuming a cardiac output of 
5L/min and dissolved oxygen will deliver only 15ml O2/min to the tissues.  The 
metabolic demand for oxygen far exceeds this value. A more potent vehicle for 
oxygen carriage is therefore required; this is delivered by haemoglobin; the principal 
oxygen carrying protein. 
 
The oxygen dissociation curve demonstrates the saturation of Hb with O2 for a given 
oxygen tension (Figure 15).  There is rapid binding of oxygen up to a PO2 of 
approximately 6.6kPa; thereafter the curve flattens. The broad plateau means that a 
moderate drop in alveolar pO2 (down to 8.7kPa for example) will have little effect on 
either the Hb saturation or the oxygen concentration in blood. The steep lower part of 
the curve facilitates unloading of oxygen into the tissues where lower oxygen tension 
exists. 
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Figure 15 Oxygen dissociation curve 
 
The normal P50 of Hb is 26.6mmHg.  The curve can be shifted by changes in the 
erythrocytes’ environment.  An increase in [H+], PCO2 or temperature will shift the 
curve to the right. This was discovered by Bohr through laboratory experiments on 
fresh dog blood and his curves are illustrated below (192) (Figure 16).   
 
Figure 16 Bohr's dissociation curves at various CO2 levels in dog blood 
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2,3-disphosphoglycerate (2,3-DPG) a product of erythrocyte metabolism, also 
pushes the curve to the right (193).  Levels are increased in states of chronic 
hypoxia, such as altitude and chronic lung disease (3.2.3.2).  A right shift in the 
oxygen dissociation curve facilitates unloading of oxygen in the peripheral tissues.   
 
The oxygen dissociation curve; the red cells’ environment (temperature; and PCO2); 
Hb concentration ([Hb]) and the saturation of the Hb allow us to predict the arterial 
oxygen content of blood.  This can be illustrated in equation form: 𝐶𝑎𝑂2   =    𝑆𝑎𝑂2  ×   𝐻𝑏   ×1.34  
Equation 6 Arterial Oxygen Content  
 
CaO2 is one of the key variables in the oxygen delivery equation. Haemoglobin 
concentration and PaCO2 can rapidly be assessed by blood gas analysis.  The 
saturation of the Hb can be estimated by using a pulse-oximeter.  The absorption 
spectra of oxy-haemoglobin and deoxy-haemoglobin differ. This gives them bright 
red and blue/purple colours respectively and allows pulse oximetry to detect the 
percentage of oxy-haemoglobin saturation in arterial blood.   
3.2.3.1 Oxygen Carrying Capacity 
One gram of Haemoglobin that is 100% saturated with oxygen can carry 1.39ml O2 
(However, a figure of 1.34ml O2/gram haemoglobin is generally used, as a fraction 
of Hb is in met-haemoglobin form and carries no oxygen). This figure is termed the 
‘Hüffner constant’.   An average male might have a [Hb] of 15g/dL. This person 
would be able to carry a maximum amount of 20.1ml oxygen bound to haemoglobin 
per 100ml blood.  Assuming a resting cardiac output at sea level of 5L/min; O2 
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delivery to the tissues would equal 1005ml O2/min (20.1 x 50 (bound to Hb) + 0.3 x 
50 (dissolved)). 
 
Clearly changes in haemoglobin concentration will influence maximum oxygen 
carrying capacity.  An anaemic Hb of 10g/dL will have a maximum bound O2 
capacity of 13.4 O2/100ml blood, reducing oxygen delivery at sea level (CO of 
5L/min) to 670ml O2/min. 
3.2.3.2 How Altitude affects the alveolar pO2    
Altitude 
pO2 air (mmHg) 
pO2 alveolus 
(mmHg) Likely SaO2 
% mmHg KPa mmHg KPa 
Sea level (0m) 160 21.3 100 13.3 98-100 
1000m 141 18.8 85 11.3 97 
2000m 128 17.1 70 9.3 93 
3000m 117 15.6 58 7.7 86 
Table 4 Partial Pressures of Oxygen at Altitude 
 
The declining alveolar pO2 at altitude reduces the concentration gradient for 
diffusion and slows equilibration of capillary and alveolar partial pressures.  
Furthermore there is a right shift in the O2 dissociation curve at altitude secondary to 
a rise in 2,3-DPG within a week of acclimatization at high altitude (194).  While this 
assists unloading of oxygen to the periphery, it slows O2 diffusion into the pulmonary 
capillary.   Much of Afghanistan lies above 2000m (Figure 17).  Injured soldiers will 
be hypoxic so oxygen would be useful even in the absence of blast lung.  
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Figure 17 Topographical Map of Afghanistan 
 
3.2.3.3 Tissue Oxygen Delivery 
Oxygen delivery (DO2) is the total amount of oxygen delivered to tissues per unit of 
time.  It is a product of blood flow through the circulation in a minute (cardiac output) 
and the amount of oxygen carried within that blood (oxygen content).   The equation 
is repeated here for clarity. 
(DO2) (ml/min) = cardiac output (CO) x arterial oxygen content (CaO2) 
Equation 7 Oxygen delivery equation. CO = Stroke Volume (SV) (ml) x Heart Rate (HR) (bpm). CaO2 = 
[Haemoglobin (Hb)] (g/dl) x Oxygen Saturation (SaO2) (%) x 1.34 x 10 / 1002.  
 
                                            
2 The amount of unbound O2 dissolved in plasma at 1 atmosphere is clinically negligible and not 
therefore included in this representation of the DO2 equation    
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In summary, the delivery of adequate quantities of oxygen to tissues is critical for 
maintaining cellular aerobic respiration.  Oxygen delivery is affected by blood flow 
and oxygen content.  Oxygen content in turn is influenced by [Hb]; the state of shift 
on the dissociation curve of Hb and the oxygen saturation of the Hb. 
3.2.4 Gas Exchange in the Periphery 
As an erythrocyte travels through a peripheral capillary, it must be able to offload its 
oxygen and take up CO2.  Again, this process occurs via diffusion. In tissues, the 
diffusion distances are greater (50 microns in muscle) than the 0.3 microns seen in 
the lung.  As oxygen diffuses from the capillary, oxygen tension decreases. 
Nevertheless, with adequate perfusion of oxygenated blood, there is still adequate 
supply to all the tissue (see Figure 18 for example of muscle tissue bridge). As 
oxygen delivery declines after trauma, a tissue bridges between adjacent capillaries 
begins to receive inadequate oxygen.  This forces cells within the zone of hypoxia to 
metabolise anaerobically and begins the process of ‘shock’.  Prolonged cellular 
ischaemia leads to loss of integrity of mitochondrial membranes with resultant 
mitochondrial dysfunction and eventually apoptosis.  The dysfunction that results will 
depend on the tissue type affected: in the kidneys for example, hypoperfusion results 
in acute tubular necrosis – a recent epidemiological study of renal failure found that 
ischaemia was the second most common cause of tubular necrosis (195). 
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Figure 18 Simplified schematic of decreasing oxygen tension in tissue between capillaries 
3.2.5 Oxygen Consumption 
Cellular metabolism requires a constant supply of energy.  Cells cannot, however, 
simply use glucose as a fuel for work. They must convert the potential energy from 
digested nutrients into a usable energy storage molecule or ‘currency’.  Adenosine 
Tri-Phosphate can be thought of as our principal energy currency and 90% of our 
absorbed oxygen is used as the terminal electron acceptor for oxidative 
phosphorylation of ADP to ATP.  ATP can be produced via either aerobic or 
anaerobic pathways.  To maintain normal conditions, aerobic pathways must form 
the principal source of energy creation and this is why oxygen delivery to the tissues’ 
mitochondria is so critical.   
 
Glycolysis is a common metabolic pathway for both aerobic and anaerobic 
metabolism.  It occurs within the cytoplasm of cells and is independent of the need 
for oxygen. Two Pyruvate molecules form the end product of glycolysis.  In aerobic 
respiration, the action then moves to the mitochondria where the Kreb’s cycle and 
electron transport generate large quantities of ATP (theoretical maximum of 34 ATP 
per molecule of glucose).   
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In shock states, respiration can still occur, but the Kreb’s cycle and electron transport 
cannot take place.  Instead glucose’s energy is extracted by lactate fermentation. 
Pyruvate is converted into lactate and ATP.  This process generates only 2 
molecules of ATP per glucose molecule. Prolonged depletion of oxygen causes 
lactic acid accumulation and the extracellular fluid becomes acidic.    
 
This thesis focuses on oxygen delivery shortfall as a key driver of early of mortality 
and morbidity after blast and haemorrhage injury, it is important that the oxygen that 
delivered to the tissues be gainfully employed - the tissues must be capable of 
undertaking aerobic metabolism..  Oxygen consumption data are presented in this 
thesis to confirm whether or not increased DO2 correspondingly increases VO2.  
Addressing the disordered mitochondrial function following haemorrhagic shock 
represents another focus for trauma research (196;197) 
3.2.6 Hypoxia after Blast 
The pathophysiology of blast lung has been described earlier (2.2.4). Hypoxia can 
result from several sequellae of blast.  Pulmonary contusion (diffuse haemorrhage) 
and oedema are most common (34).  Also discussed earlier is the cardio-respiratory 
response to blast (2.2.5). The apnoea and subsequent shallow breathing 
exacerbates the hypoxia associated with the physical sequellae of blast lung.  
 
The pathophysiological progress of blast lung over time is summarised in Table 5 
below.    
Time  Event Clinical Features CXR 
0 (h) 
Shock Wave Hypoxia 
Tachypnoea 
Haemoptysis/Cough 
Contusion 
Pneumothorax 
Haemothorax 
Alveolar capillary rupture 
Interstitial and alveolar haemorrhage 
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Physiological Shunt 
Reduced Lung Compliance 
Pneumothorax 
Haemothorax 
Air emboli 
Emphysema 
Rib Fracture 
3 
Free Hb & blood 
Hypoxic resp. failure 
High airway pressures 
Contusion 
Oedema 
Free radical reactions / Oxidative Stress 
Pro Inflammatory Response / Chemotaxis 
Increasing Oedema 
12-72 
Leukocyte Accumulation 
Disrupted tissue architecture ARDS 
SIRS 
MOF 
Diffuse 
pulmonary 
infiltrates 
Increased oxidative stress 
Increased Inflammation 
Increasing Oedema 
5 -10 
days 
Resolution 
Improved gas exchange 
Improved compliance 
Resolution of 
lung contusions 
Table 5 Natural History of Blast Lung 
 
Capillary rupture; intra-alveolar haemorrhage; tearing of the inter-alveolar septa and 
changes to the epithelium and type II pneumocytes have been demonstrated in 
blast-exposed rat lungs (156).  The result is a diffuse haemorrhage picture with 
interstitial and intra-alveolar bleeding.  The increased diffusion distance for oxygen 
exchange results in hypoxia.   
 
In addition to the localised gas exchange effects of intra-alveolar haemorrhage and 
oedema, free Hb within alveoli have been shown to recruit activated 
polymorphonuclear neutrophils.  These neutrophils, along with the extravasated 
blood, generate reactive oxygen and nitrogen species that, in turn, result in 
secondary oxidative damage to the lung tissues following intra-alveolar haemorrhage 
(198).  Gorbunov and colleagues, using rat models and shock tube overpressure, 
expanded on this work to present a temporal cascade of inflammatory alterations in 
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the injured lung following exposure.  They implicated iron dependant pathways of 
oxidative damage (199) 
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Shock Wave Influx of blood into alveoli 
Cardio-pulmonary reflex events 
Reactive Oxygen and Nitrogen species formation 
1-6h Leukocyte sequestration, migration and degranulation. 
Phagocytosis of free RBCs 
Endothelial damage 
Pulmonary oedema 
Myeloperoxidase accumulation 
Accumulation of stress proteins: Copper, Zinc Superoxide 
Dismutase (SOD) and Haem-Oxygenase Type 1 (HO-1) 
12-24h Extensive phagocytosis and lysis of RBC leading to solid phase Hb 
Hb oxidation and decomposition 
Protein nitration 
Parenchymal expression of stress Proteins SOD and HO-1 
36-56h Phagocytosis of solid phase Hb 
Free Fe deposition in parenchymal and phagocytotic cells 
Type I and II pneumocyte damage 
Alveolar exudates 
Clumping of surfactant released from lamellar bodies  
Table 6 Temporal Sequence of Haemorrhagic alterations in alveoli following Blast Overpressure - modified 
from (199) 
 
Within only 3 hours, a significant influx of leukocytes occurred within zones of 
intrapulmonary haemorrhage. Levels of Myeloperoxidase (MPO), which are 
abundant in inflammatory leukocytes, continued increasing beyond 24h – an 
indication of developing inflammation.    
 
Another paper from the same group examined changes to antioxidant levels; 
peroxidation and architecture after single and repeated low-impulse overpressure 
(200).  Vitamin C and E levels dropped significantly within 1hr after a low-level single 
exposure to 62KPa shockwave.  Lipid peroxidation increased immediately.  At the 
same time, there were few macroscopic changes noted in the lungs, with <10% of 
the lung surface recognisably altered.  Microscopic analysis demonstrated multifocal 
alveolar haemorrhage with infiltration of RBC and alveolar wall rupture – this 
progressed out to 24hr endpoint.   This paper supports the previous work and 
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discusses the link between the secondary inflammatory processes and the clinical 
picture similar to ARDS that can occur many hours after exposure to a blast 
overpressure insult (164).  While the extent of the lung injury can propagate up to 
days after exposure (159),  the worst of the respiratory compromise will normally 
occur within the first 72 hours (158).  It also illustrates that blast lung, at a cellular 
level, may occur at exposures far below those traditionally thought of as thresholds 
for lung damage. 
 
While very local pathological and inflammatory effects are occurring in the lung 
tissue shortly after blast exposure, a more systemic response is also taking place.  In 
a mouse model of isolated thoracic blast exposure, circulating TNFα and Interleukin-
6 (IL-6) were significantly elevated (and to a level seen in Systemic Inflammatory 
Response Syndrome following chest trauma) after only 3 hours (201).  Clinical 
studies have demonstrated a rise in both circulating TNFα and IL-6 very soon (at 
scene of injury and after 30 minutes) after thoracic trauma and their levels correlate 
with injury severity from major trauma (202) and with prognosis in ARDS (203).  
 
Alongside the pathological features of blast, reduced compliance is important.  
Compliance describes the volume change in the lung per unit of pressure change.  
Reduced compliance requires the chest wall to work harder to deliver gas to and 
from the respiratory zone.  This increased work of breathing increases oxygen 
consumption and, in severe cases, compromises gas exchange(158).   
 
To demonstrate how supplemental inspired oxygen should attenuate the hypoxia of 
blast, Fick’s law is again used.  Blast lung increases the diffusion distance for oxygen 
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exchange (red arrow) and the development of ‘diffusion limitation’ at the blood-gas 
barrier.  
Vgas  α  A   .   D  . (P1    -P2) 
  T  
Vgas  = Volume of gas per unit time which diffuses across a membrane 
A.  = Surface Area for Diffusion  
D.  = Diffusion Constant of the gas:    𝐷 ∝ !"#$%&#&'(!"#$%&#'(  !"#$%&  
P1-P2  = Difference in partial pressure of gas on either side of tissue 
T  = Thickness of tissue sheet across which diffusion must occur 
 
Supplemental inspired oxygen can reduce the impact of increased ‘T’ by increasing 
the difference between alveolar and blood oxygen tension on either side of the tissue 
barrier (blue arrow).  Because carbon dioxide is so soluble, the Diffusion Constant 
‘D’ is far greater than that of O2; allowing adequate exchange despite significant 
increases in ‘T’. 
3.2.6.1 Potential Side Effects of Supplemental Oxygen Therapy 
A small percentage of reactions in normal conditions during mitochondrial oxidative 
phosphorylation generate superoxide anions.  These anions are produced when 
mono-electron-reduction of oxygen occurs during the electron transport process. The 
mitochondria house large numbers of anti-oxidants that ‘mop up’ these free radicals 
and prevent organelle damage: these include manganese superoxide dismutase; 
glutathione peroxidise and Vitamins C and E.  As we have seen from Elsayed’s 
work, antioxidants are depleted very soon after blast exposure (152).  Lipid 
peroxidation and other markers of free radical reactions also appear.  These factors 
contribute to the pathophysiology of blast lung and potentially render the lungs 
vulnerable to further oxidative stress.  Adding high flow, high concentration oxygen to 
inhaled gas could provoke further free radical damage.  
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Following experimental lung insult with lipopolysaccharide, even moderate 
concentrations of supplemental oxygen (FiO2=0.6) have been shown to produce 
hyperoxia associated lung injury (204). Markers of macrophage activation, alveolar 
neutrophil counts; signs of histological injury and epithelial barrier insufficiency were 
raised.   These indicate a relationship between supplemental oxygen and secondary 
lung injury when support is offered to a damaged lung.  Our experimental model was 
resuscitated out to 8hrs post blast.  Sampling protocols included adhesion molecules 
implicated in ALI/ARDS after major trauma (ICAM and VCAM).  Lung weight indices 
were calculated at the end of each experiment, and histology performed to assess 
damage that could be correlated to oxygen therapy.  
3.2.7 Considerations for Experimental Method - Supplemental Inspired 
Oxygen 
Mechanical ventilators are not available to far-forward medical echelons.  We must 
therefore address the problem of oxygen supplementation during spontaneous 
ventilation.  Our model must reflect a practically deliverable protocol.   
 
While face mask, nasal speculums or regulators could be used to deliver the 
supplemental oxygen during spontaneous breathing, we felt a mask would provide 
the most relevant comparison to methods to oxygen support likely to be used in the 
field.  A standard human face mask would not however fit a porcine snout.  A nose 
cone was therefore adapted to include a port for oxygen tubing.  This was placed 
loosely around the animal’s snout.  The concentration of oxygen being presented to 
the airway by this method was measured using an oxygen analyser. A sensor 
attached to the endotracheal tube also measured end tidal CO2, which was used to 
confirm that no rebreathing was taking place (Figure 29).  
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While the ATLS approach of 100% oxygen (from the cylinder) flowing at a minimum 
11L min-1 (178) might seem ideal for maximising oxygen levels in the alveoli, this 
does not consider the remote pre-hospital environment: portable, cylinder-based 
systems would last only a short time at such a rate.  Furthermore, there is the 
concern regarding the side effects of oxygen therapy.  We therefore chose a 
relatively modest minimum FiO2 of 0.3 as we felt this would be enough to ameliorate 
hypoxia, while conserving supply and minimising side effects.  We used a clinically 
relevant endpoint of 95% SaO2 as the target for oxygen therapy. 
3.3 Recombinant Activated Factor VII 
As we have seen in the previous chapter, blast lung injury is characterised by diffuse 
intra-alveolar haemorrhage and a prolonged oedematous inflammatory response. 
The inflammatory response that is in part initiated by the presence of blood in lung 
parenchyma, develops over the first few hours after blast exposure, and can be 
prolonged.  Both intra-alveolar haemorrhage and pulmonary oedema compromise 
gas exchange and produce hypoxia.  An agent that could reduce both diffuse 
haemorrhage and inflammation might improve outcome after blast injury.  Since both 
problems have, to some degree, pulmonary haemorrhage as a common starting 
point, then an agent targeting the bleeding has the capacity to attenuate lung 
compromise significantly if given sufficiently early after blast exposure.   
 
Recombinant activated Factor VII (rFVIIa) was developed for, and is licensed for use 
at times of bleeding or major surgery in patients with Haemophilia A and B and 
inhibitors (antibodies) to coagulation factors VIII and IX (205).  Its first clinical use 
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was reported by Hedner in 1983 (206). The drug has since been used off licence in 
the management of a wide variety of complex clinical scenarios, in the absence of 
pre-existing coagulopathy (207). It’s first successful use in a trauma patient was 
reported by Kenet in 1999 (208) and several case reports now exist.  There has 
been one paired randomised controlled trial assessing its use in major haemorrhage 
after civilian trauma (42) (3.3.4).  There have been no prospective trials assessing its 
use in blast lung injury.  There are however several small case series and reports 
that document rFVIIa use in diffuse pulmonary haemorrhage from other causes.  
 
This chapter will discuss the mechanism of action of rFVIIa, the evidence for its 
efficacy in diffuse pulmonary haemorrhage and consider a possible anti-inflammatory 
effect.  These will be related to a potential impact on blast lung. 
3.3.1 Mechanism of rFVIIa Action 
rFVIIa is produced by Novo Nordisk A/S, Bagsvaerd, Denmark and marketed as 
Novoseven®.  It is a copy of the activated form of the plasma-derived glycoprotein 
clotting factor, factor VII.  The manufacturing process involves expression in a baby 
hamster kidney cell line; a chromatography-based purification process and includes 
a step that results in auto-activation.  The result is a protein qualitatively identical to 
plasma-derived FVIIa (205). Novoseven® is currently licensed in the US for bleeding 
haemophilia patients with inhibitors to factors VIII and IX.  In the European Union, it 
is also licensed  for use in acquired Haemophilia, FVII deficiency and Glanzmann 
Thrombasthenia refractory to platelet transfusion (209).   The use of rFVIIa in trauma 
remains an unlicensed indication, but it is prescribed off-licence on a named-
Consultant basis to treat non-surgical major haemorrhage after trauma 
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3.3.2 FVIIa’s Role in Clotting 
In 1964, Davie described the “Waterfall Sequence for Intrinsic Blood Clotting” (210). 
This cascade involved two initiator pathways: the “extrinsic” and “intrinsic” systems, 
which resulted in serial activation of clotting factor co-enzymes present in the blood.  
Both initial pathways resulted in activation of factor X, which then led to activation of 
the ‘common stem’; converting pro-thrombin to thrombin; the thrombin in turn 
promoting fibrin polymerisation.  This coagulation factor-centred model conveniently 
explained the Prothrombin Time (PT) and Activated Partial Thromboplastin Times 
(APTT), which had been designed to monitor therapeutic Warfarin levels, but did not 
account for cells or platelets and their contribution to the haemostatic process.  
Within this cascade model, FVII and Tissue Factor formed the extrinsic pathway. 
 
More recently, Hoffman proposed a “Cell-Based Model of Coagulation” (211), which 
has since gained acceptance as an improved hypothesis for in vivo coagulation.  
This model emphasises the roles of specific cell surfaces in controlling the 
coagulation process.  Three overlapping phases of coagulation are described: 
Initiation; Amplification and Propagation. 
3.3.2.1 Initiation 
Initiation takes place on cells bearing Tissue Factor (TF). TF is a trans-membrane 
protein, expressed on surface of sub-endothelial vessel wall cells when activated by 
growth factors and immune mediators (212).  Vessel injury exposes TF to FVII within 
circulating blood and binds it to form an active complex.  This in turn activates factors 
IX and X on the TF-bearing cell (211).  Factor Xa, in conjunction with its cofactor Va, 
produces a small amount of thrombin (IIa) on the TF-bearing cell. This thrombin is 
responsible for the Amplification process (Figure 19). 
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3.3.2.2 Amplification 
Amplification involves the activation of co-factors V and VIII and factor XI.  IIa also 
activates platelets as they adhere and accumulate activated cofactors on their 
surface. It occurs as the “action moves from the TF-bearing cell to the platelet 
surface” (211).  
3.3.2.3 Propagation 
In the Propagation phase of haemostasis, IXa (activated in the initiation phase) 
forms a complex with activated factor VIII (VIIIa).  This complex on the activated 
platelet surface produces large quantities of Xa.  Platelet surface-derived Xa is 
responsible for the “thrombin burst” required to make a stable and firm fibrin clot. 
 
As with the Waterfall model, plasma protease inhibitors such as Antithrombin III and 
Tissue-Factor Pathway Inhibitor (TFPI), localise the coagulation response by 
“mopping up” wandering activated cofactors. 
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Figure 19 Cell based model of haemostasis illustration - taken from www.medi-cell.co.uk 
 
As pharmaceutical rFVIIa has an identical action to the human activated factor, so it 
binds to exposed TF at the site of vascular injury (213). The resulting TF-rFVIIa 
complex catalyses the activation of factors IX and X on the TF-bearing cell surface.  
In this way, rFVIIa initiates the haemostatic pathway.  
 
Further to this, however, Allen describes a mechanism where, at pharmacologic 
levels, rFVIIa binds directly to IIa-activated platelet membranes, resulting in factor X 
cleavage (214). Although this process is a less potent producer of Xa than the first 
route, it nevertheless contributes to significant IIa generation on the platelet surface.  
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Xa on the platelet surface is necessary for the formation of the Prothrombinase 
assembly (215-217).     
3.3.3 Localised Effect at Sites of Bleeding 
So, through both of these mechanisms, rFVIIa promotes thrombin generation where 
TF is exposed to circulating blood.  TF exposure normally occurs only at sites of 
vascular injury, so rFVIIa is an intuitive drug to employ in the management of 
traumatic haemorrhage.  However, some patients will express TF elsewhere; for 
example those with unstable atherosclerotic plaques, or gram negative sepsis (212).   
As such there is a potential risk of complications, such as myocardial infarction and 
stroke and there are case reports of adverse thrombotic events associated with 
rFVIIa administration (218).  
3.3.4 Evidence for rFVIIa in Major Bleeding 
Clinical evidence supporting efficacy of rFVIIa in this role began with promising 
anecdotal reports and progressed through to large case series (219). Eventually 
NovoNordisk sponsored a prospective randomised controlled trial, performed by 
Boffard and colleagues (42). He lead two parallel, multi-centre, prospective, 
randomised, placebo-controlled, double-blind trials of rFVIIa use in trauma (42). 
Inclusion criteria were: patient had received six or more units RBC before 
administration of rFVIIa; fewer than 4hrs from injury and Glasgow Coma Score 
>8/15.  Blunt and penetrating groups were separately randomised.   An initial dose 
(200mcg/Kg) was given after the eighth unit of RBC, followed by further (100mcg/Kg) 
doses at 1 and 3 hrs if required. End points were mortality, transfusion requirements 
and organ failure. 143 blunt injuries and 137 cases of penetrating trauma were 
included into the treatment arms. There was no significant difference in mortality. 
Blunt trauma patients who received rFVIIa required significantly fewer Red Blood 
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Cells (RBC) and blood product units (after excluding those who died within 48hr) with 
a mean reduction of 2.6 units and a 56% reduction in the number of patients 
requiring >20 units of RBCs.  The penetrating injury group failed to reach 
significance for blood product requirement.  
 
The amount of blood transfused is an independent risk factor for mortality and 
development of infection and ARDS (220-222).  When blunt and penetrating cases 
were pooled, there was a significantly reduced incidence of MOF and ARDS in the 
rFVIIa-treated patients.  There was a trend towards reduced time spent on a 
ventilator and fewer Intensive Care Unit (ICU) days.   
 
Several animal studies have demonstrated haemorrhage reduction after rFVIIa 
administration in major haemorrhage models (223-228).  Survival improvement has 
been shown in only two of these studies (223;224)  
 
In 2006 Vincent attempted, with a European panel of experts, “to develop consensus 
guidelines for use of rFVIIa in massive haemorrhage” (229).  He relied heavily on 
Boffard’s paper, as it was the only published randomised controlled trial at the time.  
Lists of key recommendations were tabled:   
1. For rFVIIa to be indicated, conventional means of haemorrhage control must 
have failed.   
2. In blunt trauma, it can be recommended as an adjunct therapy to surgery and 
blood product administration.   
3. It is not recommended for use in penetrating trauma. 
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4. Monitoring of effect should be based on visual inspection and the need for 
ongoing transfusions. 
 
In the military Role 3 setting, rFVIIa is being used, often in multiple doses, as part of 
an aggressive surgical and blood product resuscitation approach for the most severely 
injured bleeding casualties, most of whom have been injured by explosion.  Anecdotal 
reports suggest potential benefit.  Despite Vincent’s attempt to provide guidelines, 
there is no consensus on the efficacy of and indications for rFVIIa use in major 
bleeding from combat trauma.  
3.3.5 Proposed Mechanism of Action in Diffuse Alveolar Haemorrhage 
Diffuse alveolar haemorrhage can occur with a range of pathologies, including 
leukaemia; malignancy; fungal infections and auto-immune diseases.  It causes 
dyspnoea, haemoptysis, hypoxia and anaemia and can be fatal.  Over 50% of 
patients require assisted positive pressure ventilation (230).  As described earlier, 
blast lung injury typically results in diffuse pulmonary haemorrhage.   
 
Alveolar macrophages, activated by acute lung injury, produce high levels of Tissue 
Factor Pathway Inhibitor (TFPI) (20 times normal) (231).  TFPI inhibits the action of 
the FVIIa/TF complex.  This inhibition renders the injured lung more vulnerable to 
ongoing diffuse haemorrhage.  By exploiting the (TF-Independent) direct factor X 
cleavage effect of rFVIIa when bound to thrombin on a platelet surface, the inhibitory 
effect of the high levels of TFPI might be overcome.  
 
The actions of intrinsic FVIIa and pharmacological rFVIIa in alveolar haemorrhage 
and the impact of TFPI are illustrated in the diagram below:  
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Figure 20 FVIIa action and TFPI in alveolar haemorrhage. Modified from (232)   
 
 
Although no work exists to prove elevated levels of TFPI following blast lung, 
inflammatory changes in the lungs and increased systemic inflammatory markers 
have been shown to occur following blast exposure (233).  It is therefore probable 
that activated macrophages produce raised TFPI levels, which then play a part in the 
pathology of diffuse haemorrhage following blast lung injury.  In this case, 
therapeutic levels of rFVIIa could ameliorate haemorrhage through the TF-
independent pathway. 
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3.3.6 Evidence for rFVIIa use in Diffuse Alveolar Haemorrhage 
No clinical studies have investigated the use of rFVIIa to attenuate the diffuse 
bleeding associated with blast lung injury.  Several reports however, describe rFVIIa 
use in the treatment of pulmonary haemorrhage.  The majority are case reports or 
small series and relate to diffuse alveolar haemorrhage.  Although positive reporting 
bias must not be overlooked, these reports do demonstrate the potential efficacy of 
rFVIIa in arresting pulmonary haemorrhage.  They are summarised below (Table 7). 
 
Authors Report Type No. Patients Condition(s) Findings 
Small vessel / diffuse bleeding 
O’Connor et 
al (234) Case report 1 Adult  
Blunt trauma  
Diffuse bilateral 
haemorrhage  
“Near instantaneous cessation 
of bleeding” after single dose 
100mcg/kg rFVIIa.  No 
adverse effect reported. 
Tien et al 
(235) Case report 1 Adult 
GSW chest  
Lung contusion and 
haemoptysis with no 
definitive source in 
non-coagulopathic 
patient. 
Control of haemoptysis, no 
adverse events. 
Kamphuisen 
et al (236) Case report 1 Adult 
Blunt trauma  
Lung contusion and 
massive pulmonary 
haemorrhage 
First 60mcg/kg dose of rFVIIa 
reduced bleeding from 
200ml/hr to 30ml/hr via drain. 
Second dose at 12h stopped 
bleeding.  No adverse effects.  
Full pulmonary recovery. 
Betensley et 
al (237) Case report 1 Adult 
DAH secondary to 
microscopic 
polyangiitis 
Bleeding resolved, patient 
survived, no thromboembolic 
complications noted 
Estella et al 
(238) Case series 2 Adults 
INTRAPULMONARY 
ADMINISTRATION 
DAH in one patient 
with leukaemia and 
another with HIV 
during post-myocardial 
infarction-thrombolysis 
Bleeding resolved, patients 
survived, no thromboembolic 
complications noted 
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Authors Report Type No. Patients Condition(s) Findings 
Henke et al 
(239) Case series 3 Adults 
DAH in 2 small-vessel 
vasculitis–associated 
diseases and bone 
marrow transplantation 
Oxygenation improved within 
minutes of rFVIIa 
administration, patients 
survived, no adverse events 
Hicks et al 
(240) Case report 1 Adult 
DAH in leukaemic 
patient after bone 
marrow transplant 
Improvement in lung function 
after multiple doses of rFVIIa, 
deterioration on 
discontinuation followed by 
resolution after further doses.  
No adverse effects 
Pastores et 
al (241) Case report 1 Adult 
DAH after allogeneic 
haematopoietic stem-
cell transplantation 
The haemoptysis rapidly 
subsided after two doses of 
rFVIIa, and no further doses of 
rFVIIa were administered. No 
adverse effects due to rFVIIa 
were observed. 
Shenoy et al 
(242) Case report 1 Adult 
DAH after stem cell 
transplantation 
Control of bleeding after two 
doses of rFVIIa.  No adverse 
effects reported. 
Wheater et al 
(243) Case report 1 Adult 
Pulmonary 
haemorrhage 
associated with 
metastatic chorio-
carcinoma 
Control of bleeding after single 
dose of rFVIIa.  No adverse 
effects reported. 
Yildrim et al 
(244) Case report 1 Adult 
DAH in a patient with  
pulmonary–renal 
syndrome 
Bleeding controlled by three 
doses of rFVIIa.  Subsequent 
episodes also controlled by 
rFVIIa and patient survived to 
discharge.  (Patient later died 
from a further episode of 
pulmonary bleeding) 
Courtney et 
al (245) Case report 1 Adult 
Bleeding from lung 
parenchyma and distal 
bronchi after 
cardiopulmonary 
bypass 
5 min after rFVIIa 
administration blood loss 
slowed substantially from the 
ETT and ventilation slowly 
improved.  No thrombotic 
complications. 
Heslet et al 
(246) Case series 6 Adults 
INTRAPULMONARY 
ADMINSTRATION 
DAH from a variety of 
medical conditions: 
leukaemia (3); stem 
cell transplant; 
Neurosarcoidosis; 
Wegener’s 
granulomatosis & HIV. 
“An excellent response, 
defined as complete and 
sustained haemostasis after a 
single dose of rFVIIa, was 
seen in 3 patients. A good 
response (sustained 
haemostasis was achieved by 
a repeated rFVIIa 
administration) was seen in 
the remaining 3 patients.”  No 
adverse effects reported. 
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Authors Report Type No. Patients Condition(s) Findings 
Large vessel / focal bleeding 
Lau et al 
(247) 
Case series 4 Adults Massive haemoptysis 
associated with cystic 
fibrosis 
Control of haemoptysis, no 
adverse events. 
Macdonald 
et al (248) 
Case report 1 Adult Massive haemoptysis 
due to necrotizing 
community-acquired 
pneumonia. 
Control of haemoptysis, no 
adverse events. 
Samarzija et 
al (249) 
Case report 1 Adult Massive haemoptysis 
associated with chronic 
necrotising 
aspergillosis. 
Control of haemoptysis.  No 
thromboembolic or other 
adverse events seen. 
White et al 
(250) 
Case report 1 Adult Pulmonary 
haemorrhage 
secondary to 
aspergillus infection 
leukaemic patient with 
acquired FVII 
deficiency 
Control of haemoptysis after 
two doses of rFVIIa, no 
adverse events. 
Felten et al 
(251) 
Case series 4 Adults Surgical bleeding from 
pulmonary artery 
during lung transplant 
A single dose, of rFVIIa 
ranging from 68 to 105 µg/kg, 
was successful and allowed 
chest closure with no need for 
surgical re-exploration.  3/4 
patients subsequently died but 
none of the adverse events 
could directly be linked to 
rFVIIa administration. 
Paediatric 
Brady et al 
(252) Case series 
9 
Children 
(2 
relevant) 
Diverse but included 2 
patients with 
pulmonary 
haemorrhage 
Bleeding resolved, no 
complications relating to rFVIIa 
found. 
Poralla et al 
(253) Case series 
3 
Children 
Massive pulmonary 
haemorrhage in 
preterm neonates 
Bleeding controlled within 
minutes of administration of a 
single dose of rFVIIa.  No 
children showed any clinical, 
laboratory or ultrasound 
derived adverse events; 
especially no signs of 
thrombotic or embolic events 
in the following clinical course. 
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Authors Report Type No. Patients Condition(s) Findings 
Yilmaz et al 
(254) 
Retrospective 
review 
13 
Children 
Diverse  
Included 8 patients 
with pulmonary 
haemorrhage 
Bleeding was stopped 
completely in 10 patients at 
least for 24 h and decreased in 
3 patients 30/45 min after 
rFVIIa administration. Two 
patients had thrombotic 
complications attributed to 
rFVIIa administration. No other 
complication was observed in 
the other patients. 
Olomu et al 
(255) Case series 
2 
Children 
Pulmonary 
haemorrhage 
associated with very 
low birth weight 
Bleeding resolved.  No 
complication associated with 
rFVIIa reported. 
Table 7 Literature Concerning rFVIIa administration in Pulmonary Haemorrhage 
 
Four reports concern paediatric patients.  While the clotting characteristics of 
children differ from adults, (longer clotting times; reduced clotting factor levels, less 
thrombin generation (256)), these reports nevertheless add to the data on pulmonary 
haemorrhage and rFVIIa use. 
 
Two of the reports describe intra-pulmonary administration, rather than IV delivery of 
rFVIIa. Heslet’s six patients all responded to therapy, even after one of them had 
failed to respond to an IV dose (257).  Estella decided on intra-pulmonary therapy as 
both patients had just received thrombolytic therapy for myocardial infarction, so 
systemic rFVIIa administration (and its potential for TF binding remote from the 
target site) was avoided (238). 
3.3.7 Timing and route of rFVIIa administration 
The timing of rFVIIa administration could affect the impact of the agent in arresting 
both major and diffuse alveolar haemorrhage.  While in the early stages of diffuse 
alveolar haemorrhage, bleeding control is of key importance to preserve gas 
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exchange and limit inflammatory sequellae, later on following injury; fibrin deposition 
and permanent scarring might be exacerbated by rFVIIa administration.  Fibrin 
deposition has been demonstrated in ARDS (258) and attributed to over-expression 
of TF and FVIIa (259).  Permanent fibrosis has also been linked to transient intra-
pulmonary fibrin deposition (260).  So great was the interest surrounding this phase 
of ARDS that an international trial was set up to investigate use of a FVII inhibitor 
during established ARDS (24-48hr following injury).  The study was terminated early 
due to excess mortality in one of the treatment cohorts (261).  However, unlike 
recovery from ARDS from other causes, it is also unclear whether transient fibrin 
deposition is even a real problem following blast lung.  The limited data suggests 
recovery of normal lung examination; radiograph and lung function testing at one 
year following blast-induced ARDS (262).   
 
Most authors reporting successful use of rFVIIa in diffuse pulmonary haemorrhage 
have employed intravenous administration of the drug.  Intrapulmonary (inhalational) 
administration has been reported by only two authors (238;257). Military blast injury 
is a combined trauma producing significant external haemorrhage as well as blast 
lung.  As a first step in investigating the efficacy of rFVIIa for improving survival in a 
blast and haemorrhage model, it seems logical to employ an intravenous 
administration route and a single-dose strategy that might be easily translated to a 
field protocol. The present study therefore seeks to establish whether early use of 
rFVIIa can improve mortality following a combined blast and haemorrhage injury.  
Therefore a single intravenous dose of human rFVIIa was used, in conjunction with 
permissive hypotensive fluid resuscitation.  A dose of 180µg/kg was selected as this 
had previously been shown to increase survival time in an animal model with 
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incompressible major vessel injury (263). The drug was administered at 30 minutes 
after the onset of fluid resuscitation.  
3.4 Study Aims  
The overarching aims of this thesis are to use a clinically relevant animal model of 
battlefield injury to provide clear answers to the following questions: 
1. Does supplemental inspired oxygen improve survival and preserve physiology 
after a combined primary blast and haemorrhage injury? 
2. Can a single intravenous dose rFVIIa improve survival and preserve 
physiology after a combined primary blast and haemorrhage injury? 
 
The following chapters will discuss the experimental model (Chapters 4 and 5) and 
present the results of the interventions (Oxygen, Chapter 6 and rFVIIa, Chapter 7). 
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4 Method Development 
A clinically relevant model of severe battlefield injury was used in terminally 
anaesthetised pigs to evaluate the efficacy of supplementary oxygen and rFVIIa as 
adjuncts to resuscitation.  The model was designed to represent a severely injured 
military casualty, wounded by an explosive munition.  Exposure of the animal to a 
blast wave detonation produced a primary blast injury.  Severe haemorrhage 
represented the bleeding sequellae of injury from energised munition fragments.  
The potential for uncontrolled haemorrhage was included in order to demonstrate 
any rebleeding.   
 
The study formed part of an ongoing programme of work at DSTL Porton Down.  A 
preceding study had employed an animal model that incorporated blast and both 
controlled and uncontrolled haemorrhage (39).  The injury model in this study was 
similar. Modifications and their rationale are described in the following sections.  
4.1.1 Explosive Charge 
Uncased 2.2Kg Octol high explosive charges were used for all blast exposures in 
this study.  This particular explosive was chosen because of the high degree of 
reproducibility in its output.  Previous experience with this explosive on the same 
breed of pig led to the stand-off (distance between animal and explosive charge) 
being set at 2.10m from the centre of the charge to the body wall at the level of the 
8th rib. Physiological changes and post mortem analysis confirmed this was reliably 
producing a severe, but not immediately overwhelming blast insult. 
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4.1.2 Haemorrhage volumes and liver section 
The original model incorporated an initial haemorrhage of 30% total estimated blood 
volume followed by a second controlled haemorrhage of 5% blood volume to 
simulate a re-bleeding episode during resuscitation.  This re-bleeding episode was 
not required in our study and was therefore removed from the experimental protocol.    
The model also incorporated a Grade IV liver injury, induced at the end of the 
controlled haemorrhage.  This led to an incompressible haemorrhage, which was 
found to be consistent between groups and provided tissue injury and a capacity for 
re-bleeding.  Although this study was not expected to produce rebleeding, the liver 
section was included because of its tissue injury.  Tissue injury is normally present 
on a large scale in victims of explosive injury, so this liver section was felt to increase 
the validity of the model. 
4.1.3 Oxygen therapy target of SaO2 95% 
A clinically relevant target was chosen to guide oxygen support.  Rather than sticking 
dogmatically to a given FiO2, oxygen therapy was titrated to a target SaO2 of 95%.  
Pulse oximetry is widely available in the field and medics of all levels are familiar with 
its application.  Both in this study, and in the field, oxygen concentration and/or flow 
can easily be titrated to achieve and maintain the target saturation.  
4.1.4 180mcg/Kg dose and intravenous administration of rFVIIa 
There is no consensus regarding the minimal effective dose of rFVIIa in trauma, nor 
in DAH.  Barletta’s review of rFVIIa use in trauma revealed that most trials had used 
doses between 60-120mcg/kg (264).  180mcg/kg therefore seems to be a relatively 
high dose in human terms. The rationale for selecting this high dose was the fact that 
human rFVIIa was used in pigs.  Although the pig is responsive to human rFVIIa, the 
sensitivity is reduced compared to humans.  The resolution to this insensitivity is to 
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increase the dose, and a dose of 180 mcg/kg in the pig has been adopted by several 
investigators of swine injury models as ‘equivalent’ in terms of effect to a human 
clinical dose (224-227;265).  Further, a previous study at DSTL Porton Down 
demonstrated improved survival in a swine model of severe incompressible 
haemorrhage in the absence of blast injury (223;266). It is noteworthy that Boffard’s 
randomised controlled clinical trials also adopted a high initial dose (200mcg/kg) of 
rFVIIa, aiming to achieve a plasma concentration of 40ng/L; an amount 
approximately three times greater than would be achievable via cryoprecipitate and 
FFP transfusion.  No safety concerns were raised from Boffard’s study.  
 
That the drug was administered intravenously in this study is also in line with 
previous work and the most common form of use in clinical practice for diffuse 
alveolar haemorrhage.   
4.1.5 Shared control group 
Both oxygen and rFVIIa groups required a control (untreated) group.  The 
corresponding control for the supplementary oxygen group is to breathe air, while the 
control for the rFVIIa group is to receive placebo.  Since both treatment strategies 
are superimposed on combined blast injury and haemorrhagic shock, followed by 
hypotensive resuscitation, a single group given air to breathe throughout and treated 
with 0.18 ml/kg body weight 0.9% saline 30 min after the onset of resuscitation 
served as a control for both oxygen and rFVIIa treatments.  The volume of placebo 
amounted to 9 ml for a 50 kg pig (0.38% estimated blood volume at the end of 
haemorrhage) and is therefore negligible as a resuscitation volume.  For these 
reasons, the control group was shared, resulting in fewer animals sacrificed 
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(consistent with the requirements of the Animals Scientific Procedures Act 1986). 
This also reduced the financial cost.  
4.1.6 Power Calculation 
A power calculation, based on an increase from 0.1 to 0.8 in the proportion surviving 
to 8 hours from the onset of resuscitation in the previous Novel Hybrid study 
indicated that 7 animals would be required in each of the hypotensive and oxygen 
treatment groups (Power 0.8, Alpha 0.05, Chi Squared test).  
 
There was insufficient clinical and experimental evidence regarding rFVIIa’s effect in 
blast lung and haemorrhage to guide group size requirement for the primary 
outcome measure.  A group of the same size was chosen and an interim analysis 
planned at n=6 for each group. This would determine whether a clear (statistical) 
conclusion had been attained and, if not, how many additional animals would be 
required to provide an unequivocal conclusion.  
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5 Methods 
5.1 Licensing and Animal Husbandry 
Prior to commencing the study, the programme of work underwent Local Ethical 
Review (DSTL Porton Down) and gained a United Kingdom Home Office Project 
Licence (PPL 30/2022). The entire study was carried out in accordance with the 
Animals (Scientific Procedures) Act 1986. 
 
Immature female Large White pigs were sourced from a commercial supplier, whose 
animals are classed as Specific Pathogen Free.  Animals were delivered by trailer at 
least 7 days in advance of the trials, attended to twice daily and fed and watered ad 
libitum (16% protein home-milled coarse mix).  The animals were weighed three 
times per week and on the afternoon before a trial. Mean trial-day weights were 51.8 
± 2.2 [48-56] Kg (mean±SD [range]).  Feeding was discontinued 18 hours before 
planned induction of anaesthesia and the animals restricted to water only.   
5.2 Anaesthesia 
Animals underwent terminal anaesthesia, i.e. anaesthesia was induced and 
maintained throughout the study, followed by humane killing at the end with an 
overdose of anaesthetic without recovery of consciousness.  
5.2.1 Induction and Intubation 
Sedation was achieved with 5ml of Midazolam hydrochloride (approx. 0.1mg/kg) via 
intramuscular injection.  Once sedated, anaesthesia was induced by inhalation of 
Isoflurane 5%, driven by a 1:1 ratio of Oxygen (O2) and Nitrous Oxide (NO) via a 
nose cone.  Endotracheal intubation with a size 8.0 silicone oral/nasal tube (Vygon 
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514.80, France) followed induction.  Aspiration, chest wall movement and end-tidal 
Carbon Dioxide (CO2) monitoring (Propaq 106 EL, Dräger Medical) confirmed 
correct tube position.  An Oesophageal Doppler Probe (CardioQ™, Deltex Medical) 
was placed.  The endotracheal tube was then secured with strong adhesive tape and 
the mouth loosely packed with gauze. 
5.2.2 Maintenance of Anaesthesia in Operating Theatre 
Once intubated, the animals were moved to the operating theatre, where 
anaesthesia continued with Isoflurane (1-2%) and a mixture of O2 and NO (ratio 1:2) 
(Blease Frontline Plus 690). The animals were then ventilated (Blease Frontline 
Manley MP3 Anaesthetic Ventilator) for the duration of the surgical procedure.  
Monitoring comprised a Propaq 106 EL (Dräger Medical) monitor for continuous 3-
lead ECG, End Tidal CO2 and rectal temperature measurements. Once central 
venous access was secured at surgery, inhalational anaesthesia was replaced by an 
intravenous (IV) infusion of Alfaxalone (Alfaxan®, Vétoquinol), at a starting rate of 
1ml/Kg/hr (IVAC Medical Systems™ P2000 syringe driver).  The anaesthetic infusion 
rate was adjusted to maintain surgical anaesthesia.  Total Intravenous anaesthesia 
continued for the remainder of the experiment.  At the end of surgery mechanical 
ventilation was discontinued and the animals breathed air spontaneously. 
5.2.3 Maintenance of Anaesthesia in Blast Arena 
For obvious safety reasons, there is a short period surrounding the time of explosion 
when nobody can be at the animal’s side. To ensure reliable anaesthesia during this 
phase, two separate anaesthetic lines were connected to independent syringe 
drivers, protected from the explosion within padded metal containers placed behind 
large concrete blocks.  One of these was connected by remote cord to the range 
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bunker as a back up system.  On returning to the animal after the blast exposure, the 
infusion status was checked immediately after airway and breathing.  
5.2.4 Maintenance of Anaesthesia in the Range Bunker 
The IV infusion of Alfaxan® continued, titrated to depth of anaesthesia. The animal 
was only ventilated (Evita 2, Dräger Medical) if its Arterial Blood Gas (ABG) showed 
a PaO2 < 7 KPa, or a PaCO2 >6 KPa.  Mechanical ventilation was discontinued if 
the animal showed signs of spontaneous breathing, (to determine if the animal had 
regained the capacity for adequate ventilation and gas exchange). 
5.2.5 Temperature Control 
Warming pads, a silver-foil blanket, a wool blanket and a portable electric heater 
were used to maintain the animal’s normal rectal temperature of 38.7-39.8°C (267).  
If the temperature rose above 39°C, the animal was fanned and cooling pads 
applied.  Resuscitation fluids were warmed in an incubator bath set to 45°C (some 
cooling occurred in the infusion lines, so the fluid entering the animal was below 
40°C).  Core body temperature was measured by a rectal temperature probe, 
connected to the Propaq 106 EL monitor (Dräger Medical). 
5.3 Surgical Preparation 
After intubation, surgical fields were shaved and prepared with Pivodine Iodine 
(Betadine®, Purdue Pharma) antiseptic.  The animal was placed supine, covered 
with a large sterile surgical drape, cut to expose the neck; abdomen and left groin.  
5.3.1 Vascular Access in the Neck 
Both carotid sheaths were exposed via a midline neck incision.  The left internal 
carotid artery and internal jugular vein were cannulated with Portex 8 French lines, 
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(Hythe, UK), flushed and sutured in position (Figure 21).  A pulmonary artery 
catheter (744MF75 Swann-Ganz, Edwards Life Sciences Ltd, Newbury, UK) was 
floated through an introducer sheath (Desivalve Catheter Introducer, Vygon, 
Cirencester UK) in the right internal jugular vein.  Pulmonary arterial placement was 
confirmed by pressure wave monitoring (Propaq 106 EL, Dräger Medical AG &Co. 
Lübeck, Germany).  The neck incision was closed with a silk blanket suture.  
 
Figure 21 Vascular Access in Neck 
  
5.3.2 Splenectomy 
Pigs’ spleens are invested with smooth muscle and the organ acts as a reservoir for 
a significant amount of blood (268). This smooth muscle contracts during the 
sympathetic response to haemorrhage; squeezing blood into the circulation.  In order 
to replicate more closely the human response to haemorrhage, the spleen was 
therefore removed in all animals.  After mobilisation, the short gastric vessels were 
ligated and divided.  With the main pedicle still patent, 1ml 1:1000 Epinephrine was 
dripped onto the surface and massaged onto the spleen. This contracted the smooth 
muscle, emptying the organ of most of its stored blood. The splenic pedicle was then 
126 
 
double-ligated and divided. The spleen was removed and weighed to estimate 
retained blood volume: this guided crystalloid fluid replacement at a ratio of 3:1.   
5.3.3 Liver Snare 
Dstl Porton Down has developed a liver snare which creates a grade IV liver injury in 
the middle lobe of the swine liver (39). Figure 22 illustrates the technique. The two 
pull-cords are exteriorised and pulled at a later stage in the experiment to create a 
mixed arterial and venous injury, with the potential to re-bleed (uncontrolled 
haemorrhage).  
 
 
Figure 22 Liver Section schematic 
 
5.3.4 Open Suprapubic Cystostomy 
Two 2/0 Polyglactin 910 (Vicryl™, Ethicon, UK) purse-string sutures were placed on 
the anterior wall of the bladder.  A cystostomy was made with diathermy in the centre 
of the purse-string and a 14G Foley Catheter placed into the bladder (Bard Ltd, 
Crawley, UK). The balloon was filled with 10ml sterile water and the sutures drawn 
up and tied.  The bladder was emptied.  
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5.3.5 Abdominal Closure 
The abdominal incision was closed en-mass with continuous size ‘0’ Nylon double-
stranded sutures (PDS™, Ethicon, UK).  The two liver snare pull-cords and the Foley 
catheter were exteriorised without snagging.  The wound was dressed with thick 
black adhesive tape. 
5.3.6 Femoral Vessel Cannulation 
Approached through a left-sided groin incision (Figure 23), the femoral vessels were 
distally ligated and cannulated with trimmed 8Fr Dog catheters (Arnolds®, Smiths 
Medical International Ltd. Hythe, UK). Three-way taps (Vyclic-Color, Vygon, Ecouen, 
France) were placed and the lines secured.  The incision was closed with a silk 
blanket stitch.  
 
In the pig, the profunda femoris artery, gluteal vessels, circumflex femoral arteries 
and their collaterals supply the musculature of the hind limb above the knee.  The 
profunda vessel separates proximally (Figure 24). The superficial femoral artery, 
which we ligate, has few branches above the knee. Below the knee in the swine, 
there is little muscle and, while some tissue ischaemia will have resulted from 
ligation, frank ischaemia was not seen in any animal even at the 8hr endpoint of the 
study.  Any distal ischemia will have been similar for all animals and worse for those 
living longest.  
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Figure 23 Femoral Vessel Cannulation 
 
 
Figure 24 - anatomic swine specimen.  Note proximal division of common femoral artery into deep and 
superficial branches. (Photograph taken from www.anselm.edu) 
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Figure 25 schematic of swine hind limb vasculature (taken from www.biologycorner.com) 
5.4 Physiological Measurements and Sampling 
Several parameters were measured continually; other measurements and samples 
were taken at intervals.  Table 8 provides an overview of the monitoring methods. 
Table 9 illustrates the blood sampling protocol: 
Time Device Uses Manufacturer 
Monitoring 
Propaq 106 EL 
Monitoring System 
End Tidal CO2, 
Respiratory Rate 
Continuous ECG 
Core Temp (°C) 
Dräger Medical AG 
&Co. Lübeck 
(Germany) 
DP12 
Oesophageal  
Doppler Probe  
CardioQ™ Monitor 
Stroke Volume, 
Haemodynamics 
Deltex Medical Ltd. 
Chichester (UK) 
Central Lines 
and Catheter 
Left Internal 
Jugular  
8Fr Dog Catheter 
Intravenous 
Anaesthetic Smiths Medical Instruments, Hythe 
(UK) Left Carotid Artery 
8Fr Dog Catheter 
Arterial Pressure 
Arterial Blood Gas 
Right Internal 
Jugular 
Desivalve Catheter 
Cardiac Output 
(Vigilance™ Monitor) 
Central Venous 
Vygon, Ecouen 
(France) 
& 
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Introducer 
& 744MF75 
Swann-Ganz 
Catheter 
Pressure 
Pulmonary Artery (PA) 
Pressure 
PA Wedge Pressure 
Temperature 
Mixed Venous Blood 
Gas  
Edwards Life 
Sciences (UK) 
& 
SensoNor 840, 
SensoNor a.s., 
(Norway) 
Left Femoral 
Artery  
8Fr Dog Catheter 
Controlled 
Haemorrhage 
Haematology Sampling 
Smiths Medical 
Instruments, Hythe 
(UK) Left Femoral Vein 
8Fr Dog Catheter 
Resuscitation Fluid 
Infusion 
Foley Catheter 
(18Ch) 
 
Urine output  
Urine biochemistry 
Microalbuminuria  
Bard, Ltd, Crawley 
(UK) 
(Blast Arena) 3-lead ECG End Tidal CO2 
Remote monitoring 
during blast exposure 
Laptop Computer 
Maclab 8/s, & 
Chart v4.2.3, 
ADInstruments, UK 
Table 8 Monitoring devices and parameters 
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Time 
Arterial 
Blood 
Gas 
Mixed 
Venous 
Blood Gas 
Full 
Blood 
Count 
TT, PT, 
APTT, 
Fibrinogen 
U&E C-RP IL-6 Calcium 
ROT
EM 
 
TEG 
ICAM  
VCAM  
Line (Carotid) ■  ■ ■ ■ ■ ■ ■ ■ ■ 
Line (Jugular) ■ ■ ■ ■     ■  
Post Surgery ■ ■ ■ ■     ■ ■ 
Baseline 1 ■ ■  ■     ■  
Baseline 2   ■ ■ ■ ■ ■ ■   
Baseline 3 ■ ■         
Post Blast ■   ■     ■  
Pre 
Haemorrhage ■ ■ ■ ■ ■ ■ ■ ■ ■  
Post 
Haemorrhage ■ ■  ■ ■  ■ ■   
T0 ■ ■ ■ ■  ■ ■ ■  ■ 
T15 ■ ■  ■   ■ ■   
T30 ■ ■ ■ ■ ■ ■ ■ ■ ■  
T45 ■          
T60 ■ ■ ■ ■  ■ ■ ■ ■ ■ 
T90 ■ ■   ■      
T120 (2hr) ■ ■ ■ ■  ■ ■ ■ ■ ■ 
T150 ■ ■   ■      
T180 (3hr) ■ ■ ■ ■  ■ ■ ■ ■  
T210 ■ ■   ■      
T240 (4hr) ■ ■ ■ ■  ■ ■ ■ ■ ■ 
T270 ■ ■   ■      
T300 (5hr) ■ ■ ■ ■  ■ ■ ■ ■  
T330 ■ ■   ■      
T360 (6hr) ■ ■ ■ ■  ■ ■ ■ ■ ■ 
T390 ■ ■   ■      
T420 (7hr) ■ ■ ■ ■  ■ ■ ■ ■  
T450 ■ ■   ■      
T480 (8hr) ■ ■ ■ ■  ■ ■ ■ ■ ■ 
(Preservative) Heparin Heparin EDTA 
Sodium 
Citrate 
(SC) 
Lithi
um 
Hep
arin 
Lithiu
m 
Hepari
n 
SC 
Lithiu
m 
Hepa
rin 
SC Serum 
Table 9 blood sampling protocol 
 
Dots indicate collection of sample 
TT   Thrombin Time 
PT Prothrombin Time 
APTT Adjusted Partial Thromboplastin Time 
U&E Urea and Electrolyte Panel 
ROTEM Thromboelastometry 
TEG Thromboelastography 
IL-6 Interleukin 6 
 
132 
 
5.4.1 Cardiovascular Measurements 
Arterial blood pressure was recorded via the carotid artery cannula.  Pulmonary 
arterial and central venous pressures were recorded via the flow-directed balloon-
tipped flotation catheter, which was also used to determine cardiac output as a 6 
minute rolling average (Vigilance™ Volumetrics CEDV, Edwards Lifesciences™, 
USA).  Additional assessments of cardiac stroke volume (stroke distance) and 
haemodynamics were made using trans-oesophageal echo (Deltex Medical Ltd. 
Chichester (UK)).  Physiological pressure measurements were made using strain 
gauge manometers (SensoNor 840, SensoNor a.s., Norway): zero pressure for all 
transducers was set at heart level.  Core body temperature was measured by rectal 
probe (Propaq 106 EL) and maintained at approximately 38°C using external 
heating/cooling and blankets as appropriate. 
 
All cardiovascular variables were recorded using a computerized data acquisition 
system (Maclab 8/s, ADInstruments, UK) and associated software (Chart v4.2.3, 
ADInstruments, UK) for subsequent analysis. 
5.4.2 Blood Gas Analysis 
Blood gas analysis was performed alongside cardiovascular measurements, but an 
extra set was taken immediately after blast exposure.  Arterial and venous blood 
samples were taken anaerobically into heparinised syringes from the carotid and 
pulmonary artery catheters respectively for blood gas, base excess and lactate 
analysis (Gem Premier 3000 Blood Gas Analyzer, Instrumentation Laboratories, 
Warrington, UK).   
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5.4.3 Biochemistry, Haematology and Urinalysis 
Table 9 above illustrates the blood sampling protocol.  Urine output was recorded 
hourly by evacuation of the bladder.  Urine samples were taken each hour for 
biochemistry and detection of microalbuminuria.  
 
For assessment of coagulation and inflammatory responses, arterial blood samples 
were collected into citrated vacutainers (9NC 0.105M Vacutainer 367691, Beckton 
Dickinson, UK), centrifuged at 1500 x g for 10 min and the plasma separated and 
stored at -80°C.  Prothrombin time (PT) was determined using the ACL Elite 
(Beckman Coulter, UK) by turbidimetry.   
5.5 Experimental Protocol 
 
Figure 26 Experimental Protocol 
5.5.1 Blast Arena and Exposure 
A large van was used to transport the instrumented animal for the 15-minute journey 
from the operating theatre to the range.  The animal was accompanied and 
Start CH Stop CH 
Haemorrhage
30% BV
Incompressible haemorrhage (Grade IV liver injury)
5 min Shock Phase
Result of injury / delay before treatment
T30T0
Start resuscitation
SBP target 80 mmHg
MERT or DrBuddy aid / 
Team Medic
Surgery
8 h monitoring post resuscitation (T0)
T480
Baseline measurements 
5 min apart
B1 B2 B3
Deploy to 
Range
Second phase (either/or)
• No adjunct (control)
• FiO2 elevated to SaO2 95%
• rFVIIa (180 µg/kg iv)
• ALL GROUPS continue SBP 
target 80 mmHg (0.9% Sal)
Field Comparison
Blast
Wounding 
Event – Blast and Haemorrhage
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monitored throughout. Once at the range, three baseline measurements and blood 
samples were taken at five minute intervals; the first one hour after the end of 
surgery. The animal was then mounted supine onto the blast rig, with the right thorax 
nearest the charge, and wrapped in a Kevlar® blanket to protect from any fragment 
injury.  ECG and respirometry were relayed to a laptop computer in a bunker.  
 
Figure 27 Blast arena prior to explosive insult. Cardboard mounting tube for placement of uncased charge (see 
Figure 28). Sliding rig on right side with animal wrapped in Kevlar to protect from fragment debris (monitoring 
and anaesthesia lines out of view). Stand-off 2.1m from charge to animal body wall.  
 
A stand-off of 2.10m was measured from the centre of the charge to the body wall at 
the level of the 8th rib.  This protocol was determined based on previous work 
performed by the Trauma and Biophysics Team at DSTL Porton Down, who have a 
broad experience in exposing large animal models to blast injury (269).  
 
The same batch of 2.2kg uncased cylindrical high explosive Octol charges was used 
for all experiments in the series.   
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Figure 28 Charge set up. See photograph of blast pad (Figure 27) for scale and position of charge in relation to 
animal on rig. 
 
After detonation of the charge and a safety check of the area, the surgical team 
quickly returned to the animal, always arriving within 120 seconds from charge 
detonation.  Airway patency, breathing and anaesthetic delivery were confirmed.  
Concurrently, blood samples were taken from the femoral arterial line. The animal 
was recovered to the range bunker for the rest of the experiment.  
5.5.2 Controlled Haemorrhage 
15 minutes after the blast, 30% of the animal’s blood volume, calculated from body 
weight (Equation 8), was pumped (MasterFlex® LIS® Computerised Drive Pump, 
Cole-Palmer Instrument Co. Il, USA) from the femoral arterial line, through silicone 
tubing (MasterFlex® Precision Tubing, Cole-Palmer), and collected into 3 blood 
donation bags (CPDA-1, Baxter Healthcare Corp. Il, USA) placed on scales 
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(Sartorius LP2201, accurate to 0.1g).  The bleed occurred over 5.3 minutes, with a 
progressively decreasing rate of bleeding, designed to reflect the reducing flow over 
time from a real arterial injury (270).  By monitoring the weight of removed blood, the 
accuracy of exsanguination volume was confirmed.  The calculations below dictate 
the quantity and rates of haemorrhage adjusted to body weight: 
 
Total Blood Volume (B0) (ml/kg) = 161.4751(Wt-0.2197) (271) 
Equation 8 Blood Volume by Swine Body Weight.  
 
Arterial Rate of Exsanguination (V) = B0(1-e(-0.04t)) (270)    
Equation 9 Haemorrhage Rates in Arterial Exsanguination (V= the total blood loss (ml/Kg) and t= the 
percent time until death) 
 
5.5.3 Uncontrolled Haemorrhage 
The two pull-cords of the previously described liver snare were pulled immediately 
after completion of the controlled haemorrhage. The ‘cheese-wire’ was pulled first to 
achieve amputation, followed by the ‘separator’ cord to ensure complete avulsion of 
the amputated segment.  The resulting grade IV liver injury (272) produces both 
arterial and venous incompressible haemorrhage with the potential for rebleeding. 
5.5.4 Shock phase and onset of fluid resuscitation 
Following completion of the haemorrhage, there was a 5 minute ‘lock-out’ period, 
designed to reflect a realistic minimum time interval before resuscitation could 
commence in a military environment.  Time ‘0’ began at the end of the lock-out 
phase.  Warmed 0.9% Normal Saline (Aquapharm®, Animalcare Limited, York, UK) 
was infused into the femoral venous line, controlled by a Masterflex® computerised 
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pump, at a rate of 3ml/kg per minute.  Fluid was given continuously until the target 
systolic blood pressure (SBP) was attained: further aliquots were given to maintain 
the target SBP whenever required for the duration of the experiment.   
5.5.5 Permissive Hypotension 
The target SBP for resuscitation was 80mmHg; representing the hypotensive 
strategy advocated by the National Institute for Health and Clinical Excellence 
(NICE) for prehospital fluid resuscitation (273).  
5.5.6 Randomisation and Death before Treatment group separation 
Animals were allocated randomly at the outset of the study to the treatment groups 
using a random number table.  The study was not designed to be ’an intention to 
treat’ analysis, but rather an investigation of physiological effects of resuscitation. 
Despite the injury being standardised as far as possible (e.g. reproducible explosive 
charges, fixed distance between charge and animal, placement of liver snares to 
anatomical landmarks) a few animals succumbed e.g. due to ventricular fibrillation 
after combined blast and haemorrhage or catastrophic blood loss during the 
uncontrolled haemorrhage (verified at post-mortem examination) before instigation of 
treatment. As such, the few animals that did not reach the point of treatment initiation 
were excluded, as they contributed no meaningful data to these physiological 
responses.  Therefore, although the intended group for each individual animal was 
pre-determined according to a random table, if a death occurred prior to 
commencement of treatment then the animal was excluded and the following animal 
allocated to the treatment paradigm.  
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5.5.7 Supplemental Oxygen Group 
For the oxygen group, oxygen support was initiated at T30. The oxygen (minimum 
FiO2 = 0.3) was delivered via an anaesthetic machine and the use of a nose cone 
overlapping the snout of the intubated animal (Figure 29).  The FiO2 was titrated to 
maintain a SaO2 of 95%. SaO2 was recorded by blood gas analysis.  The ‘Blast Air’ 
control group received no oxygen therapy, but did receive a very small saline bolus 
of approximately 9ml (0.18ml/kg), as this group also served as the control group for 
the rFVIIa study limb.  
 
Figure 29 Nose Cone set up for oxygen supplementation at desired FiO2. End tidal CO2 monitoring ensured 
animal was not 'rebreathing'. 
5.5.8 Recombinant Activated Factor VII Group 
Recombinant activated Factor VII (Novo Seven™) was purchased from 
NovoNordisk, Denmark and refrigerated at 4ºC.  After preparation, (in line with the 
manufacturer’s instructions), it was administered intravenously as a single dose at 
T30, adjusted for body weight.  The dose was 180mcg/Kg.  This dose had previously 
increased survival time in an animal model of severe incompressible haemorrhage 
(223). 
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5.5.9 Control Group 
The test groups shared a control group, termed ‘Blast Air’ or ‘Placebo’.  As placebo 
for the rFVIIa study, animals received 0.18ml/Kg of normal saline at T30 (9ml for 
50Kg animal).  This is a clinically negligible volume of fluid and does not compromise 
the use of the animals as controls for the oxygen study.  
5.5.10 Experimental End Point 
The primary end point of the experiments was survival, up to a maximum of 8 hours 
(T480) after the onset of resuscitation.  Death was defined as a pulse pressure of 
zero. If the animal died prior to T480, a Phenobarbitone overdose was administered 
IV to confirm euthanasia (Euthatal, Merial Animal Health Ltd).   If the animal survived 
to T480, the same overdose was administered to euthanize the animal.   
5.6 Post-Mortem Examination 
Immediate post mortem examination was performed.  Table 10 illustrates data sets 
and tissue sampling protocols.   
 
Abdominal sutures were cut and the abdomen carefully opened.  Free Intra-
abdominal blood was collected with suction and pre-weighed gauze packs.  The 
volume of intra-abdominal fluid as an indicator of uncontrolled haemorrhage was 
calculated.  The liver section was examined for completeness of amputation and a 
note was made of the quality of the clot on the raw surface of the middle lobe.  The 
intestines were examined to identify evidence of blast bowel injury (Figure 31).  
Sections of non-contused lung, heart, small bowel, kidney and liver were removed 
(Table 10).  Tissue samples for light microscopy were fixed in neutral buffered 
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formalin (VWR International Ltd. Lutterworth, UK) and prepared in a standard fashion 
(5.5.8).   
 
The thoracic cavity was opened and the lungs and heart removed. The lungs were 
examined for blast injury (Figure 30) and a percentage score for blast damage was 
given to each lobe.  Froth or clots in the trachea were noted.  The lungs were 
stripped of mediastinal attachments and weighed to allow calculation of the lung 
weight index (lung weight/body weight).  The heart was inspected for contusions.   
  
Figure 30 Post Mortem Blast Lung    
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Figure 31 Post mortem blast bowel 
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Animal No:                   Date:                                 Wt:                              O2     /    FVIIa 
ABDOMEN Uncontrolled Haemorrhage 
Estimation 
Volume by Suction ml 
Weight of Blood in Packs gm 
Volume of Blood in Packs  
(1ml = 1.036 gm) ml 
Total Volume of Intraperitoneal Blood ml 
LUNG Weight gm 
LIVER section Weight gm 
PM Appearance 
Chest Wall   
Liver  
Kidneys  
Heart  
Small Bowel   
Large Bowel   
Lung 
Trachea  
Right 
Upper 
         % (contused) 
 
 
Lower 
         %  
 
Left 
Upper 
         %  
  
 
Lower 
         %  
 
 
Samples Yes No  
Liver   3 samples, away from middle lobectomy: RNA later 
Lung   Not from contused area:  RNA later  
Lung wet/dry   Not from contused area, 1 sample each lobe (six). Glass pot 
Small Bowel   Formulin 
Kidney   Formulin 
Left Ventricle   Formulin 
Table 10 Post Mortem datasheet 
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Samples were also taken from the lung and liver for quantitative PCR detection of 
adhesion molecules, ICAM and VCAM.  These were preserved in ‘RNA later’ 
(Sigma, UK); an RNA stabilisation solution for tissue sections and refrigerated at 4ºC 
before analysis. The pathologists examining specimens were blinded to the animals’ 
treatment status.  
 
In order to determine the safety of systemic rFVIIa administration, lung, liver, kidney, 
small intestine and left ventricular samples were immersed in 10% neutral buffered 
formalin (NBF) for a minimum of 48hrs. Samples were sectioned to a thickness of 
3mm, rinsed in 20% alcohol and processed overnight in a Tissue-Tek Infiltration 
Processor (VIP).  The processed samples were embedded in wax, cut into 5 micron 
sections, mounted on glass slides and duplicate sections were stained with 
haematoxylin and Eosin and Martius Scarlet Blue.  The slides were examined for 
evidence of microthrombi or microemboli by Histopathologists blinded to the 
treatment groups.  
5.7 Statistics 
All data are presented as mean ± s.e. mean unless indicated otherwise.  Survival 
times in the oxygen, rFVIIa and control groups were compared using a Kaplan-Meier 
analysis (Mantel-Cox log rank test) using SPSS v10.  Data from animals still alive 
after 8 hours were treated as right-censored.  Cardiovascular, blood gas and 
chemistry data were compared using two-way analysis of variance (ANOVA) with 
repeated measures over time.  Single time-point analyses were made using a 
Student’s t test.  Where data was found to be non-normal a non-parametric 
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equivalent was used as indicated in the text.  In all cases a significance level of 
P≤0.05 (two tailed) was used. 
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6 Effects of Supplemental Inspired Oxygen 
6.1 Introduction 
This study has investigated two adjuncts to fluid resuscitation in an animal model of 
prolonged resuscitation after haemorrhage and blast injury.  Both adjuncts seek to 
improve oxygen delivery, without increasing the hydrostatic pressure exerted across 
nascent blood clots.  
 
The relevance of our blast and haemorrhage model to military clinical reality is 
brought into focus by the fact that the commonest mechanism of injury in current 
(Afghanistan) and recent (Iraq) conflicts has been the improvised explosive device.  
In Afghanistan, this has produced an 11% incidence of primary blast injury seen in 
casualties surviving to reach the field hospital in Afghanistan (186) and a 48% 
incidence in those sustaining thoracic trauma from blast (JTTR Review of 1678 
seriously injured Casualties from Iraq and Afghanistan between Jan 2003 and Oct 
2009).  Although evacuation times are short in mature theatres, entry operations and 
immature combat zones tend to incur long evacuation timelines of several hours’ 
duration.  The need to prolong life and preserve physiology in critically injured 
battlefield casualties, without relying on the ability to achieve rapid surgical 
haemorrhage control, provides the context for this work. 
 
Fluid therapy has been shown to improve survival after blast and haemorrhage, but 
the efficacy of supplementing oxygen, while adhering to a permissive hypotensive 
resuscitation fluid target has yet to be determined.  The hypoxia that results from 
blast injury impairs oxygen delivery (the key factor in shock) and haemorrhage 
reduces both oxygen carrying capacity and flow to the tissues.  Supplemental 
146 
 
oxygen has the potential to improve oxygen delivery in victims of blast and 
haemorrhage by increasing the arterial oxygen content.  It should exert no increased 
hydrostatic pressure across a nascent blood clot and will therefore be acceptable to 
clinicians who hold concerns regarding re-bleeding at sites of vascular injury.  
Modern oxygen support technologies have made feasible the possibility of supplying 
oxygen to far forward and remote units.   
6.2 Aims 
The aim of this part of the study is to provide robust data to answer the question 
whether oxygen has the potential to preserve life and physiology in critically injured 
(blast and haemorrhage) prehospital casualties.  If proven to be effective, the data 
will support investment into, and adoption of, a sustainable; remote oxygen support 
capability. 
6.3 Methods 
12 terminally anaesthetised swine were exposed to a standardised injury model of 
primary blast insult, 30% (controlled haemorrhage) blood volume haemorrhage and 
grade IV liver laceration (via deployment of surgically implanted liver snare to create 
uncontrolled haemorrhage (5.3.3).  All were resuscitated with warmed 0.9% saline to 
a hypotensive target blood pressure of 80mmHg and the study was run to 8hrs 
following onset of fluid therapy (5.5.5 and Figure 26).  Randomisation separated 
animals into two groups at 30 minutes: control (‘blast air’) or oxygen 
supplementation.   Oxygen supplementation involved titrated delivery of oxygen via 
nose cone at a minimum FiO2 0.3 to maintain SaO2 of 95% (5.5.7). Various data 
were collected throughout the experiments. 
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6.4 Results 
Three animals died before T30 and separation of treatment strategies3. These were 
excluded from the study and are not presented, nor included in statistical analysis.   
The table below illustrates pre-blast baseline data for the complete oxygen and 
control groups.   
  
                                            
3 Two animals were destined to be given supplementary oxygen after 30 min of resuscitation, one 
died of ventricular fibrillation at the end of the controlled haemorrhage and the other failed to respond 
to fluid resuscitation and died after 28 minutes of resuscitation. 
One animal, destined for the control group, failed to respond to fluid resuscitation and died after 10 
minutes of resuscitation. 
Start CH Stop CH 
Haemorrhage
30% BV
Incompressible haemorrhage (Grade IV liver injury)
5 min Shock Phase
Result of injury / delay before treatment
T30T0
Start resuscitation
SBP target 80 mmHg
MERT or DrBuddy aid / 
Team Medic
Surgery
8 h monitoring post resuscitation (T0)
T480
Baseline measurements 
5 min apart
B1 B2 B3
Deploy to 
Range
Second phase (either/or)
• No adjunct (control)
• FiO2 elevated to SaO2 95%
• Continue SBP target 80 mmHg 
(0.9% Sal)
Field Comparison
Blast
Wounding 
Event – Blast and Haemorrhage
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Blast	  O2	  	  
Mean	  ±	  SEM	  
Blast	  Air	  	  
Mean	  ±	  SEM	  
	  	  
O2	  	  vs.	  Air	  	  
(t-­‐test)	  
n	   6	  	   6	  	   	  	  
Wt	  (kg)	   51.7	  	  	  ±	  0.8	   50.8	  	  ±	  1.2	   0.563	  
PaO2	  (kPa)	   9.1	  	  	  	  	  ±	  0.2	   8.9	  	  	  	  ±	  0.3	   0.688	  
PaCO2	  (kPa)	   6.5	  	  	  	  	  ±	  0.1	   6.6	  	  	  	  ±	  0.2	   0.86	  
Art	  pH	   7.43	  	  	  ±	  0.01	   7.42	  	  ±	  0.02	   0.405	  
ABE	  (mM)	   7.0	  	  	  	  	  ±	  0.7	   6.1	  	  	  	  ±	  1.0	   0.477	  
OER	   0.27	  	  	  ±	  0.02	   0.3	  	  	  	  ±	  0.02	   0.295	  
Hct	  (%)	   38.7	  	  	  ±	  1.1	   37.8	  	  ±	  1.1	   0.562	  
T	  Hb	  (g/dl)	   12.7	  	  	  ±	  0.4	   11.6	  	  ±	  0.4	   0.102	  
CaO2	  (ml/dl)	   16.2	  	  	  ±	  0.5	   14.2	  	  ±	  0.5	   0.031*	  
Art	  K+	  (mM)	   3.8	  	  	  	  	  ±	  0.1	   3.9	  	  	  	  ±	  0.1	   0.305	  
T	  (oC)	   38.1	  	  	  ±	  0.1	   38.7	  	  ±	  0.3	   0.095	  
Table 11 Table of baseline data for oxygen support group and air control groups. P- 
values given for two tailed t-test between groups. * Although there was a 
statistically significant difference in CaO2 between groups at baseline the 
difference was small and not likely to be of clinical significance; values in both 
groups are within normal limits for the anaesthetised pig.	  
6.4.1 Efficacy of Oxygen Supplementation Method 
Blast exposure resulted in a rapid reduction in arterial partial pressure and saturation 
of oxygen from baseline values to a nadir of 58.1 ± 7.8% and 50.9 ± 6.7% 
respectively for control and oxygen supplementation groups (Figure 32)4. 
Subsequently, the animals were all given a haemorrhage of 30% blood volume and, 
by the end of the ‘shock phase’, arterial oxygen saturation had spontaneously 
recovered to 71.7 ± 4.4% and 79.9 ± 3.1% respectively for control and oxygen 
groups.  By thirty minutes after the onset of permissive hypotensive fluid 
resuscitation, arterial oxygen saturation was 68.5 ± 3.4% and 71.1 ± 6.1% 
respectively. Both groups were therefore profoundly hypoxic and there were no 
significant differences in arterial oxygen saturations between groups to this point.  
Thereafter the oxygen group received supplementary oxygen to a target SaO2 of 
                                            
4 Note: at this stage of the protocol, both groups are breathing air since oxygen therapy has not yet 
been initiated.  
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95%. Administration of oxygen by nose cone led to a significant increase in PaO2 
and arterial oxygen saturation. The target SaO2 of 95% was quickly attained and 
sustained for the remainder of the experiment.  By contrast, arterial oxygen 
saturation failed to improve and remained significantly lower in the control group, 
which continued to breathe air. There were parallel changes in arterial oxygen 
tension (Figure 32) 
 
Figure 32 Arterial oxygen tension (PaO2) and saturation (SaO2) in two groups of animals subjected to blast 
injury, haemorrhage and hypotensive resuscitation.  Time ‘0’ means onset of resuscitation and is represented by 
the first dotted line.  The second line is T30 and represents the first point where treatment separates by group. 
 
Figure 33 below illustrates the arterial oxygen content and haemoglobin levels of 
both groups.  By T30, the combined insults and 30 minutes’ hypotensive fluid 
therapy had produced a decline in Hb from baseline (12.7 ±0.4 and 11.6 ±0.4 g/dl) to 
9.4 ± 0.5 and 8.8 ± 0.5. By T60, Hb was 9.0 ± 0.5 and 7.5 ± 0.6g/dl respectively 
(P=0.093).  As recorded above, severe hypoxia had also developed at T30.  
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Accordingly the CaO2 reduced significantly in both groups from baseline (16.2 ± 0.5 
and 14.2 ± 0.5 ml/dl) to 10.6 ± 0.6 and 8.3 ± 0.3.  By T60 however, 30 minutes after 
the onset of oxygen supplementation, the CaO2 had diverged significantly between 
groups: CaO2 in the oxygen group was 12.9 ± 0.3 compared to 7.2 ± 1.1 in the air-
breathing group (P=0.006).  The CaO2 in the oxygen group remained higher than 
that in air control group at all times.  
  
Figure 33 Total haemoglobin concentration and arterial oxygen content for both groups.  
 
6.4.2 Survival 
The primary endpoint of the study was survival.  Supplemental oxygen significantly 
increased survival time from 195 [84-306] min (mean [95% CI]) in the control group 
0
5
10
15
20
-100 0 100 200 300 400 500
C
aO
2 
(m
l/d
l)
Time (min)
0
4
8
12
16
-100 0 100 200 300 400 500
TH
b 
(g
/d
l)
Time (min)0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 50 100 150
Fi
O
2
Time	  from	  start	  of	  resuscitation	  (min)
Blast	  O2
Blast	  Air
151 
 
to 414 [340-489] in the group given supplementary oxygen (P=0.014 Mantel Cox log 
rank) (Figure 34). 
 
Figure 34 Kaplan-Meier Survival plot for two groups of animals subjected to blast injury, haemorrhage and 
hypotensive resuscitation.  The Blast O2 group was given supplemental oxygen to elevate the SaO2 to ≥95% and 
was begun after 30min hypotensive resuscitation.  Blast Air animals simply breathed room air (FiO2 0.21) 
throughout. 
6.4.3 Physiology 
As well as improving survival, supplementary oxygen had an effect on the 
development of metabolic acidosis. The combined insults of blast injury and 
haemorrhagic shock led to a profound, statistically significant, fall in arterial base 
excess in all animals (Figure 35) (P=0.0151).   
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Figure 35 Arterial base excess (ABE) and Oxygen Extraction Ratio (OER) in two groups of animals subjected to 
blast injury, haemorrhage and hypotensive resuscitation. Time indicates time from onset of resuscitation which 
was initiated at the first dotted line.  Second dotted line (30 min after onset of resuscitation) represents the 
divergence of treatment groups with supplemental inspired oxygen being introduced into the Blast O2 group 
while the Blast Air group continue to breathe air and the third dotted line indicates 30 min after the divergence 
of the treatment groups.  First two values represent Baseline, followed by Post Blast, Pre and Post Haemorrhage 
and then onset of resuscitation. Open symbols indicate 66% of animals surviving.  No data plotted when 
proportion surviving fell to 50% or below.  Numbers across top of figure indicate number of surviving 
animals/original number for each group (colour coded as indicated). Mean values ± SEM. 
 
By 30 minutes after the onset of hypotensive fluid resuscitation, the ABE had 
declined to -10.6 ± 1.6mM and -10.0 ± 2.2mM for control and oxygen groups 
respectively.  At this stage there was no significant difference between groups 
(P=0.2412).  30 minutes later, ABE had declined further, to -16.2 ±1.5mM in the 
control group breathing air.  However, in the oxygen group the decline was arrested 
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and, at the same time point, the ABE was -11.5 ±2.6mM. The difference between 
treatments (air vs. oxygen) was statistically significant (P=0.0137). Beyond this time 
point there was rapid loss of animals in the control group (Figure 35).  By contrast, in 
the oxygen group, base excess remained constant without recovery or deterioration 
until 270 min from the onset of resuscitation.  Thereafter there appears to be an 
increase in base excess, however this improvement is more apparent than real since 
this is due to the death of the two most acidotic animals (Figure 36).    
. 
 
Figure 36 Individual ABE data for oxygen and blast air control animals. Oxygen group in solid lines. 
 
It is clear from Figure 36 that one animal (Ox2) did not become as acidotic as the 
others in the group, even before the administration of oxygen.  There is no 
identifiable reason for this difference as it was treated identically to the others 
throughout, and therefore the difference is likely to represent normal the normal 
biological variation that sometimes results clinically in unexpected survivors.  Since 
this animal was an outlier a ‘what if’ examination of the data was made to determine 
whether the same overall outcome would be seen in the absence of this animal.  The 
-­‐25
-­‐20
-­‐15
-­‐10
-­‐5
0
5
10
15
-­‐100 0 100 200 300 400 500 600
AB
E	  
(m
M
)
Time	  (min)
Ox1
Ox2
Ox3
Ox4
Ox5
Air1
Air2
Air3
Air4
Air5
154 
 
base excess portion of Figure 35 has been redrawn using mean data derived after 
excluding animal Ox2, and the result shown in Figure 37. 
 
Figure 37 Arterial base excess (ABE) in two groups of animals subjected to blast injury, haemorrhage and 
hypotensive resuscitation.  The data for the group that breathed air throughout (Blast Air) is identical to that 
shown in Figure 35, while the data for the group given supplemental oxygen 30 min after the onset of 
resuscitation (Blast O2) represents mean values from the group after exclusion of an outlier (Ox2). See legend to 
Figure 35 and text for further explanation. 
 
Statistical re-evaluation, with Ox2 excluded, revealed no significant difference in ABE 
between the air and supplemental oxygen groups from the onset of resuscitation to 
60 min after the start of resuscitation (P=0.4756).  Given the small number of 
animals in the study, and the dangers associated with excluding individuals without a 
clear a priori rationale, it is impossible to be certain whether supplemental oxygen 
has or has not resulted in an early, significant, improvement in base excess.  
However, regardless of this, it is clear that supplemental oxygen has had an overall 
beneficial effect, even if Ox2 is excluded, since the outcome regarding the primary 
variable, survival, is unaffected by exclusion of Ox2 (a significant difference in 
survival time still exists between air and supplemental oxygen groups even after 
exclusion of Ox2, P=0.034). 
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Returning to the full dataset, blast exposure led to a small increase in OER from 
baseline values: 0.30±0.02 and 0.27±0.02, to 0.39±0.02 and 0.35±0.02 in the control 
and oxygen groups.  Haemorrhage however led to a large increase in OER in both 
groups, to the physiological maximum 0.80±0.03% and 0.80±0.02% respectively.  At 
T30, there was no difference in OER between groups 0.74±0.02% and 0.72±0.02% 
(P=0.470). By T60 minutes there was a trend toward a slightly reduced OER in the 
oxygen group: 0.65±0.03% vs. 0.70±0.01 in the control group, (P=0.170). 
 
Consistent with the changes in OER, there were also alterations in systemic oxygen 
delivery and consumption.  Oxygen delivery (DO2) and consumption (VO2) were 
both similar between groups before the initiation of oxygen therapy (30 min after the 
onset of resuscitation).  Thereafter in the oxygen group, there was a trend towards 
increased oxygen delivery and importantly a corresponding increase in oxygen 
consumption, although neither achieved statistical significance (P=0.093 and 
P=0.181 respectively for group differences in DO2 and VO2) (Figure 38), possibly 
because of the small group sizes.   
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Figure 38 Oxygen delivery (DO2) and consumption (VO2) immediately before initiation of oxygen therapy 30 
min after the onset of resuscitation and again at 60 and 120 minutes after the onset of resuscitation.  Mean ± 
SEM. 
 
This trend could be consistent with oxygen consumption being supply-dependent 
before the initiation of oxygen therapy, and a consequent improvement in delivery 
allowing an increase in consumption in at least some of the animals given oxygen 
therapy.  Perhaps a more informative way of evaluating this possibility is to examine 
the relationship between DO2 and VO2 in individual animals (Figure 39). 
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Figure 39 Relationship between oxygen consumption (VO2) and delivery (DO2) in individual animals 
immediately before initiation of oxygen therapy (30 min after the onset of resuscitation, top panel) and again 60 
and 120 min after the onset of resuscitation (middle and bottom panels respectively).  Note that these are not 
DO2/VO2 curves for individual animals but rather single points on the DO2/VO2 relationship for each animal at 
each timepoint. 
 
Although full DO2/VO2 curves for each individual animal would be required to 
determine whether they are on the supply-dependent or supply-independent portion 
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suggests that the animals are predominantly on the supply-dependent part of the 
relationship before the administration of oxygen.  By 60 min after the onset of 
resuscitation (30 min after initiation of oxygen therapy) a number of animals in the 
oxygen group have increased DO2 and seem also to have been able to elevate VO2, 
suggesting an improvement in their oxygen transport status compared to the air-
breathing controls.  This pattern persists 120 min after the onset of resuscitation. 
 
CO2 and arterial pH levels were measured in both groups (Figure 40).  There was a 
significant rise in PaCO2 and a corresponding drop in arterial pH following blast 
injury. Haemorrhage did not further increase PaCO2, but pH dropped significantly.  
There was no difference in PaCO2 between groups, but levels remained below 
baseline in all animals. 
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Figure 40 Arterial partial pressure of CO2 and arterial pH for both groups. The apparent recovery of pH in the 
oxygen group, as mentioned for ABE, is due to the demise of the two sickest animals, rather than a true 
recovery. 
6.4.4 Coagulation 
As discussed earlier, coagulopathy in trauma is a significant problem. This institution 
has already described an ultra-early hypercoagulability after blast injury and 
haemorrhage (274).  Brohi and colleagues at The Royal London Hospital have 
revealed an early hypocoagulopathy early after trauma in civilian patients and coined 
a term ‘acute coagulopathy of trauma shock’ (17). Tissue hypoperfusion has been 
promoted as a key driver of this coagulopathy.  This study assesses interventions 
designed to improve tissue perfusion, one of which is a recombinant coagulation 
factor, so it is relevant to establish whether the improved tissue oxygen delivery 
(demonstrated above) is accompanied by an improvement in clotting parameters.  
Thromboelastography (TEG) samples were taken at standard intervals during this 
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study (Figure 41).  However, due to a high degree of variability, particularly in the air 
group, there was no significant difference between the air and supplementary 
oxygen group.  Overall a trend of worsening clotting dynamics (increased K time) 
was seen during the early phase of resuscitation in the air group when compared to 
those given supplementary oxygen. 
 
Figure 41 K Time (Mean +/- se of mean) for blast oxygen and blast air control groups. 
 
Figure 42 Maximum Amplitude (Mean +/- se of mean) for blast oxygen and blast air control groups. 
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MA (representing clot strength) was found to fall significantly between baseline and 
120 min after the onset of resuscitation (P=0.0254; statistical analysis was not 
continued beyond this point due to the loss of animals from the air-breathing group).  
As with K time, there were no significant difference in MA between treatment groups.  
 
6.4.5 Lung Inflammatory Changes 
The relative expression of the endothelial adhesion molecules, ICAM and VCAM 
from lung tissue are shown in (Figure 43).  Overall there was less expression of both 
molecules in the oxygen group.  Although this did not achieve statistical significance 
for VCAM (P=0.126), it barely failed to achieve significance for ICAM (P=0.052, Pfaffl 
method (275)).   
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Figure 43 Relative expression in oxygen group as a proportion of expression in the air control group. A value 
below 1 suggests less expression in the oxygen group 
 
Lung tissue was harvested at post-mortem for all animals. No difference was seen 
between groups on gross morphological examination.  Both groups exhibited 
clinically significant pulmonary contusions (Figure 44 and Figure 45) although this 
was not quantified.  The lungs were however weighed immediately post-mortem and 
the lung weight index calculated for each animal.  There was no significant difference 
in lung weight indices between groups: 13.2±0.7 and 12.9±0.5 g/kg respectively in 
the air and oxygen groups, (P=0.72), suggesting that the degree of lung water 
content was similar between groups.  However, this latter observation must be 
caveated with the finding that survival time; and hence the time available to develop 
pulmonary oedema; was significantly different between groups. 
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Figure 44 Post mortem photograph of blast lung injury (right side nearer explosion) 
 
Figure 45 Sectioning of same right lung demonstrates extent of contusions 
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6.5 Discussion of Oxygen Supplementation Results 
This study has shown that supplemental inspired oxygen significantly increases 
survival in a large animal model of combined blast and haemorrhage injury. In 
addition, oxygen therapy halted the physiological deterioration (increasing base 
deficit), but did not deliver recovery of physiology to normal.  There was no evidence 
of an increase in lung damage or early inflammation in animals given supplementary 
oxygen.  Furthermore, there was no evidence of increased haemorrhage associated 
with supplemental oxygen therapy. 
6.5.1 Injury model 
The details of blast exposure are discussed in the methods section (5.5.1). 
Significant blast injury was confirmed in all animals by the reflex bradycardia, apnoea 
and hypotension that immediately followed the exposure and by noticeable changes 
in PaCO2; OER; SaO2 and pH following blast exposure.  Mean SaO2 at T30 was 
69%.  Post-mortem analysis demonstrated significant lung contusions in all animals.  
At the same time, the blast loading was not immediately overwhelming and was 
compatible with survival of the animals. 
 
Liver snare deployment successfully amputated the desired section of the middle 
lobe of the liver – this was confirmed at post mortem (Figure 46). This created a 
Grade IV liver injury – a mixed arterial and venous insult with the potential for 
rebleeding at any subsequent stage of the study.   
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Figure 46 Post mortem photograph of removal of adherent clot (in hand) from raw amputation site on  middle 
lobe of liver. Note complete amputation. 
 
The controlled 30% blood volume haemorrhage was successfully completed via 
pump-controlled exsanguination from the femoral arterial line (5.5.2).  Haemorrhage 
produced significant changes in OER; ABE and pH.  By T30, (35 minutes after 
completion of controlled haemorrhage and liver snare deployment and after 30 
minutes’ hypotensive fluid therapy), all animals were in profound metabolic acidosis.  
 
The two injury mechanisms combined produced a significant physiological insult in 
the animals, but this was not so severe that all animals died regardless of treatment 
modality.  The injury model, coupled with prolonged hypotensive resuscitation 
therefore presents a significant challenge to potential resuscitation adjuncts that is 
relevant to battlefield casualty care.   
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6.5.2 Effects of supplementary oxygen on survival 
The combined insults of blast lung and haemorrhage invoke a ‘double hit’ on oxygen 
delivery: hypoxia from blast lung reduces arterial oxygen content while haemorrhage 
primarily reduces flow (although later, arterial oxygen content is also reduced 
through reduced haemoglobin concentration).  Standard trauma fluid resuscitation 
strategies attempt to restore the flow component of DO2, but when restricted to 
hypotensive resuscitation, this is very limited and, alone, incompatible with prolonged 
survival in the presence of blast injury. In the blast-injured casualty, because of the 
hypoxia, there is scope to improve the arterial oxygen content and, hence, an 
additional ‘angle’ one can employ to improve DO2.  The DO2 equation is repeated 
below for clarity and discussed in more detail earlier (Equation 1).  
(DO2) (ml/min) = cardiac output (SV x HR) x arterial oxygen content ([Hb] x SaO2 x 
1.34) 
 
Administration of oxygen improves survival by increasing arterial oxygen content 
and, hence, tissue oxygen delivery.  This is borne out by oxygen’s effect on 
physiology.  By T30, all animals were in profound metabolic acidosis, with ABE 
between -10 and -11. Thereafter, in animals given oxygen, this metabolic acidosis 
remained at similar levels, but deteriorated no further.  By contrast, control group 
animals suffered inexorable physiological decline until death. To our knowledge this 
is the first study that has systematically tested the efficacy of oxygen 
supplementation alongside hypotensive fluid therapy following combined blast injury 
and haemorrhage.  
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6.5.3 Physiology 
6.5.3.1 Oxygen effect 
At first glance, it may seem a foregone conclusion that oxygen therapy would 
improve survival in this study scenario, but there are two important reasons why this 
might not have been the case in this study.  First, the profound shock, coupled with 
prolonged hypotensive resuscitation, might have been so severe that, even despite 
increasing CaO2, animals would all have succumbed.  Second, the lung injury from 
the blast insult might have obstructed gas exchange to such an extent, that despite 
increasing FiO2 to maximum, CaO2 would not increase enough to influence 
outcome.   
 
By T30 (30 min after onset of hypotensive fluid therapy) ABE averaged between -10 
and -11mM and OER was at an almost maximal figure of 72-74%.  Despite this, 
supplemental oxygen was able to increase CaO2 to such an extent that life could be 
maintained and further development of acidosis arrested.  
 
The effects of blast lung have been described earlier (2.2.4).  Diffuse alveolar 
haemorrhage is a key very early pathological consequence and it significantly 
impairs gas exchange.  Areas of macroscopic contusion seen at post-mortem 
represent underlying diffuse haemorrhage.  When injured segments of lung cannot 
exchange gas, but perfusion to these segments continues, a shunt occurs. In the 
lungs, this describes a mismatch between ventilation and perfusion.  If large enough, 
a shunt leads to significant percentages of cardiac output passing through the lungs 
without experiencing gas exchange.  A shunt, at least in part, contributes to the 
hypoxia associated with blast wave exposure.  However, oxygen therapy was rapidly 
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able to improve saturations from 69% to >95%.  This highlights the ability of 
improved FiO2 to improve overall gas exchange, despite the presence of a shunt, in 
severely blast-injured lungs.  In addition, the additional oxygen may have improved 
oxygenation in areas of marginal gas exchange, thereby effectively reducing shunt 
fraction.  In the military setting, a casualty who has sustained ‘total’ blast lung would 
probably die at the scene.  Potentially salvageable casualties should however benefit 
from oxygen support. 
6.5.3.2 Base Deficit and Oxygen Extraction 
At T30, there was no difference in ABE or OER between groups: all animals had 
significant metabolic acidosis and maximal OER. From this point, control animals 
continued to deteriorate until all succumbed.  In contrast, oxygen therapy in 4/6 
animals halted the deterioration in ABE that occurred in control animals, but did not 
restore ABE to physiological levels (Figure 36).    This lack of physiological recovery 
demonstrates that inadequate blood flow was the limiting factor.  Improving the 
CaO2 alone does not improve DO2 enough to allow repayment of the ‘oxygen debt’ 
already acquired.   
 
OER data support this notion.  At T30 both groups had similar, almost maximal OER 
(0.72 ± 0.02 and 0.74 ± 0.02).  At T60 there was only a trend towards slight reduction 
in OER in the oxygen group (0.65±0.03% vs. 0.70±0.01 in the control group, P= 
0.170). If oxygen therapy were able to restore DO2 to physiological levels, one would 
expect to see a larger drop in OER.  In essence, DO2 is improved by oxygen therapy 
from ‘grossly inadequate’, to ‘barely adequate’ levels. 
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6.5.3.3 Carbon Dioxide 
CO2 levels were seen to drop a little in both control and oxygen supplementation 
groups.  There was no significant difference between groups.  This fall in CO2 is 
probably due to the effects of hypoxia and acidosis on central and peripheral 
chemoreceptors.  Chemoreceptors influence ventilation in response to alterations in 
plasma [H+]; PaO2 and PaCO2.   
 
Peripheral chemoreceptors lie within the carotid and aortic bodies. They primarily 
respond to decreased PaO2, but also to increased [H+]. Efferent activity from these 
receptors results in increased ventilatory drive.   All animals were rendered hypoxic 
and acidotic by the injury model. The combination of both will therefore have 
produced significant efferent activity from these peripheral chemoreceptors and, 
hence, an increase in respiratory minute volume.  Increased respiratory minute 
volume will reduce PaCO2.  The acidosis remained throughout the experiment, so 
peripheral chemoreceptors will have continued drive additional ventilation 
throughout.  In the oxygen group, hypoxia was rapidly reversed, removing one potent 
stimulator of peripheral chemoreceptors.  Acidosis also stabilized, rather than 
continuing to deteriorate, further reducing the stimulus on peripheral chemoreceptors 
in comparison to control animals. One might therefore have expected a relative rise 
in the CO2 levels in the oxygen group compared with controls as the peripheral 
chemoreceptors would be relatively unloaded (respiratory minute volume was not 
measured in this study).   There were however, no significant differences in PaCO2, 
perhaps because control animals did not live long enough to demonstrate an effect.  
In future, measuring respiratory minute volume may add clarity to these concepts. 
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 Central chemoreceptors in the medulla are relatively insensitive to PaO2 
fluctuations and cannot respond directly to plasma [H+] as H+ cannot cross the 
blood-brain-barrier (BBB).  Instead, they are acutely sensitive to changes in PaCO2.  
CO2 diffuses easily across the BBB, so levels in CSF closely match those in plasma.  
In CSF, CO2 forms carbonic acid, which then dissociates into H+ and HCO3-. The H+ 
stimulates the chemoreceptor which, via Intercostal and Phrenic nerves, increases 
rate and volume of breathing.  Blast exposure produced a reflex period of apnoea, 
which was followed by rapid, shallow breathing.  This led to a significant rise in 
PaCO2.  The increased CO2 will have triggered the central chemoreceptors to 
increase the volume and rate of breathing and contributed to the reduction in PaCO2 
that followed the initial rise. Once CO2 had reduced below baseline levels, the 
central chemoreceptors would have ceased to contribute.    
6.5.3.4 Flow limitation and oxygen carrying capacity 
Another way to improve oxygen delivery is to address the flow component.  When 
using crystalloid solutions such as normal saline, one must bear in mind that dilution 
of the intravascular fluid will occur and this will, in turn, reduce CaO2 by reducing 
haemoglobin levels and hence oxygen carrying capacity.  For a benefit to be seen, 
this reduction in CaO2 would need to be outweighed by the benefit of improved flow. 
A previous DSTL study developed the novel hybrid strategy (hypotensive target with 
normal saline fluid therapy for first hour, followed by normotensive fluid 
resuscitation), which improved DO2 to such a degree that ABE recovered to normal 
levels (39). There was no evidence of re-bleeding.  These results suggest that 
optimising the flow component overcomes the dilution effect and is more potent than 
manipulation of CaO2 (by simple increase of arterial oxygen saturation) on a 
background of hypotensive fluid therapy.  However, if novel hybrid fluid strategies 
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AND supplemental oxygen were employed in tandem, it is logical to predict that the 
consequences of hypoperfusion would more rapidly be reversed and physiology 
therefore quickly optimised in the pre-hospital environment.   
 
So, improved oxygen content and flow are both able to improve outcome.  Together, 
their effects should complement each other.  Another approach would be to employ 
a fluid which did not cause haemodilution.  Such a fluid could have a dramatic effect 
on oxygen delivery and, therefore, physiology.  This might be achieved by infusing a 
fluid that can carry oxygen. Such a fluid could increase both oxygen carrying 
capacity and restore intravascular volume: it would therefore address both the CaO2 
and the flow components of oxygen delivery.  
 
A logical first step might be to consider giving packed red blood cells (PRBC) as the 
primary resuscitation fluid.  This approach is however limited by a maximum 
haematocrit that can be tolerated, before hyperviscosity impairs microcirculation – 
this is thought to lie around 70% (276).  While limited blood products (2 units PRBC; 
2 units FFP) are now available on the Medical Emergency Response Team (MERT) 
airframe, blood is not routinely available for use at the scene of wounding.  Storage, 
resupply and issue of blood products is complex and remains beyond the scope of 
far forward units,  
 
So what other products might be used to improve oxygen carrying capacity? Much 
research effort has gone into development and evaluation of synthetic haemoglobin 
oxygen carrying (HBOC) solutions for use in trauma and high-risk surgery and four 
products have been assessed in clinical trials since 1990.  These solutions contain 
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polymerized and purified human/bovine/ recombinant haemoglobin and attempt to 
reproduce blood’s haemoglobin concentration, affinity for oxygen and osmotic 
pressure. They are an attractive pre-hospital option and, could dramatically reduce 
blood product use in the acute stages of trauma resuscitation.  Unlike blood 
products, they do not induce an inflammatory response (277) and are easily stored.  
Treatment would increase oxygen carrying capacity, independent of the need for 
oxygen support, thereby potentially removing the need for oxygen at all, or reducing 
the volume of oxygen required to achieve target saturations. This could reduce the 
logistic demands on the delivery of oxygen or blood products to remote 
environments and pacify concerns surrounding the risks of oxygen therapy in blast-
injured lungs.   
 
Despite early promise in clinical trials of HBOC use in trauma (278), products tested 
in clinical trials have shown toxicity and vasoactivity which have hampered their 
development (279).  The tendency of HBOCs to induce vasoconstriction has been 
attributed to nitric oxide scavenging by free haemoglobin (280) and oversupply of 
oxygen along the vasculature to deplete endothelial NO (279).   Increased mortality 
and ARDS / MOF rates (attributed to NO vasoactivity) have terminated two clinical 
trials and elderly patients seem particularly vulnerable (281).   
 
 No HBOC product is currently approved for use in trauma patients.  However, one 
recently developed HBOC, maleimide-polyethylene glycol haemoglobin (MP4OX or 
Hemospan) (Sangart Inc, San Diego, CA) has been developed to possess low Hb 
concentration, high affinity for oxygen and have high colloid osmotic pressure.  
These properties aim to maintain intravascular volume, thus minimizing tissue NO 
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scavenging and to target oxygen unloading to areas of hypoxia (282).   These 
designed differences should theoretically improve the safety and efficacy of MP4OX.  
It has shown preclinical promise in a large animal model of uncontrolled 
haemorrhage where survival from aortotomy-induced haemorrhage was significantly 
improved compared to crystalloid controls (283).  A recent RCT in orthopaedic hip 
surgery with spinal anaesthesia, showed reduced hypotensive episodes following 
MP4OX, but did demonstrate a transient increase in liver transaminase enzymes.  
There was however no significant difference in major adverse events.  MP40X has 
recently completed a Phase IIa international RCT in trauma haemorrhage-induced 
lactic acidosis . Full results are yet to be published, but presented headline data (51 
patients) revealed improved lactate clearance and a trend towards shorter hospital 
stay and improved 28 day survival (284).  There was also an acceptable safety 
profile. MP40X is currently undergoing a Phase IIb clinical trial (TRA-205: 
http://clinicaltrials.gov/ct/show/ NCT01262196). This will recruit 360 patients with 
similar inclusion criteria to the TRA-204 trial.    
 
So far therefore, MP40X is promising and may escape the vasoactivity that has 
limited other products.  Ongoing trials will shortly clarify its role and safety in trauma 
haemorrhage.  However, as a pre-hospital resuscitation adjunct, MP40X might be 
assessed for military value in a similar injury model to that used in this study.      
6.5.4 Coagulation 
Coagulopathy in trauma has been discussed earlier (2.1.4) and is a significant 
problem in military trauma. This institution has already described an ultra-early 
hypercoagulability after blast injury and haemorrhage(285).  Brohi and others have 
revealed an early hypocoagulopathy early after trauma in civilian patients and coined 
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a term ‘acute coagulopathy of trauma shock’ (91). Tissue hypoperfusion has been 
promoted as a key driver of this coagulopathy.  This study assesses an intervention 
designed to improve arterial oxygen content and hence oxygen delivery.  This should 
improve shock and it is therefore relevant to establish whether the improved tissue 
oxygen delivery (demonstrated above) is accompanied by an improvement in clotting 
parameters.  The current study was not designed to test this hypothesis, and no 
significant difference was seen between air and supplementary oxygen groups, 
although overall there was a trend for early improvement in coagulation dynamics in 
the group given oxygen compared to those given air throughout.  This is clearly an 
area of significant interest and future studies should be designed specifically to 
examine the relative impact of enhanced arterial oxygen content versus improved 
blood flow on acute trauma coagulopathy.  
6.5.5 Oxidative Stress and Lung Inflammation 
As discussed earlier, (3.2.6.1) lung injury increases free radical formation and 
depletes stored levels of antioxidants in the lung (152).  This renders damaged lungs 
vulnerable to further oxidative stress. Aggarwal demonstrated further oxidative lung 
damage with FiO2 0.6 oxygen therapy in lipopolysaccharide-damaged lungs (204).  
It was therefore important to determine the safety of oxygen support in this study. 
 
Two adhesion molecules were measured, VCAM and ICAM: both are described 
earlier (2.1.5.2).  ICAM-1 is expressed on the surface of damaged capillary 
endothelial cells and alveolar pneumocytes.  ICAM-1 expression is critical in 
enabling the migration of neutrophils into the tissues.  It is rapidly up-regulated in 
Goodpasture’s syndrome – a condition which produces diffuse alveolar haemorrhage 
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- and correlates with very early lung inflammation (neutrophils within 1.5hrs and 
macrophages within 6hrs) (134).   
 
VCAM is another endothelial cell adhesion molecule involved in inflammation.  It is 
almost immediately up-regulated in lung tissue in experimental models of 
haemorrhage and resuscitation (133).  Admission levels of VCAM and ICAM after 
trauma and sepsis correlate with mortality (137).  
 
VCAM and ICAM levels were lower in the oxygen group.  ICAM in the oxygen 
supplementation group reduced almost to a statistically significant level.  The study 
was not powered to detect a difference in adhesion molecules, so it is possible that 
lack of significance here represents a type II error.  Certainly, there was no increased 
expression in the oxygen group.   
 
Lung weight indices were recorded at post-mortem to establish lung water content; a 
marker of pulmonary oedema and therefore inflammation.   There was no difference 
in lung weight indices between oxygen and air control groups.  It is important to note, 
however, that the oxygen group animals survived significantly longer than air 
controls.  This allowed more time for inflammatory oedema to develop.   
 
At worst, one can therefore say that oxygen supplementation has had no deleterious 
effect on lung inflammation, but it may actually have reduced inflammation relative to 
air-breathing controls.  The concerns regarding oxygen therapy in blast damaged 
lungs are not upheld and should not preclude the adoption of oxygen support 
capability in the prehospital environment. 
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6.5.6 Logistic considerations of oxygen support 
Animals in the oxygen support group initially required an average FiO2 of 0.56 to 
achieve recovery of SaO2 to 95%.  Thereafter, the FiO2 required to maintain SaO2 
95% reduced and, by 90 minutes into oxygen support, mean FiO2 was a modest 
0.36.  
 
In the past, the logistics of delivering oxygen capability to remote military units were 
prohibitive and the indication unjustified for the vast majority of casualties.  The 
incidence of blast lung is now reported at 11% in casualties surviving to the field 
hospital in Afghanistan. This study demonstrates survival advantage from oxygen 
supplementation in a prehospital scenario. Investment into modern oxygen support 
technologies is therefore justified if this can make the field use of oxygen a practical 
proposition for a prolonged evacuation.  Two approaches to oxygen support are 
described below. 
 
A 4L cylinder filled at 200bar can store 800L O2.  At the ATLS-recommended 
minimum flow rate for trauma (11L min-1) (178), a 4L cylinder at 200bar would last 
only 1.2 h.  Advanced regulator valves can now deliver a controlled dose of oxygen 
at the leading edge of the patient’s inspiratory cycle.  This capability reduces hugely 
the wastage of gas and significantly prolongs the working time of an oxygen cylinder.  
An industry example is the Summit Oxygen products (www.summitoxygen.com).  
This company designs and manufactures oxygen support solutions for 
mountaineering applications and offers robust, integrated, battery-free systems, 
capable of delivering both constant and pulse-dosed oxygen.  Simple switch settings 
allow alteration of the dose of oxygen delivered per breath.  At lowest setting this 
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provides 16.5ml O2 per cycle, but this can be increased to 99ml O2 per breath on 
currently available systems.  Using this pulse dose system, coupled with a 4L 
lightweight cylinder filled to 200 bar, this equates to a cylinder life of 40h at setting 1 
(16.5ml O2/breath) or 6.7h at setting 6 (99ml O2/breath).  If a patient is profoundly 
hypoxic, constant flow can be used initially to achieve SaO2 target and dose 
subsequently titrated to maximise cylinder life.  This portable and versatile oxygen 
support solution makes cylinder-based oxygen support a potentially viable 
prehospital solution for the military scenario.  Of course, the logistics of refilling 
cylinders with medical grade oxygen would need to be considered.  Personal 
communication with the Managing Director of Summit Oxygen reveals that the 
product specifications could be tailored to the specific needs of the Armed Forces to 
ensure a rugged, simple and practical solution (286).  While attractive options, there 
are concerns regarding safety of pressurised cylinder use in the battlefield 
environment and any procurement process would need to consider this aspect.  
 
Another way of delivering oxygen is to use an oxygen generator system.  Modern 
FDA- approved systems have been designed with military use in mind and come in 
both airframe/vehicle mounted format or in low-weight portable sizes.  The 1Kg 
Battery has a continuous use life of 90 minutes and bolts onto the man-packable 
(4.5Kg) SarosTM concentrator. 93% filtered oxygen can be delivered at flow rates of 
3L min-1 continuous flow, or up to 96mL per pulsed dose (www.sequal.com). Oxygen 
concentrators do not require refilling and present no explosive risk to personnel.  
When vehicle mounted, power consumption is trivial (130-145 watt per minute at 3L 
flow), and battery life for the portable version is reasonable with capacity for spare 
battery carriage.  The systems are usable up to 18,000ft altitude and from 0 to 43°C. 
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Both of these technologies could and should be exploited to develop an adaptable 
and integrated oxygen support capability across the battlespace. 
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7 Effects of a Single Intravenous Dose of Recombinant 
Activated Factor VII 
7.1 Introduction 
Recombinant activated Factor VII (rFVIIa) is an engineered protein structurally 
identical to the activated from of human coagulation factor VII (287). It was designed 
for and is licensed for use in bleeding haemophilia patients.  Since development 
however, a number of preclinical studies in patients without pre-existing 
haematological pathology have shown it reduces haemorrhage from major blood 
vessel injury (263) and large clinical trials provide evidence of reduced transfusion 
requirement and organ failure rates after blunt trauma (42).  Controversies persist 
however regarding its efficacy in penetrating injury and safety concerns remain, 
related to thrombotic and embolic sequellae (288). A more detailed discussion of the 
literature surrounding the efficacy of rFVIIa in major haemorrhage can be found in 
section 3.3.4. 
 
Blast lung is associated with large areas of pulmonary contusion and intra- 
pulmonary haemorrhage.  This is a picture similar to that seen in diffuse alveolar 
haemorrhage, which can occur as a result of various pathologies.  The clinical data 
available regarding use of rFVIIa in controlling diffuse alveolar haemorrhage is scant, 
but suggests a potential effect (see section 3.3.6).   
 
There is anecdotal data from ongoing operations in Afghanistan, that rFVIIa (albeit 
often in multiple doses) is proving useful as an adjunct to aggressive surgical and 
blood product (haemostatic) resuscitation in casualties critically wounded by 
explosion (personal experience Op HERRICK 10 and personal communication with 
180 
 
Defence Professor Anaesthesia (289).  There is also anecdotal observation from 
Israel that rFVIIa improves outcome in blast lung (290). There is, however, no 
experimental data on rFVIIa use following a combined blast and haemorrhage insult.   
7.2 Aims 
The aim of the rFVIIa arm of this study is to establish whether a single intravenous 
dose of rFVIIa, which would be amenable to deployment in the far-forward military 
environment, can improve survival and/or physiology in the context of prolonged 
hypotensive resuscitation after combined blast and haemorrhage injury.  The 
rationale underpinning this study was the possibility that administration of rFVIIa 
might attenuate the early blast-induced intrapulmonary haemorrhage and thereby, 
through limiting lung compromise, improve oxygenation of blood in the lungs.  Since 
we have already shown that improvement of arterial oxygenation improves survival 
during prolonged hypotensive resuscitation (section Error! Reference source not 
found.) there is a possibility that rFVIIa may also improve survival after blast injury. 
7.3 Methods 
12 terminally anaesthetised pigs were exposed to a standardised injury model of 
primary blast insult, 30% (controlled haemorrhage) blood volume haemorrhage and 
grade IV liver laceration (uncontrolled haemorrhage).  Methods of surgical 
preparation, blast injury and haemorrhage exposure, fluid therapy and physiological 
measurement were all identical to those described for the oxygen study and details 
of these methods can be found in Chapter 5 of this thesis.  
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7.3.1 rFVIIa administration protocol 
Animals were randomly to receive either rFVIIa or placebo during the resuscitation 
phase.  Following injury, all animals were resuscitated with aliquots of warmed 
normal saline to maintain a hypotensive systolic blood pressure of 80mmHg and the 
study was run to 8hr following onset of fluid therapy.  After 30 minutes of fluid 
resuscitation, animals either received placebo or rFVIIa (Figure 26).  The rFVIIa 
group received a single intravenous 180mcg/Kg dose of rFVIIa, while the placebo 
group received an equivalent volume of normal saline (0.18 ml/kg i.e. 9ml for 50Kg 
animal).  All animals in this study breathed room air throughout the experiment. As 
mentioned in the methods section (5.5.9), the placebo group formed the control for 
both this study and the oxygen study (see Chapter 6 ). 
7.3.2 Assessment of coagulation and inflammatory responses 
Arterial blood samples were collected into citrated Vacutainers (9NC 0.105M 
Vacutainer 367691, Beckton Dickinson, UK), centrifuged at 1500 x g for 10 min and 
the plasma separated and stored at - 80°C.  Prothrombin time (PT) was determined 
by turbidimetry using the ACL Elite (Beckman Coulter (UK) Ltd).   
 
In each individual animal, prothrombin times are expressed as a proportion of that 
measured from an initial blood sample taken at start of surgery. 
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7.4 Results 
 
Three animals died before T30 and separation of treatment strategies5. These were 
excluded from the study and are not presented, nor included in statistical analysis.   
 
Table 12 illustrates pre-injury baselines for rFVIIa and placebo control groups.   
	  
Blast	  rFVIIa	   Blast	  Placebo	   rFVIIa	  vs.	  Placebo	  
Mean	   SEM	   Mean	   SEM	   (t-­‐test)	  
n	   6	   	   6	   	   	  
Wt	  (kg)	   53	   0.6	   50.8	   1.2	   	  0.127	  
PaO2	  (kPa)	   9.9	   0.4	   8.9	   0.3	   0.073	  
PaCO2	  (kPa)	   6.2	   0.2	   6.6	   0.2	   0.2544	  
Art	  pH	   7.41	   0.03	   7.42	   0.02	   0.9147	  
ABE	  (mM)	   4.3	   1.2	   6.1	   1	   0.2798	  
SaO2	  (%)	   93	   1.5	   88.3	   1.2	   	  0.0339*	  
SvO2	  (%)	   68.1	   1.2	   62.1	   1.8	   0.0211*	  
CaO2	  (ml/dl)	   14.8	   0.4	   14.2	   0.6	   0.495	  
OER	   0.23	   0.02	   0.3	   0.02	   0.0158*	  
T	  Hb	  (g/dl)	   11.8	   0.3	   11.6	   0.4	   0.7319	  
Hct	  (%)	   38.2	   1	   37.8	   1.1	   0.784	  
Art	  K+	  (mM)	   3.7	   0.1	   3.9	   0.1	   0.1702	  
T	  (oC)	   38.3	   0.3	   38.7	   0.3	   0.3493	  
Table 12 Baselines variables for rFVIIa and Placebo animals.  There were small, statistically significant, 
differences in arterial and mixed venous oxygen saturation and oxygen extraction ratio between the rFVIIa and 
placebo groups, although this did not translate to a difference in arterial oxygen content.  Although statistically 
significant, the differences are small and unlikely to be of physiological consequence.  There were no significant 
differences in the other parameters examined.  
                                            
5 Two animals were destined to be given rFVIIa after 30 min of resuscitation: one died of ventricular 
fibrillation at the end of the controlled haemorrhage and the other died after 15 minutes of 
resuscitation.  Post-mortem examination of this latter animal revealed a substantially greater volume 
of intra-abdominal haemorrhage due to transaction of unusually large hepatic vessels on creation of 
the Grade IV liver injury. 
One animal, destined for the control group, failed to respond to fluid resuscitation and died after 10 
minutes of resuscitation. 
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7.4.1 Survival 
Survival was the primary endpoint of this study.  Survival times in the rFVIIa group 
were not significantly different from the blast air control group (P=0.649) (Figure 47).  
 
Figure 47 Kaplan-Meier survival plot for two groups of animals subjected to blast injury, haemorrhage and 
hypotensive resuscitation.  Treatment with either rFVIIa or placebo (0.9% saline) was administered 30 min after 
onset of hypotensive resuscitation.  Both groups breathed air throughout. 
 
However, inspection of mean survival times: rFVIIa 253min (95%CI 167-339) vs. 
Placebo 195 min (95%CI 85-306) might suggest that treatment with rFVIIa did confer 
a small survival advantage compared with placebo. A post hoc power calculation 
(Power 0.8, alpha 0.05, Log rank test) suggested that 23 animals per group would be 
required to exclude a Type II error and determine whether there is indeed a true 
survival effect from rFVIIa therapy. 
7.4.2 Oxygen Saturation 
Prior to T30, oxygen tension and saturation levels were similar between groups 
(Figure 48).  After administration of rFVIIa, arterial oxygen saturation was higher in 
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the rFVIIa group than in placebo control group and this achieved statistical 
significance at T45 (15 min after drug administration).   
 
Figure 48 Arterial oxygen tension (PaO2) and saturation (SaO2) in two groups of animals subjected to blast 
injury, haemorrhage and hypotensive resuscitation.  Time (min) indicates time from onset of resuscitation (T0).  
T30 represents the divergence of treatment groups, with rFVIIa (180 µg/kg iv) being given to the Blast rFVIIa 
group, and placebo (0.18ml/Kg saline) to the placebo control group.  First two values represent Baseline, 
followed by Post Blast, Pre and Post Haemorrhage and then onset of resuscitation. Open symbols indicate 66% 
of animals surviving.  No data plotted when proportion surviving fell to 50% or below.  Mean values ± SEM. 
 
7.4.3 Physiology 
The injury model (blast injury plus haemorrhagic shock) induced a significant 
elevation of oxygen extraction ratio (OER), from baseline of approximately 0.25, to 
the physiological maximum of 0.80 in all groups by the onset of fluid resuscitation 
(Figure 49). OER in both rFVIIa and control groups remained at almost maximum 
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levels and the base deficit in both groups continued to increase over time until 
animals succumbed.  There was no significant difference between rFVIIa and 
placebo control groups in ABE or OER. 
 
Figure 49 Arterial base excess (ABE) and Oxygen Extraction Ratio (OER) in animals subjected to blast injury, 
haemorrhage and hypotensive resuscitation. 
7.4.4 Coagulation and Haemorrhage 
Prothrombin time (PT) showed a small but statistically significant increase (P=0.043) 
following combined blast injury and haemorrhagic shock, but there was no difference 
between treatment groups from baseline to 30 min into the fluid resuscitation phase 
of the study (P=0.558, two way ANOVA, Figure 50).  rFVIIa (or placebo) was 
administered immediately after the blood sample representing 30 min of 
resuscitation was taken.  By 60 min after the onset of resuscitation, PT had fallen to 
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below baseline in the rFVIIa group, in contrast to the placebo-treated group where 
there had been a marked increase in PT coincident with the development of a shock 
state (Figure 51).  By 60 min after the onset of resuscitation there was a significant 
difference in PT between rFVIIa and placebo-treated groups (P=0.001). 
 
Figure 50 Prothrombin time (PT) normalised in each individual animal to the level seen immediately after 
implantation of the first intravascular cannula (value pre-surgery) in two groups of animals treated with either 
rFVIIa or placebo immediately after the taking of the blood sample representing the 30 min time point.  Time 0 
min represents the onset of fluid resuscitation.  Mean values ± SEM. Further analysis found that the change in 
PT between 30 and 60 min after onset of resuscitation was significantly different between treatment groups 
(P=0.009, Mann Whitney U test, Figure 51). 
 
 
Figure 51  Change in normalised PT (for explanation see legend to Figure 50) between 30 and 60 min (T30 and 
T60, respectively) after onset of resuscitation.  rFVIIa or placebo was administered immediately after the T30 
sample was taken.  Negative value indicates fall in PT between T30 and T60.  Median, interquartile range. 
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Beyond T60, PT increased in individual animals in both groups (Figure 52).  Due to 
progressive loss of animals in both groups beyond this time-point, no further 
statistical analysis was performed on this data. 
  
Figure 52  Normalised PT (for explanation see legend to Figure 51) in individual animals from the rFVIIa (left) 
and placebo (right) treated groups. 
7.4.5 Histopathology and tissue microthrombi 
Two independent Histopathologists, blinded to the treatment status of the animals, 
analyzed tissue sections. There was no evidence of identifiable micro-thrombus 
formation in any of the sections.  All sections of (non-contused) lung did show 
positive staining for fibrin within some small-calibre vessels; however this was 
interpreted as post-mortem clot formation rather than ante-mortem thrombus 
formation on basis of morphology. 
7.4.6 Lung Inflammation and pulmonary oedema 
7.4.6.1 ICAM and VCAM 
There were no significant differences in expression of ICAM or VCAM in lung tissue 
when the rFVIIa group was compared to that treated with placebo (P=0.65, ICAM; 
P=0.29, VCAM) 
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Figure 53 Expression of two inflammatory genes ICAM (Intercellular Adhesion Molecule 1) and VCAM 
(vascular cell adhesion molecule 1) in lung tissue from animals treated with rFVIIa; expressed as a proportion of 
levels seen in the placebo-treated group.  Boxes represent interquartile range. The dotted line represents the 
median gene expression. Whiskers represent the minimum and maximum observations. 
 
7.4.6.2 Lung weight indices 
There was a trend towards a reduced lung weight index in the group given rFVIIa, 
compared to placebo, however this did not achieve statistical significance (P=0.07) 
(Figure 54). 
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Figure 54 Lung weight index (LWI) in two groups of pigs treated with a single intravenous dose of either rFVIIa 
or placebo (saline) 30 min after the onset of resuscitation.  Mean ±SEM. 
7.5 Discussion of rFVIIa Results 
This study has demonstrated no significant survival advantage from a single dose of 
rFVIIa given intravenously after 30 minutes of hypotensive-target saline resuscitation 
(Figure 47), compared to placebo given at the same time.  
 
There is however the possibility that the lack of significance reflects too small a study 
group (Type II error), rather than a true failure of the intervention. The survival time 
showed a trend towards improvement and there was marginal improvement in 
oxygenation of the rFVIIa animals after treatment (Figure 48).  Based on these 
results, a post hoc power calculation indicated that 23 animals per group would be 
required to establish whether there is indeed a small survival advantage.  However, 
the clinical impact of such a small increase does not justify sacrificing the number of 
animals required (34 extra), nor the expense of completing the work. This is 
particularly pertinent given the efficacy of the other adjunct assessed in this thesis, 
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supplemental oxygen, which resulted in both statistically and clinically significant 
survival improvement (Figure 34). 
7.5.1 Dosing 
It is important to be confident that the dose of rFVIIa administered was sufficient to 
be expected to produce a clinical effect.  There are three points that support this 
assumption.  
 
First, Prothrombin time reduced significantly after drug administration in the rFVIIa 
group compared to placebo controls (Figure 51). This reduction in PT was 
accompanied by a slight but significant improvement in oxygenation of the animals 
(Figure 48). 
 
Secondly, a previous study at DSTL; using the same breed of anaesthetised swine 
and an identical intravenous dose; demonstrated a significantly prolonged survival 
time in an aortotomy model of major arterial haemorrhage (263).  
 
Third, reports of rFVIIa use in DAH have shown significant clinical improvement 
following intravenous doses of only 60 and 100mcg/kg (291;292) which is 
considerably less than the dose used in this study. 
 
It is therefore concluded that a single intravenous dose of rFVIIa given 30 min after 
the onset of resuscitation does not produce a significant improvement in survival 
time, or in the physiological status associated with oxygen delivery to tissues, in our 
model of combined blast injury and haemorrhagic shock.  This is in marked contrast 
to the beneficial effects of rFVIIa seen in large vessel bleeding, where single dose 
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rFVIIa was shown to produce a clinical and statistically significant improvement in 
survival in a porcine model of haemorrhagic shock and incompressible arterial 
bleeding (263).  Furthermore, the lack of efficacy of rFVIIa in blast lung contrasts 
with anecdotal reports of a beneficial effect in diffuse alveolar haemorrhage from a 
variety of disease states (see Table 7).   
7.5.2 Physiology 
7.5.2.1 Oxygenation 
The slight rise in oxygen saturations in the rFVIIa group was statistically significant 
15min after drug administration (Figure 48).  All animals however remained hypoxic, 
with the SaO2 recovering only to 80% (PaO2 below 10KPa).  The improvement in 
oxygen saturation occurs very quickly (within 15 min) after drug administration, which 
makes it unlikely that the difference is due to an anti-inflammatory effect of rFVIIa. 
One must conclude therefore that the marginal improvement is due to a reduction in 
pulmonary haemorrhage following administration of a haemostatic agent.  
7.5.2.2 Acid Base and Oxygen Extraction 
Despite the slight improvement in oxygenation, there was no difference in the 
progression of metabolic acidosis, or the maintenance of maximal oxygen extraction 
ratio (Figure 49). 
 
The failure to halt the progression of metabolic acidosis in the rFVIIa group reflects 
insufficient improvement in oxygen delivery to address the gross inadequacy of 
perfusion generated by the injury model and hypotensive fluid resuscitation.  Any 
marginal improvement in arterial oxygen content due to rFVIIa was not enough to 
cross the threshold into acidosis stabilisation and survivability.  This is in contrast to 
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the oxygen group discussed in Section 6, where metabolic acidosis progression was 
rapidly arrested by oxygen support.  
7.5.3 Coagulation  
rFVIIa administration reduced PT from elevated levels, due to the injury model and 
hypotensive resuscitation, to below baseline.  Control group animals showed no 
such decrease in PT.  Beyond 60min however, PT in all rFVIIa animals again 
increased without further recovery (Figure 50).  
 
Recombinant Factor VII has been shown to have a half-life of 2.4hrs in bleeding 
trauma patients (293). Effective rFVIIa dosing regimens in major trauma 
haemorrhage studies have involved an initial 200mcg/Kg dose, followed by repeat 
boluses (100mcg/kg) at one and 3 hours as required (42).  It is likely that the short 
term effect on PT of rFVIIa represents clearance and reduced active concentrations, 
but it is also possible that ongoing hypoperfusion (from the injury model and 
hypotensive fluid therapy) drives coagulopathy to such an extent that rFVIIa activity 
on blood coagulation is rapidly overwhelmed.   
 
The principal aim for assessing rFVIIa in this study was not, however, to look at 
major haemorrhage control as this has been addressed in other preclinical and 
clinical studies (see section 3.3.4).  The target site for drug action was the pulmonary 
haemorrhage and subsequent lung inflammation generated by blast lung.  We have 
not directly determined the duration of any haemostatic effect on coagulation in the 
lungs from intravenous rFVIIa in this study, but we have seen that the systemic PT 
effect is short-lived, while the improvement in oxygen saturation after rFVIIa 
administration is maintained for the duration of the experiment.  We have already 
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mentioned that haemorrhage control in the lungs is responsible for the improvement 
in arterial oxygen saturation as it occurs too early for an anti-inflammatory effect to 
have made an impact. However, ongoing improvement in oxygen saturation does not 
mean that there is ongoing rFVIIa activity: once bleeding points in the lungs have 
been controlled with stable clot, re-bleeding in the lungs should not occur in this 
model as all animals are resuscitated to a hypotensive 80mmHg SBP target 
 
Repeat dosing would generate higher plasma drug concentrations and should 
prolong the PT effect seen initially in this study.  It could also augment the beneficial 
effect on arterial oxygenation saturation after rFVIIa.  Both of these features would 
potentially improve outcome, but there are logistic and practical issues related to the 
intended military role of the prehospital adjuncts we assess.  It is very unlikely that 
repeat dosing would occur in the field setting.  
7.5.4 Inflammatory markers and lung weight index 
In order to gauge potential differential inflammatory responses, we have focussed on 
gene expression of the inflammatory markers, ICAM and VCAM. Both were 
quantitatively measured from non-contused lung post-mortem harvest.  Their 
expression is upregulated very early in shock states - raised ICAM and VCAM have 
been shown almost immediately in lung tissue in rat models of haemorrhage and 
resuscitation (133).  Circulating ICAM can be detected in blood within 4h of shock 
onset (132) and VCAM levels on hospital admission after trauma are predictive of 
outcome (137). Gene expression of these markers would be more likely to show a 
difference than circulating cytokine levels such as Interleukins, given the short 
survival times of some animals.  Neither ICAM nor VCAM expression was altered 
compared to placebo by rFVIIa single dose administration in this study (Figure 53).   
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The trend towards reduced lung weight index in the rFVIIa group (Figure 54) could 
be due to an anti-inflammatory effect, but this is unlikely in the context of no change 
in inflammatory marker gene expression.  It is more likely that the trend is a result of 
reduced bleeding from the blast lung injury caused by the administration of the 
potent haemostatic agent, rFVIIa.  
 
Overall, there is no evidence from this study that a single intravenous dose of rFVIIa 
attenuates the lung or systemic inflammatory response following blast injury with 
haemorrhage. 
7.5.5 Safety of rFVIIa 
rFVIIa requires expression of tissue factor to generate thrombin so its action should 
be confined to sites of vessel injury. However, tissue factor can be expressed in 
other sites, such as atherosclerotic plaques or in the microcirculation in gram 
negative sepsis.  There is a theoretical risk of thrombotic complications following 
rFVIIa therapy and adverse events have been reported.  It is important therefore to 
consider the safety implications of this 180mcg/kg intravenous dose in the context of 
its use as a potential pre-hospital intervention following blast injury and 
haemorrhage.  
 
As mentioned in section 5.6, organ tissue samples were harvested at post mortem 
and inspected for evidence of microthrombi formation.  In order to prevent bias, two 
independent Histopathologists were asked to assess the samples and both were 
blinded to the treatment status of animals.  There was no evidence of any pre-
mortem thrombi in any harvested tissue sections. It is concluded therefore, that there 
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was no evidence of any safety issue with this single dose of 180mcg/Kg rFVIIa in our 
study. 
7.5.6 Future work with rFVIIa in blast and haemorrhage 
rFVIIa was not an effective adjunct as a single intravenous dose in this study and we 
cannot recommend its use in the prehospital environment in this form.   
 
Another route of administration of rFVIIa may however produce an effect in a similar 
injury context.  While the pathologies of blast lung and DAH have not been directly 
compared, there are similarities that make comparison of therapies relevant.  Both 
conditions result in pulmonary alveolar haemorrhage and an inflammatory response 
(Sections 2.2.4 and 3.3.5).  Both result in significant lung function compromise and 
potentially recover with supportive treatment. High elevation of Tissue Factor 
Pathway Inhibitor (TFPI) has been demonstrated in DAH and impedes normal 
function of the TF/FVIIa complex.  This renders the lungs more vulnerable to ongoing 
haemorrhage.  Although not assessed in blast lung, TFPI is also likely to be raised. 
Pharmacological doses of rFVIIa have been shown to generate thrombin via a TF-
independent pathway in the presence of raised TFPI (Figure 20).  Of course, blast 
lung injury can also include events such as pneumothorax and large vessel rupture, 
but these are both rare and victims with these features are likely to suffer 
overwhelming injury and succumb.  Intrapulmonary administration, via broncho-
alveolar-lavage or nebulizer, has been reported in only a very few cases of DAH. 
Heslet’s report of 6 cases noted good or excellent efficacy of rFVIIa in all cases 
(257). In one case, intra-pulmonary administration succeeded, where intravenous 
rFVIIa had failed to work.  There is no randomized data to confirm this effect, but 
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perhaps the intra-pulmonary route represents a more potent route for rFVIIa in blast 
lung?   
 
The use of intra-pulmonary rFVIIa will be assessed in future work to clarify this point 
and a similar injury model, or small animal study might be employed to achieve this.  
From this study, however, there is no data to support field use of rFVIIa as a 
resuscitation adjunct.  
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8 Overarching Discussion 
Modern combat trauma is characterized by injuries from explosive devices.  
Haemorrhage from devastating tissue injury is the primary cause of death on the 
battlefield, but the added effects of primary blast injury are evident in over 10% of 
wounded casualties (186).  The combined insults of blast and haemorrhage invoke a 
‘double hit’ on oxygen delivery and present significant challenges to prehospital life 
support algorithms.  This randomised controlled trial assessed two adjuncts to fluid 
resuscitation for their potential to improve survival and maintain physiology for a 
prolonged period following a clinically relevant injury model of combined blast and 
haemorrhage (see section 3.4).    
 
Supplemental oxygen significantly improved survival compared to control group, but 
rFVIIa did not (Figure 55).  Oxygen significantly improved physiology compared to 
control groups, arresting the deterioration of base deficit (Figure 56).  Both adjuncts 
significantly improved arterial oxygenation, but the rFVIIa animals remained hypoxic 
and the improvement was not sufficient to improve base deficit compared to control 
group. 
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Figure 55 Kaplan-Meier survival plot for three groups of animals subjected to blast injury, haemorrhage and 
hypotensive resuscitation.  The Blast rFVIIa and O2 groups were respectively given rFVIIa (180 µg/kg) or 
supplemental oxygen 30 min after the onset of resuscitation. Placebo breathed air throughout and received 
equivalent volume normal saline at T30 (0.018ml/kg). 
 
 
Figure 56 Arterial oxygen saturation and adjusted base excess plots for the three groups of animals.  All groups 
received the same injury model and fluid therapy throughout.  At T30, the oxygen group began to receive 
supplemental oxygen min (FiO2 0.3) to maintain SaO2 >95%.  The rFVIIa group received a single intravenous 
dose of 180mcg/kg and the placebo control group received an identical volume of normal saline.   
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Supplemental oxygen is therefore a potent adjunct to fluid resuscitation following 
blast and haemorrhage injury.  For the same scenario, rFVIIa, as a single 
intravenous dose given at 30 minutes after onset of resuscitation, cannot be 
recommended for use in the field.  
 
It is however possible that any pro-coagulation effect of rFVIIa on pulmonary 
haemorrhage might be greater if the drug were given even earlier.  This could 
improve the efficacy of the drug by reducing the hypoxic penalty of blast lung.  
Realistically however, an agent such as rFVIIa is unlikely to be administered any 
sooner than 30min following injury in the battlefield environment, so this avenue will 
not be pursued further in this programme of work. Intrapulmonary administration of 
rFVIIa is however a relevant concept to explore and has shown promise in clinical 
cases of DAH; a similar condition in terms of haemorrhage and hypoxia to blast lung. 
As discussed earlier (see section 7.5.6), this will be assessed in future work. 
 
Previous work at Dstl Porton Down has identified a ‘Novel Hybrid’ (NH) fluid 
resuscitation strategy that is able to maintain life, and enable physiological recovery 
after a similar injury model (39). Although the study did not demonstrate any 
evidence of increased rebleeding with this NH fluid strategy, there will be casualties 
for whom the risk of rebleeding is simply too great for clinicians to consider 
increasing blood pressure to normal levels in the prehospital environment.  For these 
patients, supplemental oxygen might offset the penalties of the reduced flow 
imposed by hypotensive therapy and enable prolonged prehospital survival.   
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In conjunction with NH, oxygen therapy should improve further the overall oxygen 
delivery (DO2) and optimise prehospital resuscitation. It can be considered that 
oxygen therapy essentially ‘negates’ the hypoxia effect of blast lung and leaves 
behind only the challenge of haemorrhage for the fluid therapy strategy to overcome. 
8.1 Limitations of the Study 
This randomised controlled large animal study has assessed two adjuncts to fluid 
therapy in a challenging injury model of primary blast injury and haemorrhage.  
Overall, the research questions have been answered and we have been able to 
make recommendations regarding potential clinical deployment of oxygen and 
suggest future work that might clarify whether or not there is any role for rFVIIa in the 
management of blast lung injury.  Of course, there are areas where alterations in 
study design or future work might improve upon the clarity of our findings. 
8.1.1 Recombinant FVIIa group 
As mentioned in the Method Development Section (4.1.6), there was insufficient data 
to inform an initial power calculation with respect to group size required to show a 
survival effect of rFVIIa.  The planned interim analysis at n=6 for each group allowed 
a timely re-evaluation of group size required to determine whether indeed rFVIIa had 
a positive effect on survival in this injury model.  This post-hoc power calculation 
demonstrated that a further 23 animals per group would be required.  This number of 
animals not only represents a large cost to the programme, but also a large number 
of animals that would need to be sacrificed.  Given the success of supplemental 
oxygen in the same injury model, and of the novel hybrid fluid strategy in a very 
similar model, it was felt that this investment and sacrifice was unjustified, as it would 
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be unlikely to translate into clinical practice given such a marginal effect, if indeed 
any were shown to exist. 
 
It might also be argued that inclusion of the liver snare potentially reduced any 
activity that intravenously-administered rFVIIa might have in blast-injured lungs. 
However large-scale tissue destruction is normally present in combat trauma victims.  
An injury model, which excluded any tissue injury, would therefore not be 
representative of the ‘real world’.  If rendered ineffective in addressing blast lung 
because of the diversion of a relatively small area of tissue injury, then an 
intravenous dose of rFVIIa is likely to be ineffective in the clinical setting.  
 
rFVIIa treatment in this study did produce an increase in oxygenation, an 
improvement in clotting parameters to beyond baseline and a trend towards 
increased survival time.  This suggests that the dose given was sufficient to ensure 
systemic effect even if some of the drug was being ‘used up’ at the site of the liver 
injury.   
 
If one were determined to establish whether or not the liver snare had impacted on 
the efficacy of rFVIIa in addressing the blast lung, it would of course be possible to 
repeat the experiment without the liver snare, (the degree of controlled haemorrhage 
may need to be increased to maintain the severity of injury).  It may be more relevant 
however, to assess the administration of rFVIIa via a more targeted route, so it is 
delivered directly to the area where its action is required: this work is already 
underway in a small animal model of blast lung and haemorrhage at Dstl Porton 
Down (see 7.5.6).   
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8.1.2 Oxygen Supplementation Group 
We chose to use hypotensive fluid therapy as the baseline therapy control for this 
study.  The Novel Hybrid programme recently completed at Dstl demonstrated 
significant survival and physiologic advantage of the Novel Hybrid fluid therapy 
strategy over prolonged hypotensive resuscitation following blast injury and 
haemorrhage - without increasing rebleeding (39).  It might be argued that, for 
military trauma prehospital management, this Novel Hybrid fluid strategy represents 
the new standard, against which all future strategies need testing.  However, the NH 
strategy has only recently been adopted into clinical practice, so the evidence as yet 
remains experimental. Furthermore, in the civilian setting, hypotensive therapy 
remains the standard of care.  Another reason to persist with hypotensive therapy in 
this study is that we were seeking to address not the flow component, but the arterial 
oxygen content component of the oxygen delivery equation.  The appropriate control 
is therefore one in which we know that oxygen delivery is unsurvivably low – this will 
best demonstrate any positive survival effect of our adjunct.  It is logical to expect 
that a combination of novel hybrid resuscitation and supplemental oxygen would 
achieve excellent survival and physiological recovery in a similar injury model.  We 
have shown no detrimental effects of oxygen and demonstrated improved DO2 (and 
a trend to improved VO2) by improving CaO2.  NH improved DO2 by increasing the 
flow component.  To assess both together, one could employ a similar animal model 
and compare combined therapy against NH alone.  Given high NH survival however, 
it may require large numbers of animals to demonstrate a survival advantage of 
combined therapy.   
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8.2 Future Research 
Dstl Porton Down has already studied interventions which address the flow 
component of DO2 by assessing fluid therapy strategies (39).  The current study has 
approached the issue from the oxygen content point of view and clear answers to the 
research questions have been achieved: oxygen is effective; single dose intravenous 
rFVIIa is not.  Another aspect of DO2 and oxygen content is oxygen carrying 
capacity.  Future work could examine the effects of administering doses of packed 
red cells and/or HBOC compounds in the context of a similar combined blast and 
haemorrhage model and assessed against hypotensive fluid therapy controls.  Both 
of these strategies should increase oxygen delivery to the organs and significantly 
improve the potential benefit of supplementary oxygen.  Consequently, where 
supplementary oxygen by itself (current study) was able to arrest the physiological 
deterioration, a combination of supplementary oxygen and packed red cells (or 
HBOCs) might reverse the physiological deterioration.  This combination clearly 
merits investigation since currently the only way shown to reverse the physiological 
deterioration has been to improve blood flow (novel hybrid resuscitation) by 
increasing blood pressure with the attendant risk of ‘popping clots’ and causing re-
bleeding.  A combined treatment of packed red cells (or HBOCs) and supplementary 
oxygen might therefore prove to be a safer alternative to novel hybrid resuscitation in 
casualties at particular risk of re-bleeding. 
 
However, with respect to red cell transfusion, it is important to appreciate that stored 
blood behaves differently to fresh blood. Some features of stored blood are 
presented in Table 13 below. 
Storage Lesion Clinical Effect 
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Up to 25% of PRBC rapidly cleared by reticulo-
endothelial system 
Stress on R-E system 
Reduced impact of PRBC on CaO2 
ATP depletion (>50% at 6 weeks) Impaired NO-mediated vasodilation 
in response to hypoxia: 
microcirculatory problem 
2,3 DPG levels negligible beyond 2 weeks 
(Takes 7hrs to regenerate 50% normal levels) 
Reduced unloading of oxygen in 
tissues  
Reduced deformability of erythrocytes RBC less able to enter capillaries: 
microcirculatory problem 
Increased free radicals Transfusion related tissue damage 
and inflammation 
Table 13 Storage lesion of blood 
 
The net effect of this ‘storage lesion’ is that stored red cells are both less effective at 
delivering oxygen to the microcirculation and carry significant risks: in SIRS patients, 
red cells transfusions increase mortality and morbidity, independent of shock severity 
(294).  Shah’s study of red cell transfusion in 8 critical care patients after trauma 
demonstrated that; although transfusion increased Hb and hence CaO2; it did not 
increase oxygen consumption (295).  The P50 of haemoglobin dropped significantly 
following two units of transfusion and was cited as the primary reason that VO2 was 
not improved.  
 
HBOCs may however prove effective in increasing the oxygen content and 
consumption, while avoiding the problems associated with stored red cell 
transfusion.  
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Oxygen support capability is not currently available in forward military echelons.  
New technologies minimise the previously prohibitive logistic burdens of maintaining 
such a capability.  Investment in these technologies will potentially improve 
survivability from modern combat wounds and is recommended. 
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